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Zusammenfassung 
Das Vici-Syndrom ist eine seltene autosomal-rezessive Erkrankung mit schwerer 
Funktionsstörung mehrerer Organsysteme. Als genetische Ursache für das Vici-Syndrom 
werden Mutationen im EPG5-Gen angesehen, die für das ektopische P-Granulat-Autophagie-
Protein 5 kodieren und zu Defekten in der Autophagie führen. In etwa 80% der Fälle wird die 
Entwicklung dilativer und hypertropher Kardiomyopathieformen beobachtet. Die Mechanismen 
der Kardiomyopathieentwicklung und mögliche therapeutische Ziele müssen jedoch noch 
geklärt werden. Interessanterweise zeigten frühere Arbeiten bei Caenorhabditis elegans, dass 
Hemmung der Enzymaktivität der N-Acetylglucosamintransferase (OGT) in EPG5-defizienten 
Nematoden die voll funktionsfähige Autophagie wiederherstellte. Wie sich diese Behandlung 
bei Menschen auswirkt, ist jedoch noch unbekannt. Um mehr über die Mechanismen von Vici-
Kardiomyopathien und die Auswrikungen einer Hemmung der OGT beim Vici-Syndrom zu 
erfahren, haben wir ein Vici-patientenspezifisches in-vitro-Krankheitsmodell erstellt. Dazu 
haben wir aus Fibroblasten eines Vici-Patienten pluripotente Kardiomyozyten induziert (iVici 
iPSC-CMs). Der Vici-Patient trug eine homologe EPG5-Mutation (c.4952 + 1G> A), die zum 
aberranten Spleißen des EPG5-Transkripts und zur Entfernung von Exon 28 führt. Weiterhin 
kommt es  einer Frame-Verschiebung und einer Einführung eines Stoppcodons bei Exon 29. 
Im iVici iPSC-CMs-Modell beobachteten wir einige der bekannten Vici-assoziierten 
Kardiomyopathiephänotypen, einschließlich zellulärer Hypertrophie und Sarkomstörung. Das 
Ziel dieser Studie war es, potenzielle molekulare Defekte in iVici iPSC-CMs zu untersuchen, 
um dadurch ein Verständnis der molekularen Mechanismen zu bekommen, die der 
Entwicklung Vici-Syndrom bedingter Kardiomyopathien zugrunde liegen. In dieser Studie 
haben wir auch die Wirkung von pharmakologischen OGT-Inhibitoren in iVici iPSC-CMs 
getestet. Wir haben gezeigt, dass iVici iPSC-CMs Defekte in der Autophagosom- und 
Lysosomenfusion aufweisen und eine langsamere Schlagfrequenz sowie veränderte 
Schlagkinetik aufweisen, die möglicherweise auf Änderungen im Calciumstoffwechsel in iVici 
iPSC-CMs zurückzuführen sind. Wir beobachteten die Akkumulation fragmentierter 
Mitochondrien und den Anstieg des oxidativen Stresses und der Protein-O-GlcNAcylierung in 
iVici iPSC-CMs. Dies sind mögliche Ursachen für die mit dem Vici-Syndrom verbundenen 
Kardiomyopathien. Darüber hinaus fanden wir heraus, dass der unspezifische OGT-Inhibitor 
Alloxan und der spezifische OGT-Inhibitor ST045849 die Fusion zwischen dem Autophagosom 
und dem Lysosom in iVici iPSC-CMs verbessern können. Zusammenfassend haben wir in der 
aktuellen Arbeit gezeigt, dass das iVici iPSC-CMs-Modell den Phänotyp des Vici-Syndroms 
gut wiederspiegelt und dadurch weitere Einblicke in die zugrunde liegenden Mechanismen der 
Vici-Kardiomyopathie liefert. Dies ermöglicht die Erforschung potentieller Therapeutiker. 
Zukünftige Studien sollten sich auf die weitere Untersuchung der OGT-Hemmung als 
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therapeutischen Ansatz und der zugrunde liegenden Mechanismen zur Identifizierung neuer 
therapeutischer Ziele unter Verwendung von iVici iPSC-CMs konzentrieren. 
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Summary 
Vici syndrome is a rare, autosomal recessive disorder with severe dysfunction of multiple organ 
systems. Mutations in the EPG5 gene encoding ectopic P-granule autophagy protein 5, which 
lead to defects in the autophagic flux, are found as the genetic cause of Vici syndrome. In 
around 80% of cases, development of dilated and hypertrophic forms of cardiomyopathies is 
observed. However, the mechanisms of cardiomyopathy development and possible 
therapeutic targets remain to be elucidated. Interestingly, previous work in Caenorhabditis 
elegans showed that targeting the enzyme N-acetylglucosamine transferase (OGT) in EPG5-
deficient nematodes restored fully functional autophagy. However, the effect of targeting OGT 
in a human Vici disease model is unknown. In order to understand more about the mechanisms 
of Vici cardiomyopathies and the effect of targeting OGT in Vici syndrome, we established a 
Vici patient-specific in vitro disease model by generating induced pluripotent stem cell-derived 
cardiomyocytes (iVici iPSC-CMs) from fibroblasts obtained from a Vici patient. The Vici patient 
carried a homologous EPG5 mutation (c.4952+1G>A), which results in the aberrant splicing of 
the EPG5 transcript and the removal of exon 28 and introduces a frameshift and a premature 
stop codon at exon 29. In the iVici iPSC-CMs model, we observed some of the known Vici-
associated cardiomyopathy phenotypes including cellular hypertrophy and sarcomere 
disarray. The aims of this study were to investigate physiological and functional properties of 
iVici iPSC-CMs and to provide an understanding of the molecular mechanisms driving 
cardiomyopathy development in Vici patients by investigating the presence of potential 
molecular defects in iVici iPSC-CMs. In this study we also tested the effect of pharmacological 
OGT inhibitors in iVici iPSC-CMs. We showed that iVici iPSC-CMs exhibited defects in the 
autophagosome and lysosome fusion and displayed slower beating frequency and altered 
beating kinetics possibly resulting from the alterations in calcium handling in iVici iPSC-CMs. 
We observed the accumulation of fragmented mitochondria and increase in oxidative stress 
and protein O-GlcNAcylation in iVici iPSC-CMs, which are possible causes of the Vici 
Syndrome-associated cardiomyopathies. Moreover, we found that the non-specific OGT 
inhibitor alloxan and the specific OGT inhibitor ST045849 could enhance the fusion between 
the autophagosome and the lysosome in iVici iPSC-CMs. Taken together, in the current work, 
we demonstrated that iVici iPSC-CMs model can recapitulate some of the disease phenotypes 
of Vici syndrome, and at the same time, provided further insight into the underlying 
mechanisms of Vici cardiomyopathy and possible pharmacological therapeutics. Future 
studies should focus on further investigation of the feasibility of using OGT inhibition as a 
therapeutic approach and of the underlying mechanisms to identify new therapeutic targets 
using iVici iPSC-CMs. 
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1. Introduction 
 
1.1 Autophagy 
 
Autophagy is a catabolic cellular process responsible for protein and organelle turnover 
through the delivery of cellular cargo destined for degradation to the lysosome, an organelle 
containing several degradative enzymes (De Duve & Berthet, 1953; De Duve & Wattiaux, 
1966). Under normal conditions, autophagy maintains cellular homeostasis through constant 
protein and organelle turnover whereas under stress conditions, such as starvation, autophagy 
recycles essential cellular nutrients including amino acids, lipids and carbohydrates to provide 
fuel for adenosine triphosphate (ATP) production (Kaur & Debnath, 2015). Three forms of 
autophagy are characterized, macroautophagy, microautophagy, and chaperone-mediated 
autophagy (CMA).  
Macroautophagy (hereafter autophagy) involves the sequestration of cytoplasmic organelles 
and proteins by the autophagosome and delivery of the engulfed cargo to the lysosome for 
degradation. Autophagy begins with the formation of the isolation membrane (IM, 
autophagosome precursor) at the phagophore assembly site (PAS) at vicinity of the 
endoplasmic reticulum (ER) where the protein vacuole membrane protein 1 (VMP1) regulates 
the dissociation between the IM and the ER (Zhao et al., 2017). Upon autophagy induction, 
the UNC51-like kinase (ULK-1) complex, including autophagy related (ATG) 13 (ATG13), 
ATG101, and the FAK family kinase interacting protein of 200 kDa (FIP200), is activated. The 
active ULK-1 complex initiates the nucleation of the phagophore by phosphorylating Beclin1 
on serine 14 leading to the activation of the class III phosphoinositide 3-kinases (PI3K) complex 
comprised of PI3K, Beclin1, vacuolar protein sorting 15 (VSP15), and ATG14 (Russell et al., 
2013). During the nucleation stage, a pool of phosphatidylinositol 3-phosphate specific for the 
autophagosome is produced. The final stage of the autophagosome formation is the expansion 
and closure stage, during which the ATG12–ATG5–ATG16 complex is recruited to the 
autophagosome membrane where it facilitates conjugation of the microtubule-associated 
protein 1 light chain 3 (LC3) with phosphatidylethanolamine (PE) moiety, hence the conversion 
of LC3I to LC3II also known as LC3-PE (He & Klionsky, 2009; Kaur & Debnath, 2015; 
Nakamura & Yoshimori, 2017) (Figure 1A). Afterwards, the closed mature autophagosome 
fuses with the lysosome to deliver the engulfed cargo for degradation. The fusion process is 
tightly regulated by autophagosomal and lysosomal snap receptor (SNARE) proteins, tethering 
factors, and RAB GTPases. Upon closure of the autophagosome, the Qa SNARE protein 
syntaxin 17 (STX17) is recruited from the cytoplasm to the autophagosome and interacts via 
its LC3-interacting region (LIR) with LC3II on the mature autophagosome membrane. STX17 
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on the autophagosome membrane recruits the Qbc SNARE synaptosomal-associated protein 
29 (SNAP29). Together they mediate the fusion with the lysosomal R-SNARE VAMP8 (vesicle-
associated membrane protein 8) and hence successful delivery of the engulfed cargo for 
degradation (Corona & Jackson, 2018; Itakura et al., 2012).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. Schematic representation of different forms of autophagy. (A) Macroautophagy 
is initiated at the phagophore assembly site (PAS) (1), followed by the nucleation stage during 
which cytoplasmic proteins and organelles are engulfed by the expanding phagophore (2). 
Next, membrane expansion takes place where the phagophore is closed to form the completed 
autophagosome (3). Finally, the autophagosome fuses with the lysosome to deliver the 
engulfed cargo for degradation (4). Microautophagy involves direct uptake of cytoplasmic 
components by the lysosomes via membrane invagination (5). Chaperone-mediated 
autophagy (CMA) involves the delivery of cytoplasmic proteins with the exposed KFERQ 
pentapeptide sequence, recognized and bound by HSC70, which in turn binds to the lysosome-
associated membrane glycoprotein 2A (LAMP2A) and delivers the protein to the lysosome (6). 
(B) Illustration of mitophagy as an example of selective autophagy process. Upon 
mitochondrial membrane depolarization, PINK1 (PTEN-induced putative kinase 1) is stabilized 
on the outer mitochondrial membrane (OMM), where it recruits the E3 Ligase parkin which 
ubiquitinates several proteins on the OMM. The ubiquitinated proteins are recognized by 
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autophagy receptor P62 which directs the dysfunctional mitochondria to the autophagosome 
via its LC3-interacting region (LIR) domain for degradation by the lysosome. 
Several tethering factors ensure specificity and facilitate docking and fusion between the 
autophagosome and the lysosome. For instance, the homotypic fusion and protein sorting 
complex (HOPS) is recruited to the mature autophagosome and binds to STX17 where it 
mediates the fusion with the lysosome R-SNARE VAMP8 (Baker et al., 2015; Jiang et al., 
2014). Furthermore, a RNAi screening to identify novel ubiquitin modifiers involved in the 
regulation of starvation-induced autophagy revealed that the BIR-repeat-containing ubiquitin-
conjugating enzyme (BRUCE) binds to STX17 on the mature autophagosome where it 
mediates the fusion between the autophagosome and the lysosome (Ebner et al., 2018).  
Moreover, previous work showed that ATG14 is recruited to the mature autophagosome as a 
tethering factor where it binds to the STX17-SNAP29 complex. This interaction stabilizes the 
STX17-SNAP29 complex and primes it for the fusion with the lysosomal VAMP8 (Diao et al., 
2015). Another key tethering factor is ectopic P granules protein 5 homolog (EPG5). EPG5 is 
recruited to the late endosomes/lysosomes via direct interaction with RAB7 and the R-SNARE 
VAMP8. In addition, EPG5 binds to the assembled Qabc STX17-SNAP29 SNARE complex on 
the autophagosome through its LIR motif. Through this interaction, EPG5 enhances and 
ensures the specific fusion between the autophagosome and the lysosome (Tian et al., 2010; 
Wang et al., 2016) (Figure 2).  
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Figure 2. Schematic illustration of the different factors mediating the fusion between 
the autophagosome and the lysosome.  
Autophagy was believed to be a nonselective process, during which bulk cytoplasmic 
components are engulfed by the autophagosome. However, the identification of the autophagy 
receptors such as ubiquitin-binding protein P62 and neighbor of BRCA1 gene 1 (NBR1) 
indicates that the autophagy process possesses a high degree of selectivity and regulation in 
eliminating intracellular protein aggregates and damaged organelles including the 
mitochondria (Bjørkøy et al., 2005; Kirkin et al., 2009). Selective elimination of aggregated 
proteins and damaged cellular organelles via autophagy involves the binding of the autophagy 
receptors NBR1 or P62 to ubiquitinated proteins via their C-terminus, which then delivers them 
to the autophagosome through binding to the IM via their LIR (Kaur & Debnath, 2015; Stolz et 
al., 2014).  
An example of selective autophagy in the prevention of cellular damage is the elimination of 
dysfunctional mitochondria (mitophagy) to maintain a healthy mitochondrial network. Defects 
in mitophagy lead to the accumulation of depolarized fragmented mitochondria (Hashem et al., 
2017). A healthy mitochondrial network is fused and degrades the PTEN-induced putative 
kinase 1 (PINK1) on the outer mitochondrial membrane (OMM). However, dysfunctional and 
depolarized mitochondria are fragmented to prime mitochondrial removal via mitophagy and 
do not degrade PINK1, which results in PINK1 accumulation on the OMM. PINK1 recruits the 
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E3 Ligase parkin, which ubiquitinates several proteins on the OMM. The ubiquitinated proteins 
are recognized by autophagy receptor P62 which directs the dysfunctional mitochondria to the 
autophagosome via its LIR domain for degradation by the lysosome (Friedman & Nunnari, 
2014; Stolz et al., 2014; Youle & Van Der Bliek, 2012) (Figure 1B).  
Besides macroautophagy, two other forms of autophagy are characterized. Microautophagy, 
the least characterized form of autophagy, involves direct engulfment of cellular proteins and/or 
organelles by the lysosomes via membrane invaginations independent of SNAP and SNARE 
proteins. It is suggested that in mammalian cells microautophagy is responsible for the basal 
protein turnover (Mijaljica et al., 2011; Sahu et al., 2011) (Figure 1A). Chaperone-mediated 
autophagy (CMA) involves the delivery of cellular proteins destined for degradation to the 
lysosomes directly via the lysosome-associated membrane glycoprotein 2A (LAMP2A), the 
only LAMP2 isoform playing a role in CMA. Proteins that contain the pentapeptide KFERQ are 
the only substrates degraded via CMA (Figure 1A) where almost 40% of mammalian proteins 
contain this pentapeptide sequence. The heat shock protein family A member 8 HSC70 
recognizes and binds to the exposed KFERQ motif of target protein, which in turn binds to 
LAMP2A and delivers the protein to the lysosome for degradation (Kaushik & Cuervo, 2018) 
(Figure 1A).  
1.2 Vici syndrome overview  
 
Vici syndrome [OMIM 242840] is a rare multiorgan developmental disorder characterized by 
five main pathological features including cutaneous hypopigmentation, bilateral cataract, 
combined immunodeficiency, agenesis of the corpus callosum and cardiomyopathy (Byrne et 
al., 2016a; Byrne et al., 2016b). It was first described in two brothers in Rome, Italy in 1988 by 
Carlo Dionisi-Vici as a malformation syndrome (Dionisi Vici et al., 1988). This malformation 
syndrome was designated the name Vici syndrome in 1999 as more similar cases were 
observed and documented (Del Campo et al., 1999). Besides the five key pathological 
features, Vici patients usually display profound developmental delay, failure to thrive, skeletal 
myopathy, and progressive microcephaly. Furthermore, every organ in the body can be 
affected including the lungs, thyroid, liver and kidneys (Byrne et al., 2016a; Byrne et al., 2016b; 
Ebrahimi-Fakhari et al., 2016). Until the year 2018, around 78 cases were reported (Alzahrani 
et al., 2018). 
In 2012 Vici syndrome was identified to develop due to autosomal recessive inheritance of 
mutations in EPG5 (18q12.3) (Cullup et al., 2012). Following this study, several different EPG5 
mutations were reported to occur in Vici patients supporting the finding that mutation(s) in 
EPG5 is the causative factor of Vici syndrome (Alzahrani et al., 2018; Byrne et al., 2016b; 
Demiral et al., 2018; Hedberg-Oldfors et al., 2017; Kane et al., 2019; Shimada et al., 2018). 
Introduction 
 
6 
 
EPG5 consists of 44 exons and encodes a protein of 2570 amino acids. It is mainly expressed 
in the central nervous system, cardiac muscle, immune cells, lungs, skeletal muscle and 
kidneys (Cullup et al., 2012; Waldrop et al., 2018). The essential role of EPG5 in mediating the 
specific fusion between the autophagosome and the lysosome during autophagy pointed out 
that Vici syndrome develops due to a defect in the process of autophagosome and lysosome 
fusion (Cullup et al., 2012; Hori et al., 2017). Interestingly, Vici syndrome shares several clinical 
features with glycogen storage disease, mitochondrial disorders and disorders with primary 
and secondary defects of the autophagy pathway such as Danon disease (Balasubramaniam 
et al., 2018; Byrne et al., 2016b).  
Vici patients usually don’t survive infancy and the main reason for death is infections and 
cardiomyopathy (Alzahrani et al., 2018; Rogers et al., 2011). The cardiomyopathy phenotype 
in Vici patients includes left ventricular hypertrophic and dilated forms of cardiomyopathy 
(Alzahrani et al., 2018), in addition, some patients showed some degree of fibrosis, membrane 
bound cytoplasmic inclusions, increased staining for autophagy markers and sarcomere 
disorganization. In myofibrils of Vici syndrome patients, mitochondria were of variable sized 
and showed abnormal distribution and morphology (Cullup et al., 2012; Miyata et al., 2014; 
Rogers et al., 2011). Although these clinical observations clearly indicate the cardiac defects 
in Vici patients and the possible accumulation of dysfunctional mitochondria, the exact 
molecular mechanisms leading to the development of cardiomyopathy are currently unknown.  
1.3 Autophagy role in the heart 
 
Defects in autophagy have been linked to several diseases including cancer, diabetes, 
neurodegenerative diseases, diabetic cardiomyopathy, cardiac hypertrophy and heart failure 
(HF) (Hara et al., 2006; Jiang et al., 2013; Komatsu et al., 2006; Ren et al., 2018). In post 
mitotic tissues such as the heart, autophagy is responsible for maintaining cellular homeostasis 
as well as responding to stress conditions such as hypoxia and changes in nutrient supply 
(Kubli & Gustafsson, 2014; Lampert & Gustafsson, 2018). Furthermore, the aging related 
decline of autophagy in several organs including the heart has been linked to accumulation of 
damaged proteins and organelles and organ dysfunction (Cuervo et al., 2005; Kaur & Debnath, 
2015; Leidal et al., 2018; Shirakabe et al., 2016).  
Cardiac aging is characterized by cardiomyopathy with systolic dysfunction, sarcomere 
disorganization and mitochondrial dysfunction. Cardiac-specific knockout of ATG5 in mice 
showed no cardiac phenotype until 10 weeks of age. By three months of age, development of 
mitochondrial dysfunction was observed. Furthermore, at 10 months of age the ATG5-/- mice 
developed contractile dysfunction, cardiac remodeling, fibrosis, sarcomere disorganization, 
oxidative stress and increased apoptosis in the heart (Taneike et al., 2010). Moreover, 
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pharmacological and genetic induction of autophagy in mice has been shown to play a 
protective role against age-dependent decline in cardiac function (Eisenberg et al., 2016; 
Fernández et al., 2018). Together, these studies supported the notion that autophagy 
deficiency leads to age-related cardiomyopathy and that autophagy induction during aging has 
a protective role.  
The role of autophagy under acute hemodynamic stress is controversial. For instance, mice 
with heterozygous Beclin1+/- with diminished autophagy activity showed enhanced protection 
against severe hemodynamic stress-induced pathological heart remodeling, and the 
overexpression of Beclin1 resulted in increased autophagy activity and pathological cardiac 
remodeling (Zhu et al., 2007). On the other hand, cardiac-specific ATG5 deficient mice showed 
no phenotype under basal conditions, however, induction of hemodynamic stress at 10 weeks 
of age resulted in the development of severe cardiac dysfunction and HF (Nakai et al., 2007). 
Furthermore, autophagy activated by rapamycin treatment for three weeks after acute 
myocardial infarction (MI) in mice attenuated the decrease in cardiac function and cardiac 
remodeling (Wu et al., 2014). Moreover, in the chronic pathological phase after MI there is 
reduced autophagy activity and activation of autophagy via the administration of trehalose, a 
natural occurring disaccharide, for four weeks after MI in mice attenuated cardiac remodeling 
and improved systolic and diastolic function compared to placebo-treated mice (Sciarretta et 
al., 2018). Finally, several studies illustrated a protective role of autophagy during 
hemodynamic stress by providing nutrients and removing aggregated proteins and damaged 
organelles and prevention of increased damaging oxidative stress (Kubli & Gustafsson, 2014).   
Moreover, studies with human heart samples supported that excessive autophagy induction 
can lead to autophagic cell death contributing to HF progression and that chronic autophagy 
activation contributes to heart damage (Kubli & Gustafsson, 2014). However, completely 
blocking autophagy leads to the development of cardiomyopathy (Gatica et al., 2015). Taken 
together, similar to all biological processes, a delicate balance should be maintained as neither 
chronic decrease nor increase in autophagy is beneficial for the cardiomyocytes (CMs) under 
basal and stress conditions. In addition, the findings discussed further support the notion that 
Vici patients develop cardiomyopathy due to the autophagy dysfunction.  
1.4 Cellular conditions and pathways regulating autophagy 
 
Two nutrient sensing pathways have been implicated in the regulation of autophagy, 
mammalian target of rapamycin (mTOR) which senses cellular nutrient, oxygen, and energy 
levels (Tokunaga et al., 2004) and 5' AMP-activated protein kinase (AMPK) which senses 
cellular ATP levels. Under nutrient rich conditions activation of insulin receptor leads to 
increased protein kinase B (PKB/AKT) activity. The active AKT phosphorylates and inactivates 
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the tuberous sclerosis (TSC) 1/2 complex, which negatively regulates the mTOR complex 1 
(mTORC1) activity through promoting the conversion of the active GTP-bound Ras homolog 
enriched in brain (RHEB) to the inactive GDP-bound RHEB. Hence, inactivation of the TSC 
1/2 complex by AKT leads to increased GTP-bound RHEB which directly binds and activates 
mTORC1 (He & Klionsky, 2009; Inoki et al., 2002; Sancak et al., 2008). The active mTORC1 
phosphorylates ULK-1 at serine 757 leading to its inactivation and sequestration in a complex 
with ATG13 and FIP200 and, as a result, autophagy inhibition (Ganley et al., 2011). 
AMPK is composed of a catalytic α subunit and regulatory γ and β subunits. Increase in 
adenosine monophosphate (AMP) levels leads to allosteric activation of AMPK by 
phosphorylation of threonine 183 of the α1 catalytic subunit and threonine 172 of the α2 
catalytic subunit (Herzig & Shaw, 2018). The active AMPK induces autophagy activation via 
two distinct mechanisms. The first is through activation of TSC 1/2 by phosphorylation of the 
TSC 1/2 complex at serine 1345 and threonine 1227 leading to the mTORC1 inhibition. The 
second is through direct phosphorylation of ULK-1 at  serine 317 and threonine 777, which 
promotes the early steps of autophagosome formation and autophagy induction (Inoki et al., 
2003; Kim et al., 2011). 
Moreover, several cellular conditions have been shown to induce autophagy. Starvation 
conditions are a known inducer of autophagy, due to the decrease in cellular ATP levels and 
the increase in cellular AMP levels (Takeshige et al.,1992). Furthermore, several pieces of 
evidence indicated that mitochondrial dysfunction and mitochondria-derived oxidative stress 
(mitochondrial reactive oxygen species; mtROS) are direct inducers of autophagy through 
AMPK activation (Filomeni,et al., 2015; Scherz-Shouval & Elazar, 2007). Another known stress 
condition stimulating the activation of autophagy is ER stress, through the inositol-requiring 
enzyme 1 α (IRE1α)-X-box binding protein 1 (XBP-1) pathway and the activating transcription 
factor 4 (ATF4) pathway (Li et al., 2015; Maiuri, 2007; Ogata et al., 2006; Yorimitsu et al., 
2006). Autophagy activation during ER stress promotes the degradation of accumulated 
protein, acting as a pro-survival mechanism (Kaur & Debnath, 2015). Interestingly, 
mitochondrial dysfunction, mtROS and chronic activation of ER stress are known contributors 
of cardiac function decline and heart failure development and at the same time, defects in 
autophagy induce mitochondrial dysfunction, oxidative stress and ER stress.  
1.5 Attempts to fix autophagy defect in Vici syndrome 
 
Vici syndrome develops due to EPG5 mutations and the resulting defect in the fusion between 
the autophagosome and the lysosome during autophagy, hence it’s rational to hypothesize 
that improving the fusion between the autophagosome and the lysosome in Vici patients can 
lead to improved prognosis. Two approaches have been utilized to attenuate the fusion defect 
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resulting from loss of EPG5 in HeLa cells and Caenorhabditis elegans. Previous studies 
demonstrated that knockdown of human EPG5 (hEPG5 KD) in HeLa cells led to increased 
interaction and complex formation between SNAP25, STX17 and VAMP8 instead of interaction 
and complex formation between SNAP29, STX17 and VAMP8 resulting in abnormal fusion of 
the autophagosome with endocytic vesicles. Interestingly, SNAP25 knockdown in hEPG5 KD 
HeLa cells led to reduced levels of the autophagy markers P62 and LC3II, which were 
accumulated in hEPG5 KD HeLa cells. This effect was repressed upon treatment with the 
inhibitor of lysosomal degradation bafilomycin A1. These findings indicated that SNAP25 
knockdown in hEPG5 KD HeLa cells promotes autophagic flux (Wang et al., 2016).   
In addition, previous work showed that Caenorhabditis elegans double mutants for OGT (N-
acetylglucoseamine transferase) and EPG5 reveal suppressed autophagy defect normally 
observed in the single EPG5 mutants. Interestingly, RNA knockdown of glucosamine—
fructose-6-phosphate aminotransferase isomerizing (GFAT) also attenuated the autophagy 
defect in EPG5 mutants. GFAT is the rate-limiting enzyme of the hexosamine biosynthesis 
pathway (HBP), which generates the substrate utilized by OGT in Caenorhabditis elegans. The 
authors also validated these findings by genetic knockdown of OGT and hEPG5 in HeLa cells 
and pharmacological treatment with the nonspecific OGT inhibitor alloxan. These interventions 
attenuated the autophagy defect resulting from hEPG5 KD and promoted fusion between the 
autophagosome and the lysosome. This study illustrated that loss of EPG5 leads to increased 
O-linked-N-acetylglucosamine modification (O-GlcNAcylation) of SNAP29, which impairs 
SNAP29 function during the fusion between the autophagosome and the lysosome. Upon OGT 
inhibition or genetic knockdown, SNAP29 O-GlcNAcylation is reduced and, as a result, 
SNAP29 regains its function in mediating the fusion between the autophagosome and the 
lysosome (Guo et al., 2014).   
Taken together, these pieces of evidence reveal that the autophagy defect resulting from EPG5 
mutation or loss of function can be attenuated by pharmacological or genetic targeting of at 
least two targets: SNAP25 and OGT. Whether these approaches work in humans and can be 
adapted in patients remains to be elucidated. 
1.6 Protein O-GlcNAcylation modification 
 
Around 2-3% of glucose entering the cell is directed to the HBP, which integrates the 
metabolism of glucose, amino acid (glutamine), fatty acids (acetyl-CoA) and nucleotides 
(uridine triphosphate) for producing the uridine diphosphate N-acetylglucosamine (UDP-
GlcNAc) moiety as an end product. The UDP-GlcNAc donates the N-acetylglucosamine 
(GlcNAc) moiety utilized by the enzyme OGT which catalyzes attachment of the GlcNAc moiety 
to the hydroxyl group of serine and threonine amino acids of cytoplasmic, nuclear and 
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mitochondrial proteins resulting in protein O-GlcNAcylation (Shafi et al., 2000; Torres & Hart, 
1984). 
Protein O-GlcNAcylation is a reversible post translational modification (PTM) which modulates 
protein function similar to phosphorylation (Hart et al., 2011). However, in contrast to 
phosphorylation, O-GlcNAcylation is controlled by only one pair of enzymes. The first is OGT 
which is responsible for attaching the O-GlcNAc sugar moiety to the serine of threonine of 
proteins. The second is O-GlcNAcase (OGA) which is responsible for the removal of the -
GlcNAc sugar moiety from the modified proteins. Three isoforms exist for the enzyme OGT, 
nucleocytoplasmic (ncOGT), mitochondrial (mOGT) and short OGT (sOGT), which result from 
alternative splicing of OGT. Two isoforms exist for the enzyme OGA, nucleocytoplasmic and a 
short isoform, which also result from alternative splicing of meningioma expressed antigen 5 
(MGEA5) (Yang et al., 2017).  
Since its discovery, protein O-GlcNAcylation has been shown to modulate several cellular 
processes, and to play a protective role under stress conditions (Yang et al., 2002). For 
instance, under heat stress protein O-GlcNAcylation induces the inactivation of glycogen 
synthase kinase 3β (GSK-3β) leading to increased expression of the heat shock protein 72 
(HSP72) (Kazemi et al., 2010). Furthermore, ER stress leads to increased cellular O-
GlcNAcylation through the IRE1α-XBP-1 arm which directly upregulates genes involved in the 
HBP leading to increased generation of the substrate utilized by OGT, UDP-GlcNAc (Zhao et 
al., 2014). The upregulation of protein O-GlcNAcylation during the ER stress has been shown 
to play a protective role in preventing toxic protein aggregation and facilitate protein folding via 
the recruitment of chaperones (Yang & Qian, 2017).   
Despite the protective role of cellular protein O-GlcNAcylation illustrated under stress 
conditions (Zachara et al., 2004; Zhao et al., 2014), previous work demonstrated the 
importance of maintaining cellular protein O-GlcNAcylation homeostasis as disruption of O-
GlcNAcylation homeostasis has been linked to several conditions including cancer, diabetes, 
neurodegeneration and cardiomyopathy (Hart et al., 2011; Soesanto et al., 2008; Yang et al., 
2008).  
1.7 Protein O-GlcNAcylation regulation of autophagy 
 
Protein O-GlcNAcylation has been shown to regulate autophagy both positively and negatively. 
Several reports highlighted the role of O-GlcNAcylation protein modification in the initiation of 
autophagy. For instance, under starvation conditions, glucagon induces autophagy in the liver 
to provide amino acid substrates required for gluconeogenesis so that the liver can supply the 
body with glucose (Ezaki et al., 2011). Interestingly, the mechanism through which glucagon 
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induces autophagy in the liver is the activation of OGT by Ca2+/calmodulin-dependent protein 
kinase IIγ (CAMKIIγ). This leads to O-GlcNAcylation modification of ULK-1, which facilitates 
ULK-1 phosphorylation and activation by AMPK (Ruan et al., 2017). Another study further 
elucidated the mechanism through which O-GlcNAcylation modification of ULK-1 facilitates 
autophagy initiation. In this study, the authors showed that upon glucose deprivation ULK-1 is 
modified by O-GlcNAcylation at threonine 754 leading to increased interaction with ATG14L 
and activation of VSP34 lipid kinase activity essential for phagophore formation and autophagy 
initiation (Pyo et al., 2018).  
In contrast, several studies elucidated an inhibitory effect of increased O-GlcNAcylation protein 
modification on autophagy, particularly by negatively modulating proteins involved in the fusion 
step between the autophagosome and the lysosome. GRASP55, a protein involved in the 
stacking of Golgi apparatus, has been shown to be modified by O-GlcNAcylation under nutrient 
rich conditions. However, upon starvation and autophagy induction, it is de-O-GlcNAcylated 
and targeted to the autophagosome. Through binding with LC3IIB on the autophagosome and 
with LAMP2B on the lysosome, GRASP55 functions as a membrane tether to mediate the 
fusion between the autophagosome and the lysosome (Zhang et al., 2018).  
Furthermore, diabetic conditions and the associated decrease in autophagy activity in the heart 
have been linked to increased protein O-GlcNAcylation. Autophagy was shown to be blunted 
in CMs isolated from db/db mice, which carry mutations in leptin receptor and show insulin 
resistance and hyperglycemia, modeling human type II diabetes; and this was reversed via the 
inhibition of HBP (Ducheix et al., 2018). In addition, CMs harvested from db/db mice exhibited 
increased O-GlcNAcylation modification of Beclin1 resulting in blunting of autophagy (Gélinas 
et al., 2018; Marsh et al., 2013).  Furthermore, O-GlcNAcylation modification of SNAP29 has 
been shown to impair the fusion between the autophagosome and the lysosome in HeLa cells, 
Caenorhabditis elegans, streptozotocin (STZ)-induced diabetic rats and in response to arsenic 
toxicity (Guo et al., 2014; Huang et al., 2018). 
1.8 Disease models for studying Vici syndrome 
 
Since the description of Vici syndrome in 1988 and the identification of EPG5 mutations as the 
causative factor of Vici syndrome in 2012, two animal models were generated. The first is a 
homozygous EPG5 knockout (EPG5-/-) mouse model. EPG5-/- mice were normal at birth but 
developed progressive growth retardation with reduced survival. EPG5 knockout mice showed 
the expected autophagy defect evidenced by increased accumulation of P62 and LC3IIB. 
Furthermore, EPG5 knockout mice developed progressive neurodegeneration, specifically in 
the spinal motor neurons, resembling the phenotype associated with amyotrophic lateral 
sclerosis (ALS). Although EPG5 knockout mice recapitulated the neurodegeneration 
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phenotype associated with Vici syndrome, they did not recapitulate all of the phenotypes 
associated with Vici syndrome, for instance, they did not show signs of cardiomyopathy (Zhao 
et al., 2013). Furthermore, using clustered regularly interspaced short palindromic repeats 
(CRISPR)-CRISPR associated protein 9 (CRISPR-Cas9)-directed mutagenesis, a zebrafish 
EPG5-/- mutant was generated. The EPG5-/- zebrafish showed the autophagy defect expected 
to occur as a result of EPG5 mutation. In addition, adult EPG5-/-  zebrafish recapitulated 
several phenotypes of Vici syndrome including the presence of swollen mitochondria, 
neurodegeneration evidenced by impaired motility, and variable degrees of dilated 
cardiomyopathy (Meneghetti et al., 2019).  
Taken together, the defect in autophagy observed in zebrafish and mouse EPG5 mutants 
indicated the conserved function of EPG5 across different species. In addition, despite of the 
autophagy defect, neither the mouse model nor the zebrafish model fully recapitulated the 
phenotypes observed in Vici patients. This indicates that both animal models could be 
beneficial to understand specific aspects and molecular mechanisms associated with Vici 
syndrome in vivo, however, a more relevant human disease model should be utilized to offer 
the potential of understanding molecular disease mechanisms and potential therapeutic 
targets.  
1.9 Induced pluripotent stem cells and disease modeling  
 
The introduction of induced pluripotent stem cells (iPSCs) technology in 2006 by Takahashi 
and Yamanaka is a groundbreaking achievement which holds enormous potential for stem cell 
research and therapy (Takahashi & Yamanaka, 2006). The ability of driving human iPSCs 
differentiation into several specialized cells including chamber-specific subtypes of 
cardiomyocytes such as ventricular, atrial and nodal-like cells (Cyganek et al., 2018; Devalla 
& Passier, 2018; Strauss & Blinova, 2017) allowed establishing of human in vitro platforms that 
can be utilized for in vitro drug testing, and in vitro disease modeling (Matsa et al., 2014; 
Strauss & Blinova, 2017). This overcame the scarcity of human cells and tissue especially of 
post-mitotic organs such as the heart required for in vitro disease modeling and drug testing 
platforms.  
Human iPSCs-derived cardiomyocytes (iPSC-CMs) show several characteristics of immature 
fetal cardiomyocytes, including high proliferative potential, round shape, fetal ion channel 
expression and fetal metabolism (Yang et al., 2014). Nevertheless, they could be successfully 
utilized to model different forms of cardiomyopathies including channelopathies such as long 
QT syndrome and catecholaminergic polymorphic ventricular tachycardia  (CPVT) (Itzhaki et 
al., 2012; Matsa et al., 2011; Moretti et al., 2010), dilated cardiomyopathy and hypertrophic 
cardiomyopathy (Cohn et al., 2019; Lan et al., 2013; Li et al., 2018; Lin et al., 2015; 
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Ovchinnikova et al., 2018; Sun et al., 2012)  as well as mitochondrial myopathies (Duan et al., 
2017; Dudek et al., 2016; Wang et al., 2014). Furthermore, iPSC-CMs showed potential as an 
in vitro toxicity and drug testing platform (Burridge et al., 2016; Drawnel et al., 2014; Liang et 
al., 2013; Strauss & Blinova, 2017). 
Moreover, iPSC-CMs have been shown to be a reliable in vitro disease model to study the 
cardiomyopathy associated with multiorgan syndromes such as Leopard syndrome (Carvajal-
Vergara et al., 2010). In addition, iPSC-CMs successfully recapitulated the autophagy defect 
in an in vitro disease model of Danon disease which exhibited abnormal calcium handling, 
oxidative stress and mitochondrial damage as a result of the defective autophagy process 
(Hashem et al., 2017, 2015). Taken together, previous work illustrated the potential of 
understanding detailed molecular mechanisms of Vici syndrome associated cardiomyopathy 
and testing of potential pharmacological interventions through the establishment of Vici patient-
specific iPSC-CMs as a reliable in vitro disease model. 
1.10 The generation of Vici patient-specific in vitro disease model 
 
In our group we obtained Vici patient-specific fibroblasts carrying a homologous EPG5 
mutation (c.4952+1G>A) from Dr. Mathias Gautel’s lab at King’s College London. The 
(c.4952+1G>A) mutation results in the aberrant splicing of the EPG5 transcript and the removal 
of exon 28 and introduces a frameshift and a premature stop codon at exon 29 
p.Phe1604Glyfs*20 (Cullup et al., 2013). The Vici patient-specific fibroblasts were 
reprogrammed to Vici patient-specific iPSCs using the SETMCAA lentiviral system containing 
the four reprogramming factors OCT4, SOX2, KLF4 and cMYC in a single plasmid (Streckfuss-
Bömeke et al., 2013). Three Vici iPSCs cell lines generated from the same patient (iVici 1.2, 
iVici 1.3, and iVici 1.5) were selected for further investigation. After confirming that the selected 
cell lines are pluripotent and retain the EPG5 mutation (Qi, 2016). We could differentiate Vici 
patient-specific iPSCs to iPSC-CMs following a modified version of the recently published 
approach (Cyganek et al., 2018) which yielded iPSC-CMs with more than 90% purity (Figure 
3A, B).  In order to validate the generated iVici iPSC-CMs as a reliable in vitro disease model 
of Vici syndrome, Jing Qi confirmed the presence of the autophagy defect using 
immunostaining as well as western blot analysis of autophagy markers. Interestingly, similar 
to the phenotypes described in Vici patients (Cullup et al., 2012; Miyata et al., 2014; Rogers et 
al., 2011), iVici iPSC-CMs displayed larger surface area than iPSC-CMs derived from healthy 
controls, sarcomere disorganization and reduced AKT, FOXO1, FOXO3 and mTOR 
phosphorylation (Qi, 2016). These findings indicate the reliability of the generated iVici iPSC-
CMs as an in vitro disease model of Vici syndrome.  
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Figure 3. Characterization and purity of the used iPSC-CMs used in the study. (A) 
Confocal images of WT and iVici iPSC-CMs stained with α-actinin, cardiac troponin T (cTNT), 
connexin 43 (CX43) and myosin light chain 2, ventricular isoform (MLC2V). Scale bar = 50 µm. 
(B) Flow cytometry analysis of the purity of the generated iPSC-CMs. Differentiated iPSC-CMs 
were stained with secondary antibody only as a negative control, then WT iPSC-CMs (Ctr1 
and Ctr2) and iVici iPSC-CMs (iVici1.2, iVici 1.3 and iVici 1.5) were stained with primary 
antibody against cTNT and secondary antibody to determine the percentage of 
cardiomyocytes in our culture after differentiation (Qi, 2016). Together, these data showed that 
we could differentiate Vici patient-specific iPSCs to iPSC-CMs with a purity more than 90%. 
 
 
A 
WT 
iVici 
DAPI α-actinin DAPI cTnT CX43 DAPI MLC2V 
B 
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1.11 Study aims  
 
Based on the preliminary findings in the lab (Qi, 2016), we hypothesize that due to the 
autophagy defect, iVici iPSC-CMs may accumulate several cellular defects including 
mitochondrial dysfunction, energy starvation, oxidative stress and ER stress. These defects 
will lead to chronic autophagy activation and as a result, iVici iPSC-CMs are stuck in a viscous 
cycle of defective autophagy induction, and potentiating of molecular defects, which will further 
aggravate the disease phenotype. Given that cardiac dysfunction is often accompanied by 
accumulation of aggregated proteins, oxidative stress, calcium overload, mitochondrial 
dysfunction and ER stress (Sciarretta et al., 2018), investigation of molecular defects in iVici 
iPSC-CMs due to the autophagy defect could help us better understanding the molecular 
mechanisms contributing to the development of cardiomyopathy in Vici syndrome.  
Accordingly, the first aim of my study was to provide an understanding of the molecular 
mechanisms driving cardiomyopathy development in Vici patients through investigating the 
presence of potential molecular defects in iVici iPSC-CMs including mitochondrial dysfunction, 
oxidative stress and ER stress. Furthermore, previous work showed that pharmacological 
inhibition of the enzyme OGT attenuates the autophagy defect resulting from EPG5 
knockdown in HeLa cells. My second aim was to explore whether pharmacological inhibition 
of OGT in iVici iPSC-CMs can result in improved fusion between the autophagosome and the 
lysosome and to explore the mechanism leading to the improved fusion (Figure 4). 
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Figure 4. Schematic representation of the working hypothesis of the study. Dysfunctional 
EPG5 leads to impaired fusion between the autophagosome and the lysosome. As a result, 
iVici iPSC-CMs accumulate dysfunctional mitochondria, oxidative stress and chronic ER 
stress. These cellular insults contribute to the development of cardiomyopathy and at the same 
time will further activate autophagy. Hence, iVici iPSC-CMs are stuck in a viscous cycle of 
dysfunctional autophagy induction, leading to further accumulation of cellular insults and 
cardiac dysfunction. The first aim of the study was to investigate the presence of the 
abovementioned cellular insults in iVici iPSC-CMs. Moreover, previous work illustrated the 
improved fusion between the autophagosome and the lysosome in EPG5 deficient HeLa cells 
upon pharmacological OGT inhibition. In this study, the effect of four different pharmacological 
OGT inhibitors on the fusion between the autophagosome and the lysosome was investigated
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2. Materials and methods 
 
2.1 Materials  
 
 
* All iPSC lines used in this study were generated in our lab. The iBM76 and the iWTD2 cell 
lines were generated from two different healthy donors. The iVici 1.2 and iVici 1.3 cell lines 
were generated from the same Vici patient carrying a homologous intronic mutation in EPG5 
(c.4952+1G>A). 
 
 
 
 
 
 
 
2.1.1 Cell lines 
iPSCs lines Donor Donor cell type Reprogramming 
system 
iBM76.1 and iBM76.3 
(Cyganek et al., 2018; 
Streckfuss-Bömeke et al., 
2013) 
Healthy Mesenchymal 
stem cells 
STEMCCA lentivirus  
iVici 1.2 (Qi, 2016) Vici 
syndrome 
Dermal fibroblasts STEMCCA lentivirus  
iVici 1.3 (Qi, 2016) Vici 
syndrome 
Dermal fibroblasts STEMCCA lentivirus  
iWTD 2.1 and iWTD2.3 
(Cyganek et al., 2018; 
Streckfuss-Bömeke et al., 
2013) 
Healthy Dermal fibroblasts STEMCCA lentivirus  
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2.1.2 Primary antibodies 
 
Antibody 
 
Source 
 
Cat# 
 
Dilution 
AMPK α2 polyclonal IgG (Rabbit) Bethyl Laboratories A300-508A WB: 1:1000 
AMPK α1 (pT183) + AMPK α2 
(pT172) monoclonal IgG (Rabbit) 
Abcam ab133448 WB: 1:1000 
ATF-4 monoclonal IgG (Rabbit) Cell Signaling 
Technology 
11815 WB: 1:1000 
BiP polyclonal (Rabbit) Cell Signaling 
Technology 
3183 WB: 1:1000 
EEF2/Elongation factor 2 
polyclonal IgG (Rabbit) 
Abcam ab40812 WB: 1:50,000 
IRE1α monoclonal IgG (Rabbit) Cell Signaling 
Technology 
3294 WB: 1:1000 
O-linked N-acetylglucosamine 
monoclonal IgG (Mouse) 
Abcam ab2739 WB: 1:1000 
LAMP1 monoclonal IgG1 (Mouse) Abcam ab25630 IF: 1:100 
LC3B monoclonal IgG (Rabbit) Cell Signaling 
Technology 
3868 WB: 1:1000 
IF: 1:100 
SNAP25 polyclonal IgG (Rabbit) Sigma-Aldrich S9684 WB: 1:2000 
SNAP29 monoclonal IgG (Rabbit) Abcam ab138500 WB: 1:1000 
Syntaxin17 polyclonal IgG 
(Rabbit) 
Abcam ab116113 WB: 1:500 
VAMP8 monoclonal IgG (Rabbit) Abcam ab76021 WB: 1:10,000 
 
2.1.3 Secondary antibodies 
 
Antibody 
 
Source 
 
Cat# 
 
Dilution 
Goat anti-Mouse polyclonal IgG, 
Alexa Fluor 488 
Thermo Fisher 
Scientific 
A-11001 IF: 1:400 
Goat anti-Mouse polyclonal IgG, 
Alexa Fluor 546 
Thermo Fisher 
Scientific 
A-11030 IF: 1:400 
Goat anti-rabbit polyclonal IgG, 
Alexa Fluor 488 
Thermo Fisher 
Scientific 
A-11008 IF: 1:400 
* IF: Immunofluoresence/ WB: Westernblot 
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2.1.3 Secondary antibodies cont. 
 
Antibody 
 
Source 
 
Cat# 
 
Dilution 
Goat anti-Rabbit polyclonal 
IgG, Alexa Fluor 546 
Thermo Fisher 
Scientific 
A-11035 IF: 1:400 
Goat Anti-Mouse polyclonal 
IgG (Fab specific)–Peroxidase 
Sigma-Aldrich A3682 1: 20,000 
Goat anti-rabbit IgG, HRP-
linked 
Cell Signaling 
Technology 
7074 1: 20,000 
 
2.1.4 Pharmacological agents 
 
Agent 
 
Source 
 
Cat# 
Alloxan monohydrate Sigma-Aldrich A7413 
Bafilomycin A1, from 
Streptomyces griseus 
Sigma-Aldrich B1793 
Caffeine Sigma-Aldrich C0750 
OSMI-1 Sigma-Aldrich SML1621 
PUGNAc Sigma-Aldrich A7229 
Rapamycin, from 
Streptomyces 
hygroscopicus 
Sigma-Aldrich R0395 
ST045849 TimTec NA 
ST078925 TimTec NA 
Tetracaine Sigma-Aldrich T7383 
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2.1.5 Chemicals 
 
Chemical 
 
Source 
 
Cat# 
Ammonium persulfate (APS) Bio-Rad  1610700 
30% acrylamide Rotiphorese® Roth 3029.1 
Acetone Merck 1000141011 
Bromophenol blue Fluka 18040 
Calcium chloride Roth A119 
Dithiothreitol (DTT) Applichem A1101,0025 
Digitonin Serva 19550.02 
Dimethylpimelimidat Sigma-Aldrich D8388 
Ethylenediaminetetraacetic acid (EDTA) Sigma-Aldrich E6758 
EDTA disodium salt dihydrate Klinik Apotheke, 
Dresden 
NA 
Ethylene glycol bis(β-aminoethylether) 
tetraacetic acid (EGTA) 
Roth 3054 
Gelatin from porcine skin Sigma-Aldrich 48720 
D (+)-Glucose Merck 1.08337 
Glycine Applichem 131340 
99.5% Glycerol Roth 3783 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 
Serva 25245 
LE Agarose Biozym 840004 
Lithium chloride Roth P007 
Lithium hydroxide Sigma-Aldrich 545856 
Methanol VWR 20847.307 
Magnesium chloride hexahydrate Merck 1.05833 
Nonidet™ P-40 substitute (NP40) Fluka 74385 
Nonfat dried milk powder Applichem A0830 
2- Propanol VWR 20842.312 
Ponceau S Roth 5938.1 
Potassium chloride Merck 1.04936 
Potassium dihydrogen phosphate Merck 104873 
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2.1.5 Chemicals cont. 
 
Chemical 
 
Source 
 
Cat# 
di-potassium hydrogen phosphate 
Trihydrate 
Klinik Apotheke, 
Dresden 
NA 
Phenylmethylsulfonyl fluoride (PMSF) Sigma-Aldrich P7626 
Sodium dodecyl sulfate (SDS) Serva 20765 
Sodium borate Merck 106308 
Sodium chloride Roth 3957 
Sodium deoxycholate Sigma-Aldrich D6750 
Sodium phosphate monobasic Sigma-Aldrich S0751 
Sodium hydroxide solution Merck 1.09956 
Sodium fluoride Roth 4503.1 
Trichloroacetic acid (TCA) Roth 8789.2 
Tetramethylethylenediamine (TEMED) Bio-Rad 1610801 
Tris ultrapure Applichem A1086 
Triton X100 Sigma-Aldrich X100 
TWEEN20 Serva 37470.01 
 
2.1.6 Kits and dyes 
 
Kit/Dye 
 
Source 
 
Cat# 
CM-H2DCFDA Invitrogen C6827 
Fura-2, AM, cell permeant Thermo Fisher 
Scientific 
F1221 
HDGreen® Plus Safe DNA Dye Intas Science 
Imaging 
ISII-HDGreen Plus 
MitoTracker™ Green FM Thermo Fisher 
Scientific 
M7514 
MitoSOX™ Red Thermo Fisher 
Scientific 
M36008 
Pierce™ BCA Protein Assay Thermo Fisher 
Scientific 
23227 
RNeasy Mini Kit 250 Prep Qiagen 74106 
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2.1.6 Kits and dyes cont. 
 
Kit/Dye 
 
Source 
 
Cat# 
SuperSignal™ West Dura Extended 
Duration Substrate 
Thermo Fisher 
Scientific 
34076 
SuperSignal™ West Femto Maximum 
Sensitivity 
Thermo Fisher 
Scientific 
34096 
SV Total RNA Isolation System Promega Z3105 
Tetramethylrhodamine, Methyl Ester, 
(TMRM) 
Thermo Fisher 
Scientific 
T668 
 
2.1.7 Immunofluorescence 
 
Reagent/Resource 
 
Source 
 
Cat# 
Bovine serum albumin (BSA) Sigma-Aldrich F7524 
Hoechst 33342, Trihydrochloride, 10 mg/ml Thermo Fisher 
Scientific 
H3570 
Fluoromount-G Southern Biotech 0100-01 
Glass coverslips (20 mm diameter) Langenbrinck 01-0020/1 
 
2.1.8 Molecular biology 
 
Reagent/Resource 
 
Source 
 
Cat# 
dNTP Mix Bioline BIO-39029 
Go Taq G2 DNA Polymerase 500u Promega M7845 
GeneRuler 100 bp DNA Ladder Thermo Fisher 
Scientific 
SM0241 
MuLV Reverse transcriptase 5000u Thermo Fisher 
Scientific 
N8080018 
Protector RNAse Inhibitor 2000u Thermo Fisher 
Scientific 
N8080119 
Oligo (dt) 16 Primer Thermo Fisher 
Scientific 
N8080128 
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2.1.8 Molecular biology cont. 
 
Reagent/Resource 
 
Source 
 
Cat# 
Nuclease free water Promega P119C 
 
2.1.9 Immunoblot and immunoprecipitation 
 
Reagent/Resource 
 
Source 
 
Cat# 
Protein A agarose Iba Lifesciences 6-2010-001 
Ahlstrom Blotting paper Neolab 2-4325 
Amersham™ western blotting membranes, 
nitrocellulose 
Sigma-Aldrich GE10600002 
 
cOmplete™, Mini Protease Inhibitor Cocktail Roche 04693124001 
4–15% Mini-PROTEAN® TGX™ Precast 
Protein Gels 
Bio-Rad 4561084 
PhosSTOP Roche 4906837001 
Precision Plus Protein™ Dual Color 
Standards 
Bio-Rad 1610374 
 
 
2.1.10 Cell culture media and reagents 
 
Reagent/Resource 
 
Source 
 
Cat# 
Albumin, human recombinant, expressed in 
rice 
Sigma-Aldrich A9731 
 
L-ascorbic acid 2-phosphate Sigma-Aldrich A8960 
B27 Supplement Thermo Fisher 
Scientific 
17504044 
CHIR99021 Merck 361559 
Collagenase B, Animal Origin Free CLSAFB Worthington 
Biochemical 
LS004147 
 
Dulbecco's Modified Eagle Medium 
(DMEM)/F-12 
Thermo Fisher 
Scientific 
11320074 
 
Dimethyl sulfoxide (DMSO) Sigma-Aldrich D8418 
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2.1.10 Cell culture media and reagents cont. 
 
Reagent/Resource 
 
Source 
 
Cat# 
Essential 8 (E8) Medium Kit Thermo Fisher 
Scientific 
A1517001 
Fetal Bovine Serum (FBS) Sigma-Aldrich F7524 
Geltrex (Growth Factor Reduced), 12-18 
mg/ml 
Thermo Fisher 
Scientific 
A1413302 
Hydroxyethyl-piperazineethane-sulfonic acid 
(HEPES) buffer, 1 M, (pH 7.0-7.6) 
Sigma-Aldrich H0887 
Inhibitor of WNT production-2 (IWP2) Merck 681671 
1X Phosphate-buffered saline (PBS) Sigma-Aldrich D8537 
Roswell Park Memorial Institute (RPMI) 
1640 medium with Glutamax and HEPES 
Thermo Fisher 
Scientific 
72400021 
RPMI 1640 without HEPES without Glucose Thermo Fisher 
Scientific 
11879020 
Sodium DL-lactate solution (7 M) Sigma-Aldrich L4263 
Trypsin-EDTA (0.25%) Thermo Fisher 
Scientific 
25200056 
Thiazovivin (TZV) Merck 420220 
Versene solution Thermo Fisher 
Scientific 
15040033 
 
2.1.11 Plastic disposals 
 
Resource 
 
Source 
 
Cat# 
Cell scraper 25 cm Sarstedt 83.1830 
CELLSTAR® 15 ml, CONICAL BOTTOM, 
sterile tube 
Greiner Bio-One 188271 
CELLSTAR® 50 ml CONICAL BOTTOM, 
sterile tube 
Greiner Bio-One 227261 
Cell culture plate 6 well Starlab CC7682-7506 
Cell culture plate 12 well Starlab CC7682-7512 
Cell culture plates 96 well Greiner Bio-One 655090 
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2.1.11 Plastic disposals cont.  
 
Resource 
 
Source 
 
Cat# 
Corning® Serological pipettes 5 mL Sigma-Aldrich CLS4487 
Corning® Serological pipettes 10 mL Sigma-Aldrich CLS4488 
Corning® Serological pipettes 25 mL Sigma-Aldrich CLS4489 
Corning® 0.1 – 10 μL filter tips Sigma-Aldrich CLS4135 
Corning® 1 – 20 μL filter tips Sigma-Aldrich CLS4136 
Corning® 1 – 200 μL filter tips Sigma-Aldrich CLS4138 
Corning® 100 – 1000 μL filter tips Sigma-Aldrich CLS4140 
Falcon® 100 µm Cell Strainer Corning 352360 
Filtropur S 0.2 µm Sarstedt 83.1826.102 
Greiner 96 well plates F-bottom Greiner bio 655101 
PCR SingleCap 8er-SoftStrips 0.2 ml Biozym 710980 
Steriflip-GP 0.22 µm Merck SCGP00525 
 
2.1.12 Appliances 
 
Appliance 
 
Source 
Axiovert 100 microscope Carl Zeiss 
BD FACS CantoTM II BD Biosciences 
BZ-X710 microscope Keyence 
Eppendorf® Mastercycler® Nexus Thermal 
Cyclers 
Sigma-Aldrich 
Fireboy plus Integra Biosciences 
Fusion FX Vilber Lourmat 
Hera Safe 2020 Thermo Fisher Scientific 
Heracell™ VIOS 160i CO2-Incubator Thermo Fisher Scientific 
Heraeus™ Fresco™ 21 microcentrifuge Thermo Fisher Scientific 
Heraeus™ Megafuge™ 8 Thermo Fisher Scientific 
IX70 microscope Olympus 
LSM510 Carl Zeiss 
LSM880 airyscan Carl Zeiss 
MC170 HD camera Leica 
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2.1.12 Appliances cont.  
 
Appliance 
 
Source 
MyoCam Ionoptix 
MyoPacer field stimulator Ionoptix 
NanoDrop™ One/One Thermo Fisher Scientific 
PowerPac™ Power Supply Bio-Rad 
Pipetus® Pipette boy Hirschmann 
Synergy HTX Multi-Mode plate reader BioTek 
TC-344B temperature controller Warner Instruments 
Thermomixer compact Sigma-Aldrich  
Video Power Ionoptix 
 
2.1.13 Software 
 
Software 
 
Source 
BD FACS Diva Software version 8.0.2   BD Biosciences 
Fiji (Schindelin et al., 2012) 
Flowing software Perttu Terho at the Turku Centre for 
Biotechnology 
IonWizard Ionoptix 
LabChart 7 ADInstruments 
Motion vector NA 
Mendelay Elsevier 
Prism 8 GraphPad Software 
Zen blue Carl Zeiss 
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2.1.14 List of primers 
 
Primer 
 
Sequence 
Melting 
temperature 
PCR Product 
size 
EPG5 1 For CACTCAGGTCTGGTTTGCCT 59.4°C  
287 base pairs EPG5 1 Rev GTCCCGGACGGTGAAGATAC 61.4°C 
EPG5 2 For AGAGACGTTTGACCGAGGTG 59.4°C  
288 base pairs EPG5 2 Rev ACTCCATCCACAGATCCTGC 59.4°C 
GAPDH For AGAGGCAGGGATGATGTTCT 57.3°C  
258 base pairs GAPDH Rev TCTGCTGATGCCCCCATGTT 59.4°C 
 
* All primers were obtained from Eurofins genomics. 
*EPG5 primer pair 1covers part of exon 22 
*EPG5 primer pair 2 Covers part of exons 23 and 24.  
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2.2 Preparation of stock solutions 
 
 
2.2.1 Pharmacological agents 
Agent Stock 
concentration 
Preparation 
 
Alloxan monohydrate 
 
1 M 
• Dissolve 0.4 g alloxan in 2.5 ml 
B27 medium 
• Filter sterilize  
• Store at 4°C 
 
Bafilomycin A1  
 
200 μM 
• Dissolve 10 μg bafilomycin A1 in 
80.2 μl DMSO 
• Aliquot 
• Store in -20°C 
 
 
Caffeine 
 
 
10 mM 
• Dissolve 10.42 mg caffeine in 10 
ml Tyrode solution without sodium 
and calcium 
• Prepare fresh for each experiment 
 
OSMI-1 
 
20 mM 
• Dissolve 5 mg OSMI-1 in 444 µl 
DMSO 
• Aliquot 
• Store in -20°C 
 
PUGNAc 
 
40 mM 
• Dissolve 5 mg PUGNAc in 354 µl 
DMSO 
• Aliquot 
• Store in -20°C 
 
Rapamycin  
 
100 mM 
• Dissolve 1 mg rapamycin in 11 µl 
DMSO 
• Aliquot 
• Store in -20°C 
 
ST045849 
 
50 mM 
• Dissolve 5 mg ST045849 in 224 µl 
DMSO 
• Aliquot 
• Store in -20°C 
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2.2.1 Pharmacological agents cont. 
Agent Stock 
concentration 
Preparation 
 
ST078925 
 
50 mM 
• Dissolve 5 mg ST078925 in 246 µl 
DMSO 
• Aliquot 
• Store in -20°C 
 
Tetracaine 
 
200 mM 
• Dissolve 264.36 mg tetracaine in 5 
ml ethanol 
• Aliquot 
• Store in -20°C 
 
2.2.2 Chemicals 
Chemical Stock 
concentration 
Preparation 
 
Calcium chloride 
 
1 M 
• Dissolve 27.7 g calcium chloride in 
250 ml Milli-Q H2O 
• Store at room temperature 
 
 
Digitonin 
 
 
5% 
• Dissolve 100 mg digitonin in 2 ml 
Milli-Q H2O 
• Heat at 90°C with constant stirring 
for 30 minutes, protected from light 
• Store at 4°C 
 
 
EDTA pH 8.0 
 
 
0.5 M 
• Dissolve 5.8 g EDTA in 30 ml Milli-
Q H2O 
• Adjust pH to 8.0 with sodium 
hydroxide 
• Complete to 40 ml Milli-Q H2O 
• Store at room temperature 
 
 
Gelatin 
 
 
1% 
• Dissolve 1 g gelatin in 100 ml Milli-
Q H2O 
• Heat at 50°C with constant stirring 
until complete dissolution. 
• Autoclave to sterilize, store at 4°C 
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2.2.2 Chemicals cont. 
Chemical Stock 
concentration 
Preparation 
 
 
Glycine pH 2.5 
 
 
100 mM 
• Dissolve 7.5 g glycine in 900 ml 
Milli-Q H2O 
• Adjust pH to 2.5 using hydrochloric 
acid 
• Complete to 1-liter with Milli-Q H2O 
• Store at room temperature 
 
Magnesium chloride 
 
1 M 
• Dissolve 50.8 g magnesium 
chloride in 250 ml Milli-Q H2O 
• Store at room temperature 
 
PMSF 
 
200 mM 
• Dissolve 0.35 g PMSF in 10 ml 
isopropanol 
• Store at room temperature 
 
 
 
Sodium borate pH 9.0 
 
 
 
100 mM 
• Dissolve 38.15 g sodium borate in 
900 ml Milli-Q H2O 
• pH is usually 9.0 directly after 
preparation  
• Adjust pH using boric acid if 
needed 
• Complete to 1-liter with Milli-Q H2O 
• Store at room temperature 
 
Sodium chloride 
 
1.5 M 
• Dissolve 3.5 g sodium chloride in 
40 ml Milli-Q H2O 
• Store at room temperature 
 
Sodium phosphate 
monobasic 
 
1 M 
• Dissolve 29.9 g sodium phosphate 
monobasic in 250 ml Milli-Q H2O 
• Store at room temperature 
 
Sodium fluoride 
 
1 M 
• Dissolve 420 mg sodium fluoride in 
10 ml Milli-Q H2O 
• Store at room temperature 
 
SDS 
 
10% 
• Dissolve 4 g SDS in 40 ml Milli-Q 
H2O and store at room temperature 
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2.2.2 Chemicals cont. 
Chemical Stock 
concentration 
Preparation 
 
 
Tris-HCl pH 8.0 
 
 
1.5 M 
• Dissolve 7.27 g Tris in 30 ml Milli-Q 
H2O 
• Adjust pH to 8.0 with hydrochloric 
acid 
• Complete to 40 ml with Milli-Q H2O 
• Store at room temperature 
 
 
Tris-HCl pH 7.5 
 
 
1 M 
• Dissolve 4.85 g Tris in 30 ml Milli-Q 
H2O 
• Adjust pH to 7.5 with hydrochloric 
acid 
• Complete to 40 ml with Milli-Q H2O 
• Store at room temperature 
 
 
Tris-HCl pH 6.8 
 
 
0.5 M 
• Dissolve 15.14 g Tris in 225 ml 
Milli-Q H2O 
• Adjust pH to 6.8 with hydrochloric 
acid 
• Complete to 250 ml with Milli-Q 
H2O 
• Store at room temperature 
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2.2.3 Cell culture reagents 
Reagent Stock 
concentration 
Preparation 
 
CHIR99021 
 
12 mM 
• Dissolve 5 mg CHIR99021 in 
894 µl DMSO 
• Aliquot 
• Store in -20°C 
 
IWP2 
 
5 mM 
• Dissolve 10 mg IWP2 in 4.28 
ml DMSO and incubate for 10 
minutes at 37°C 
• Aliquot 
• Store in -20°C 
 
Lactate / HEPES 
 
1 M 
• Dilute 3 ml sodium DL-lactate 
solution (7 M) in 18 ml 1 M 
HEPES solution  
• Aliquot 
• Store in -20°C 
 
TZV 
 
2 mM 
• Dissolve 10 mg TZV in 16.06 
ml DMSO  
• Aliquot 
• Store in -20°C 
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2.2.4 Dyes 
Reagent Stock 
concentration 
Preparation 
 
CM-H2DCFDA 
 
1 mM 
• Dissolve the content of one 
tube (50 µg) in 86 µl DMSO 
• Store in -20°C 
 
Fura-2 AM 
 
500 µM 
• Dissolve the content of one 
tube (50 µg) in 100 µl DMSO 
• Aliquot  
• Store in -20°C 
 
MitoTracker™ Green FM 
 
1 mM 
• Dissolve the content of one 
tube (50 µg) in 74.5 µl DMSO 
• Aliquot 
• Store in -20°C 
 
MitoSOX™ Red 
 
5 mM 
• Dissolve the content of one 
tube (50 µg) in 13 µl DMSO 
• Store in -20°C 
 
TMRM 
 
10 mM 
• Dissolve the content of one 
tube (25 mg) in 5 ml DMSO 
• Aliquot and store in -20°C 
 
* Preparation of stock solutions of staining dyes was followed according to the manufacturer 
protocol.  
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2.3 Composition of media and buffers  
 
 
2.3.1 Cell culture media 
Medium Composition 
 
B27 medium 
• 500 ml RPMI 1640 with HEPES and 
GlutaMax 
• 10 ml B27 Supplement 
 
Cardiac differentiation medium 
• 500 ml RPMI 1640 with HEPES and 
GlutaMax 
• 250 mg albumin 
• 100 mg L-ascorbic acid 2-phosphate 
 
 
Cardiac selection medium 
• 500 ml RPMI 1640 without Glucose 
without HEPES 
• 2 ml 1 M lactate/HEPES 
• 250 mg albumin 
• 100 mg L-ascobic acid 2-phosphate 
• Filter sterilize  
 
Cardiac digestion medium 
• B27 medium 
• 20% inactivated FBS 
• 1 μl/ml 2 mM TZV 
 
Collagenase B 
• RPMI 1640 with HEPES and GlutaMax 
• 1 mg/ml collagenase B 
• Filter sterilize 
 
iPSC-CMs cryopreservation medium 
 
• 8 ml FBS 
• 2 ml DMSO 
• 2 μl/ml 2 mM TZV  
 
iPSCs cryopreservation medium 
 
• 8 ml E8 medium  
• 2 ml DMSO 
• 2 μl/ml 2 mM TZV 
E8 medium • 500 ml E8 basal medium 
• 10 ml E8 supplement 
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2.3.2 Calcium imaging buffers 
Buffer Composition/Preparation 
 
 
 
 
Tyrode solution without sodium and 
calcium 
• 2.925 g lithium chloride 
• 0.149 g potassium chloride 
• 1.902 g EGTA 
• 0.5 ml (1 M) magnesium chloride 
• 0.901 g glucose 
• 1.192 g HEPES 
• Complete to 500 ml with Mili-Q-H2O 
• Adjust pH to 7.3 with lithium hydroxide 
• Store at 4°C 
 
 
 
 
Tyrode solution with 1.8 mM calcium  
• 4.03 g sodium chloride  
• 0.149 g potassium chloride 
• 0.9 ml (1 M) calcium chloride  
• 0.5 ml (1 M) magnesium chloride 
• 0.165 ml (1 M) sodium phosphate 
monobasic 
• 0.901 g glucose 
• 1.192 g HEPES 
• Complete to 500 ml with Mili-Q-H2O 
• Adjust pH to 7.3 with sodium hydroxide 
• Store at 4°C 
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2.3.3 Immunoblot buffers 
Buffer Composition/Preparation 
10% APS • 0.1 mg APS/µl Milli-Q H2O 
 
Blot buffer 
 
• 6.05 g Tris 
• 28.8 g glycine 
• 400 ml methanol  
• Complete to 2-liters with Mili-Q-H2O 
• Store at 4°C 
 
10X electrophoresis running buffer 
• 30.2 g Tris 
• 144 g glycine 
• 10 g SDS  
• Dissolve in 1-liter Mili-Q-H2O 
• Store at room temperature 
 
 
 
6X Lämmli buffer (Laemmli, 1970) 
 
• 3 g SDS 
• 15 mg bromophenol blue 
• 15 g glycerol 99.5% 
• 3 ml 0.5 M Tris-HCl pH 6.8 
• 2.3 g DTT  
• Dissolve in 25 ml Mili-Q-H2O 
• Warm all ingredients except the DTT until 
they are dissolved, then add DTT 
• Store at -20°C 
 
Ponceau S solution 
• 0.5 g Ponceau S 
• 1 ml TCA 
• Dissolve in 100 ml Mili-Q-H2O 
• Store at room temperature 
 
 
RIPA lysis buffer 
• 3 ml 1 M Tris-HCl pH 7.5  
• 0.2 ml 0.5 M EDTA pH 8.0  
• 10 ml 1.5 M sodium chloride 
• 1 ml NP-40  
• 1 ml 10% SDS  
• Complete to 100 ml with Mili-Q-H2O  
• Aliquot and store at -20°C 
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2.3.3 Immunoblot buffers cont. 
Buffer Composition/Preparation 
 
 
10X TBS 
• 242.28 g Tris 
• 87.65 g sodium chloride  
• Dissolve in 2-liters Mili-Q-H2O 
• Adjust pH to 7.5 with hydrochloric acid 
 
0.1% TBST 
• 1X TBS 
• 0.1% TWEEN20  
• In Mili-Q-H2O 
 
2.3.4 Immunoprecipitation buffers 
Buffer Composition/Preparation 
 
2X Lysis buffer 
• 2 ml 1.5 M sodium chloride 
• 260 μl 1.5 M Tris-HCl pH 8.0 
• 400 μl 1 M sodium fluoride  
• 40 μl 0.5 M EDTA pH 8.0 
• 100 μl 200 mM PMSF  
• Complete to 10 ml with Mili-Q-H2O 
 
Solubilization buffer 
• 5 ml 2X lysis buffer 
• 1 ml 5% digitonin 
• 150 μl NP-40 
• 100 μl Triton-X100 
• Complete to 10 ml with Mili-Q-H2O 
Equilibration buffer • 1 ml 2X lysis buffer  
• 1 ml Mili-Q-H2O 
0.1 M Potassium phosphate buffer pH 
7.4 (KPi) 
• 12.12 g di-potassium hydrogen phosphate 
Trihydrate 
• 4.14 g potassium dihydrogen phosphate 
• Dissolve in 1-liter Mili-Q-H2O 
 
Wash buffer 
• 5 ml 2X lysis buffer 
• 200 μl 5% digitonin 
• 20 μl NP-40  
• Complete to 10 ml with Mili-Q-H2O  
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2.3.5 Immunostaining solutions 
Solution Composition 
Methanol/acetone fixation solution • 70% Methanol 
• 30% Acetone 
BSA blocking solution • 1% BSA in 1X PBS 
 
2.3.6 Molecular biology reagents 
Reagent Composition 
 
50X TEA buffer 
• 242 g Tris 
• 37.2 g EDTA disodium salt dihydrate 
• 57.1 ml TCA 
• Complete to 1-liter with Mili-Q-H2O 
 
1.5% TEA agarose gel 
• 3 g LE agarose 
• Dissolve in 200 ml 1X TEA buffer 
• Boil until completely dissolved 
• Leave to cool at room temperature 
• Add 14 μl HDGreen® Plus Safe DNA Dye 
• Pour gel in the pre-assembled chamber  
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2.4 Methods 
 
2.4.1 Cell culture and pharmacological treatments 
 
2.4.1.1 Cultivation and passaging of iPSCs  
 
For feeder-free cultivation of human iPSCs, 6-well plates were pre-coated with 17 μg/cm2 
geltrex and 12-well plates with 21 μg/cm2 geltrex. IPSCs were cultured in E8 medium with daily 
medium change. Upon reaching 80-90% confluency, iPSCs were passaged. Briefly, iPSCs 
were washed once with versene solution and then incubated in fresh versene solution for 4-5 
minutes at room temperature. The versene solution was aspirated and cells were dissociated 
in E8 medium supplemented with 2 µM TZV via pipetting up and down with 1 ml pipette. The 
dissociated iPSCs were seeded into new geltrex-coated cell culture plates in E8 medium 
supplemented with 2 µM TZV. Medium was changed to E8 without TZV 24 hours after 
passaging. For iPSCs maintenance, iPSCs were passaged into six well plates, whereas for 
differentiation into iPSC-CMs, iPSCs were passaged into 12 well plates.   
2.4.1.2 Differentiation of WT iPSCs into iPSC-CMs 
 
For the differentiation of WT iPSCs derived from two healthy donors (iBM76 and iWTD2) into 
iPSC-CMs, a protocol was followed as previously described (Cyganek et al., 2018). Briefly, at 
85 to 95% iPSCs confluency, mesodermal induction was initiated (Day 0) by culturing iPSCs 
in cardiac differentiation medium supplemented with 4 µM CHIR99021 for 48 hours. After 48 
hours (Day 2), iPSCs were cultured in cardiac differentiation medium supplemented with 5 µM 
IWP2 for 48 hours for cardiac lineage induction. After cardiac linage induction (Day 4), iPSCs 
were incubated in cardiac differentiation medium without any supplements till day 8 with 
medium change at day 6. At day 8, cardiac differentiation medium was changed to B27 
medium. First beating was observed around day 8-12. Differentiation efficiency was 
determined by observation of contracting cells and only cultures with ≥ 90% of contracting 
areas were used for further experiments. 
2.4.1.3 Differentiation of iVici iPSCs into iPSC-CMs 
 
For differentiation of iVici iPSCs derived from the patient with Vici syndrome (iVici1.2 and 
iVici1.3) into iPSC-CMs, the same protocol described for WT iPSCs was followed with slight 
modifications. At 80-90% confluency of iVici iPSCs, mesodermal induction (Day 0) was 
initiated by culturing iVici iPSCs in cardiac differentiation medium supplemented with 4 µM 
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CHIR99021 for 24 hours. After 24 hours (Day 1), medium was changed to cardiac 
differentiation medium without any supplements for 48 hours. After 48 hours (Day 3), iVici 
iPSCs were cultured in cardiac differentiation medium supplemented with 2.5 µM IWP2 for 48 
hours. After 48 hours (Day 5) iVici iPSCs were cultured in differentiation medium without any 
supplements until day 8 when medium was changed to B27 medium. First beating was 
observed around day 10-14. Differentiation efficiency was determined by observation of 
contracting cells and only cultures with ≥ 90% of contracting areas were used for further 
experiments.  
2.4.1.4 Digestion of iPSC-CMs for long term culture and experiments  
 
On differentiation day 15-20, beating iPSC-CMs were digested into lower density for long term 
culture. First, iPSC-CMs were incubated in 1 mg/ml collagenase B in RPMI 1640 with HEPES 
and GlutaMax for one to two hours at 37°C. The detached cell clusters were transferred to 15 
ml falcon tube and centrifuged for 5 minutes at 200xg. Afterwards, the cell clusters were 
incubated in 0.25% trypsin-EDTA for 5 minutes to singularize the iPSC-CMs. This was followed 
by the addition of cardiac digestion medium to inactivate trypsin and centrifugation for 5 
minutes at 200xg. Cells were then re-suspended in cardiac digestion medium and counted. 
Subsequently, 0.8 million cells/well were cultured in geltrex-coated six well plates in cardiac 
digestion medium for 24 hours. After 24 hours, medium was changed to B27 medium with 
medium change every two days. To prepare for experiments, 75-80-day-old iPSC-CMs with 
differentiation efficiency ≥ 90% were digested into the appropriate cell culture plate with the 
appropriate cell number using the same protocol described above.  
2.4.1.5 Selection of iPSC-CMs  
 
After the first digestion of iPSC-CMs around day 15-20, purity of the digested iPSC-CMs was 
visually inspected. Wells which contained ≥ 50% fibroblasts were cultured in cardiac selection 
medium instead of B27 medium for four days, with medium change every two days. Then, 
medium was switched back to B27 medium with medium change every two days. Selection of 
iPSC-CMs is possible until day 30 of differentiation.  
2.4.1.6 Cryopreservation and thawing of iPSCs and iPSC-CMs 
 
For long-term preservation of iPSCs, cryopreservation was performed. Upon reaching 70-90% 
confluency, same steps for passaging of iPSCs were followed except that in the last step, 
iPSCs were dissociated in 1 ml E8 medium and 1 ml of iPSCs cryopreservation medium was 
added. The iPSCs suspension was mixed gently and 1 ml of the iPSCs suspension was 
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transferred to pre-labeled cryopreservation tube and subsequently stored in an isopropanol 
chamber for one day at -80°C to allow slow freezing of the cells to prevent the formation of ice 
crystals. On the next day, the cryopreserved cells are stored in liquid nitrogen for long-term 
storage. For thawing of the cryopreserved iPSCs, the cryopreservation tube was thawed in 
37°C water bath and the content was slowly transferred to 10 ml cold E8 medium and then 
centrifuged at 200xg for 5 minutes. Supernatant was carefully aspirated, and the iPSCs pellet 
was re-suspended in E8 medium supplemented with 2 μM TZV and plated on geltrex-coated 
plates. 24 hours after thawing, medium was changed to E8 medium without TZV.  
For long-term preservation of iPSC-CMs, cryopreservation was performed between 
differentiation day 30 and 45. Same protocol for iPSC-CMs digestion was followed, except that 
in the last step, the dissociated iPSC-CMs were re-suspended in 750 µl FBS and 750 µl iPSC-
CMs cryopreservation medium was added. The cell suspension was transferred to pre-labelled 
cryopreservation tube and subsequently stored in liquid nitrogen as described above. For 
thawing of cryopreserved iPSC-CMs, the cryopreservation tube was thawed in 37°C water 
bath and the content was slowly transferred to 10 ml cold B27 medium, and then centrifuged 
at 200xg for 5 minutes. Supernatant was carefully aspirated, and the iPSC-CMs pellet was re-
suspended in cardiac digestion medium and plated on geltrex-coated cell culture plates. 24 
hours after thawing, medium was changed to B27 medium.  
2.4.1.7 Pharmacological treatments 
 
All pharmacological treatments were initiated 5-6 days after digestion of iPSC-CMs at day 75-
80. Pharmacological agents were diluted in B27 medium to reach the final working 
concentration and the appropriate vehicle control was used for each agent. Alloxan stock 
solution was prepared in B27 medium. Alloxan stock solution was diluted in B27 medium to 
reach the final working concentration of 5 mM whereas the stock solutions of the OGT inhibitors 
ST078925, ST045849, and OSMI-1 were prepared in DMSO. ST078925, ST045849, and 
OSMI-1 stock solutions were diluted in B27 medium to a reach the final working concentration 
of 25 μM, 25 μM and 20 μM, respectively. The treatment duration with the pharmacological 
agents ranged from 24 hours to 7 days. The specific duration of treatment for each 
pharmacological agent is indicated in the results part. 
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2.4.2 Immunostaining 
 
For immunostaining of iPSC-CMs, iPSC-CMs were digested as described above and cultured 
on geltrex-coated coverslips in 12-well plates to recover for at least one week with B27 medium 
change every two days. IPSC-CMs were fixed in methanol/acetone fixation solution for 10 
minutes at -20°C. This was followed by 3 times washes in 1X PBS and incubation in 1% BSA 
blocking solution overnight (O/N) at 4°C. On the next day, iPSC-CMs were incubated in the 
primary antibody diluted in blocking solution O/N at 4°C. On the next day, iPSC-CMs were 
washed three times in 1X PBS and incubated in the secondary antibody diluted in blocking 
solution for 1 hour at room temperature protected from light. After incubation in the secondary 
antibody solution, iPSC-CMs were washed three times in 1X PBS and the nuclei were 
counterstained with Hoechst 33342 (12.5 µg/ml). IPSC-CMs were washed three times in 1X 
PBS and coverslips were mounted using fluoromount-G on glass slides. Coverslips were 
sealed with nail polish. Images were then captured using the LSM510 or the LSM880 airyscan 
microscopes. 
2.4.3 Morphology analysis of mitochondrial network 
 
To visualize mitochondrial network structure in iPSC-CMs, iPSC-CMs were digested and 
cultured on geltrex-coated coverslips in 12-well plates. 50,000 iPSC-CMs were added per well 
and were allowed to recover for at least one week with B27 medium change every two days. 
For mitochondrial staining, iPSC-CMs were washed twice with warm 1X PBS. Then 1 ml of 
mitochondrial staining solution consisting of 100 nM MitoTracker™ green FM in 1X PBS was 
added per well for 30 minutes at 37°C. Afterwards, iPSC-CMs were washed twice with 1X 
PBS, and coverslips were mounted on glass slides using 1X PBS to prevent drying out of 
samples and to maintain live cells in good condition during imaging. Mounted iPSC-CMs were 
imaged directly using the Keyence fluorescent microscope BZ-X710, GFP filter set, 60x lens 
oil immersion with numerical aperture 1.4. Multiple images of different fields were taken per 
coverslip. To obtain quantifiable indicator of mitochondrial morphology (elongated or 
fragmented), calculating of the mitochondrial aspect ratio was adapted following the previously 
published protocols using ImageJ (De Vos et al., 2005; O-Uchi et al., 2013). In brief, convolve 
filter to obtain isolated and equalized fluorescent pixels (Figure 5B) was applied to the original 
image (Figure 5A), followed by converting the image to a binary mask (Figure 5C). Then, the 
particle analyzer tool was applied where the particle size limit was set in the range of 30-
100,000,000-pixel units. After applying the particle analyzer tool, the analyzed mitochondrial 
structures were outlined (Figure 5D) and a table was generated with several parameters 
including the major and minor axis of an ellipse fitted around each mitochondrial structure 
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analyzed. The aspect ratio was calculated by dividing the major axis by the minor axis of an 
ellipse, where a higher aspect ratio indicates elongated mitochondria and a lower aspect ratio 
indicates fragmented mitochondria (Figure 5E).   
 
 
 
 
 
 
 
 
 
Figure 5. Stepwise illustration of calculating mitochondrial aspect ratio using imageJ. 
Original image (A) was opened using ImageJ and a convolve filter was applied to obtain 
isolated and equalized fluorescent pixels (B). After applying the convolve filter, the image was 
converted to a binary mask (C), followed by applying the particle analyzer tool. Applying the 
particle analyzer tool generated a new image where all quantified mitochondrial structures are 
outlined (D) and a table with the quantified parameters for each mitochondrial structure is given 
(E). From the quantified parameters, the mitochondrial aspect ratio can be calculated by 
dividing the major axis by the minor axis of an ellipse (red square).  
2.4.4 Detection of general oxidative stress using microplate reader 
 
For detection of general oxidative stress levels in iPSC-CMs in 96-well cell culture plates, 
iPSC-CMs were digested into geltrex-coated 96-well cell culture plates, where 35,000 cells 
were added per well. IPSC-CMs were allowed to recover for one week after digestion with B27 
medium change every two days prior to measurement. On the day of the measurement, visual 
inspection of each well ensured confluency and viability of iPSC-CMs. Each well was washed 
twice with warm 1X PBS, and incubated for 30 minutes with 5 μM CM-H2DCFDA diluted in 1X 
PBS at 37°C. After 30 minutes, each well was washed twice with 1X PBS, then CM-H2DCFDA 
fluorescence intensity was measured directly using the Synergy HTX Multi-Mode Reader with 
excitation set at 495 nm +/- 9 nm and emission set at 520 nm +/- 9 nm.  
A B C 
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2.4.5 Flow cytometry analysis of iPSC-CMs  
 
Flow cytometry analysis was adapted in this study to quantify general oxidative stress, 
mitochondrial-derived superoxide and mitochondrial membrane potential in iPSC-CMs using 
the dyes CM-H2DCFDA, MitoSOX red and TMRM, respectively. Briefly, iPSC-CMs were 
digested into geltrex-coated 6-well or 96-well plates, where equal number of WT and iVici 
iPSC-CMs were added per well (1.5 million cells per well of six-well plate, and 35,000 cells per 
well of 96-well plate) and were allowed to recover for at least one week with B27 medium 
change every two days. 96-well plates were used for high throughput flow cytometry analysis. 
Importantly, the fluorescence intensity of dyes used is sensitive to the number of cells per well, 
the higher the number of cells per well, the lower the fluorescence intensity of the used dyes. 
Hence it was critical for this experiment to ensure that equal number of WT and iVici iPSC-
CMs were added per well to obtain reliable results. To measure general oxidative stress levels, 
iPSC-CMs were incubated in 5 μM CM-H2DCFDA diluted in 1X PBS for 30 minutes at 37°C. 
To measure mitochondrial-derived superoxide levels, iPSC-CMs were incubated in 5 μM 
MitoSOX red diluted in 1X PBS for 30 minutes at 37°C. To measure mitochondrial membrane 
potential, iPSC-CMs were incubated in 100 nM TMRM diluted in 1X PBS for 30 minutes at 
37°C. Independent of the dye used for iPSC-CM staining, on the day of the analysis, cells were 
washed three times using 1X PBS prior to adding the staining solution. After incubating the 
iPSC-CMs in the staining solution, iPSC-CMs were washed three times in 1X PBS, 
singularized and detached using trypsin and finally suspended in 250 µl FACS buffer (1X PBS 
with 5% FBS). For FACS analysis, BD FACSCantoTM II Flow Cytometer with the BD FACS 
Diva Software version 8.0.2 was used to analyze the iPSC-CMs samples and 50,000 events 
were collected per sample. The raw data were then evaluated using the free flow cytometry 
data analysis software “Flowing Software” version 2.5.1.  
2.4.6 Video recording of iPSC-CMs and analysis of beating parameters  
 
To analyze the beating properties of iPSC-CMs, iPSC-CMs were digested and cultured in 
geltrex-coated 6-well plates, where 1.5 million cells were added per well. For basal beating 
parameters, iPSC-CMs were allowed to recover for two weeks with B27 medium change every 
two days before videos acquisition. For beating parameters of iPSC-CMs in response to 
pharmacological treatment, videos were obtained at day 6 after the initiation of the 
pharmacological treatment. Videos were obtained using Zeiss Axiovert 100 microscope 
preheated to 37°C and equipped with the Leica MC170 HD camera. 3-4 videos each for 20 
seconds were captured for each well. The beating rate as well as contraction and relaxation 
parameters of beating iPSC-CMs were quantified via motion analysis of the video sequences 
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using a MATLAB script developed by a group at UC Berkeley. The motion vector field was 
calculated (Huebsch et al., 2014) followed by a post-processing with an in-house developed 
vector analysis program to define color maps, alignment and contractility parameters 
(Kolanowski et al., 2020). 
2.4.7 Calcium imaging  
 
2.4.7.1 Digestion of iPSC-CMs for calcium imaging 
 
To prepare WT and iVici iPSC-CMs for calcium imaging analysis, 25 mm coverslips were 
transferred to 6-well plates and coated with 0.1% gelatin for 1 hour at 37°C. Gelatin was used 
for coating for calcium imaging due to its lower stiffness compared to geltrex. After preparing 
the gelatin-coated coverslips, WT and iVici iPSC-CMs were digested as described above 
where 200,000 cells were seeded per coverslip. Cells were left to recover for two weeks prior 
to calcium imaging analysis.  
2.4.7.2 Measurement of spontaneous calcium transients in iPSC-CMs 
 
In order to measure spontaneous calcium transients in WT and iVici iPSC-CMs grown on 25 
mm coverslips, WT and iVici iPSC-CMs were incubated with 5 µM Fura-2 AM calcium indicator 
in B27 medium for 30 minutes at 37°C followed by two washes in B27 medium. After that, 
iPSC-CMs were incubated for 10 minutes in B27 medium at 37°C to allow complete de-
esterification of intracellular Fura-2 AM calcium indicator. After that, coverslips were 
transferred to imaging chamber with Tyrode solution containing 1.8 mM calcium and the Fura-
2 signal was recorded by excitation at 340 and 380 nm with a switching frequency of 200 Hz 
and collecting the emitted fluorescence at 510 nm. A 40x objective on an Olympus IX70 
microscopy fitted with an IonOptix system were used. Analysis of the captured spontaneous 
calcium transients was performed using the LabChart Pro software. The analysis produced 
several parameters including the cytosolic calcium levels, systolic calcium levels, time constant 
during decay, and duration of calcium transients. 
2.4.7.3 Evaluation of diastolic SR calcium leak and SR calcium content in iPSC-CMs 
 
In order to evaluate SR calcium leak and SR calcium content, the protocol published by 
Shannon and Bers was adapted (Shannon et al., 2002). In brief, iPSC-CMs loaded with Fura-
2 AM calcium imaging solution were incubated in Tyrode solution with 1.8 mM calcium and 
stimulated at 0.5 Hz until cells reached a steady state. At least 20 paced calcium transients 
were recorded and then the solution was switched to Tyrode solution without sodium and 
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calcium supplemented with 1 mM of the ryanodine receptor inhibitor tetracaine. After 50 
seconds, the solution was switched to Tyrode solution without sodium and calcium for 40 
seconds followed by the application of 10 mM caffeine to estimate SR calcium content. SR 
calcium content was estimated based on the change of Fura-2 AM ratio upon caffeine 
treatment.  
2.4.8 Immunoblot  
 
2.4.8.1 Protein isolation from iPSC-CMs 
 
In order to obtain protein lysates from iPSC-CMs, iPSC-CMs were washed with 1X PBS while 
on ice. After that, 100 µl of RIPA lysis buffer supplemented with PhosSTOP phosphatase 
inhibitor, complete protease inhibitor, and 40 µM of PUGNAc, an OGA inhibitor, were added 
per well of six-well plate. Using a cell scraper, iPSC-CMs were detached and suspended in the 
RIPA lysis buffer and transferred to a 1.5-ml Eppendorf tube using a 1-ml pipette. iPSC-CMs 
were incubated on ice for at least 10 minutes in the RIPA lysis buffer, and then centrifuged at 
14,000xg at 4°C for 10 minutes. Supernatant containing the protein lysates was transferred to 
a new 1.5-ml Eppendorf tube and stored at -80°C for long term storage or were further 
processed for determination of protein concentration and SDS polyacrylamide gel 
electrophoresis (PAGE). 
2.4.8.2 Determination of protein concentration using Pierce BCA assay 
 
To determine protein concentration, the Pierce BCA assay was used following the 
manufacturer’s protocol. In brief, the iPSC-CMs protein lysates were diluted 1:10 in H2O and 
were loaded as triplicates in a 96-well plate. Blank wells were filled with RIPA lysis buffer and 
protein standards for the standard curve were prepared as described in table 1. 25 µl of diluted 
samples and protein standards were added per well. This was followed by the addition of 200 
µl of the working solution prepared by mixing 1 part of BCA assay solution B with 50 parts of 
BCA assay solution A on top of standards and the iPSC-CMs protein lysates. The plate with 
iPSC-CMs protein lysates and protein standards was incubated for 30 minutes at 37°C, and 
then the absorbance at 562 nm was measured using Synergy HTX microplate reader. Protein 
concentrations were determined using the best fit curve method of the loaded protein 
standards.  
 
 
Materials and methods 
 
47 
 
 
Table 1. Recipe of protein standard preparation for BCA protein assay.  
 
2.4.8.3 SDS-PAGE  
 
In order to separate proteins by mass, SDS-PAGE was performed. Polyacrylamide gels were 
prepared according to the recipes in table 2. The prepared gels were assembled in the Bio-
Rad chambers which were subsequently filled with 1X SDS running buffer. Protein lysates 
were mixed with 1/6 volume of 6X Lämmli buffer and boiled for 10 minutes at 70°C. Afterwards, 
40 µg protein were loaded per well. Electrophoresis was performed for 2 hours at 80 volts at 
room temperature.  
 Table 2. Recipes for polyacrylamide gels 
 
 
 
 
 
 
 
2.4.8.4 Protein transfer, antibody staining and detection 
 
Proteins separated via SDS-PAGE were transferred from the polyacrylamide gels to 
nitrocellulose membrane at 350 mA for 1 hour at 4°C in 1X blotting buffer. After the protein 
transfer step, membranes were stained with ponceau S to ensure equal transfer and loading 
Standard # BSA concentration [µg/ml] Volume of BSA stock [µl] Volume of H2O [µl] 
S1 2000 1000 0 
S2 1500 750 250 
S3 1000 500 500 
S4 750 375 625 
S5 500 250 750 
S6 250 125 875 
S7 125 62.5 937.5 
Polyacrylamide gel % 10% 12% 
Suitable for proteins with sizes  90-25 kDa 60-20 kDa 
Milli-Q H2O 4.0 ml 3.3 ml 
30% Acrylamide 3.3 ml 4.0 ml 
1.5 M Tris pH 8.8 2.5 ml 2.5 ml 
10% SDS 0.1 ml 0.1 ml 
10% APS 0.1 ml 0.1 ml 
TEMED 0.008 ml 0.008 ml 
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of proteins, then membranes were blocked for one hour at room temperature in 5% non-fat 
milk in 0.1% TBST. Membranes were then incubated O/N at 4°C with constant agitation in the 
primary antibody diluted in 0.1% TBST. Membranes were then washed with 0.1% TBST 3 
times each for 10 minutes and incubated in the secondary antibody diluted in 0.1% TBST for 
one hour at room temperature. After that, membranes were washed 3 times each for 10 
minutes in 0.1% TBST and then kept in H2O until signal detection. Signals were detected by 
using the superSignal™ femto maximum sensitivity or the superSignal™ dura extended 
duration substrate and imaging fusion FX using the full resolution parameter.  
2.4.9 Immunoprecipitation (IP) 
 
2.4.9.1 Preparation of antibody-coupled beads 
 
To couple antibodies with protein A agarose beads for immunoprecipitation (IP), 350 µl protein 
A agarose beads were washed twice with 4 ml of 0.1 M KPi (pH 7.4) and centrifuged for 5 
minutes at 1,000 rpm between each wash. After the second wash, the beads were suspended 
in 1.5 ml of 0.1 M KPi (pH 7.4) and 40 µl of SNAP29 antibody or 100 µl of STX17, respectively, 
to generate SNAP29 and STX17 antibody-coupled protein A agarose beads. The mixed beads 
and antibodies were incubated for 1 hour at room temperature head over head. After one hour, 
the mixed beads and antibodies were washed twice in 3.5 ml of 0.1 M sodium borate solution 
(pH 9.0) with centrifugation for 5 minutes at 1,000 rpm between each wash. After the second 
wash, the antibody-coupled beads were resuspended in 1.75 ml of 0.1 M sodium borate 
solution (pH 9.0) and 12.25 mg of dimethyl pimelimidate was added directly to the solution 
followed by incubation for 30 minutes at room temperature. Afterwards, the antibody-coupled 
beads were washed three times in 1 M Tris-HCl (pH 7.4), with centrifugation for 5 minutes at 
1,000 rpm between each wash. After the last wash, the beads were resuspended in 3 ml of 1 
M Tris-HCl (pH 7.4) and incubated for 2 hours at room temperature head over head. Then, the 
beads were centrifuged for 5 minutes at 1,000 rpm at room temperature and resuspended in 
0.3 ml of 1X TBS and stored at 4°C until use.  
2.4.9.2 Cell solubilization 
 
In order to obtain protein lysates from iPSC-CMs to use for IP, iPSC-CMs were washed with 
1X PBS while on ice. After that, 100 µl of 1X PBS was added per well of six-well plate. Using 
a cell scraper, iPSC-CMs were detached and suspended in 1X PBS and transferred to 1.5 ml 
Eppendorf tube using a 1 ml pipette. IPSC-CMs were centrifuged for 5 minutes at 200xg. 
Supernatant was discarded and the iPSC-CMs pellets were resuspended in 100-250 µl 
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(depending on pellet size) of solubilization buffer. The iPSC-CMs pellets were incubated in the 
solubilization buffer for 30 minutes at 4°C in a thermal cycler with 300 rpm shaking and then 
centrifuged for 15 minutes at 5,000xg at 2°C. The supernatant containing the protein lysates 
was then moved to a new 1.5 ml Eppendorf tube using a 1 ml pipette and protein 
concentrations were measured using the BCA assay as described above.  
2.4.9.3 Immunoprecipitation 
 
Before each IP experiment, the antibody-coupled agarose A beads were washed 3 times by 
incubating the beads in 50 µl of 100 mM glycine (pH 2.5) and centrifuged for 1 minute at 
2,000xg at 2°C between each wash step. The antibody-coupled agarose A beads were then 
washed twice in 500 µl of 1X TBS and centrifuged for 1 minute at 2,000xg at 2°C between 
each wash step. After the last washing step, the antibody-coupled agarose A beads were 
resuspended in 500 µl equilibration buffer, centrifuged for 1 minute at 2,000xg at 2°C and 
stored on ice until use for IP. For immunoprecipitation, 300 µg protein lysate were incubated 
with 200 μl of the antibody-coupled agarose A beads for 2 hours at 4°C. After the two-hour 
incubation, the mixtures of the agarose A beads and the lysates were centrifuged for 2 minutes 
at 2,000xg at 2°C, supernatant was discarded and the beads were washed 6 times in 200 μl 
washing buffer, with centrifugation for 2 minutes at 2,000xg at 2°C between each washing 
step. After the last washing step, the antibody-coupled beads were incubated in 60 μl of 100 
mM glycine (pH 2.5) solution for 3 minutes at 37°C in a thermal cycler with 300 rpm shaking to 
elute the proteins bound to the antibody-coupled agarose A beads. The beads were then 
centrifuged for 2 minutes at 2,000xg at 2°C and the supernatant containing the eluted proteins 
was transferred to a new 1.5 ml Eppendorf tube containing 18 µl of 1 M Tris-HCl (pH 8.5). This 
step was performed three times in total. After the third and last elution step, the eluate was 
kept on ice, and the beads were washed in 500 μl of 1X TBS, centrifuged for 2 minutes at 
2,000xg at 2°C, supernatant was discarded and the beads were resuspended in 100 μl of 1X 
TBS and stored at 4°C for reuse.  
2.4.9.4 Precipitation of the eluted proteins and SDS PAGE  
 
In order to precipitate the eluted proteins and re-dissolve them in a smaller volume suitable for 
SDS-PAGE, 50 μl TCA was added to the eluted proteins (≈ 200 μl). The eluate, TCA mixture 
was incubated on ice for 30 minutes, followed by centrifugation for 30 minutes at 2°C at 
21,100xg. The supernatant was discarded, and the protein pellet was washed with 500 μl cold 
acetone and was centrifuged for 10 minutes at 2°C at the highest speed. Supernatant was 
discarded, the protein pellet was left to dry for 5-10 minutes at 37°C, and then was dissolved 
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in 50 μl 1X Lämmli buffer for 5 minutes at 70°C in a thermal cycler with 350 rpm shaking. For 
IP experiments using the STX17 antibody-coupled protein A agarose beads, 45 μl of protein 
eluate in 1X Lämmli buffer was loaded per well for SDS-PAGE, whereas for experiments using 
the SNAP29 antibody-coupled protein A agarose beads, the protein eluate was equally divided 
between two gels and 25 μl of protein eluate in 1X Lämmli buffer was loaded per well per gel 
for SDS-PAGE. For IP experiments, the 4–15% Mini-PROTEAN® TGX™ Precast Protein Gels 
were used. Following SDS-PAGE for the protein eluates, the same steps were followed as 
described above for immunoblots for protein transfer, antibody staining and detection.  
2.4.10 Gene expression analysis 
 
2.4.10.1 RNA isolation from iPSC-CMs 
 
To isolate RNA from iPSC-CMs the SV Total RNA Isolations System was used following the 
manufacturer protocol. In brief, 400-800 μl (depending on the cell pellet size) of RNA lysis 
buffer was added to the cell pellet, and the cell pellet was resuspended by pipetting up and 
down. After that 400 μl of the cell lysate was transferred to 1.5 ml Eppendorf tube and was 
mixed with 400 μl of 95% ethanol by inverting. The mixture was then transferred to the 
assembled spin column and centrifuged at 13,000xg for 1 minute. Eluate was discarded and 
600 μl RNA wash solution was added to the assembled spin column and centrifuged at 
13,000xg for 1 minute. Eluate was discarded and then 50 μl of the freshly prepared DNAase 
mix was added to the assembled spin column. The DNAase mix was absorbed onto the 
membrane and incubated for 15 minutes at room temperature followed by centrifugation at 
13,000xg for 1 minute. Eluate was discarded and 200 μl of DNA stop solution was added to 
the assembled spin column followed by centrifugation at 13,000xg for 1 minute. Eluate was 
discarded and 600 μl of RNA wash solution was added to the assembled spin column followed 
by centrifugation at 13,000xg for 1 minute. Eluate was discarded and 250 μl of RNA wash 
solution was added to the assembled spin column followed by centrifugation at 13,000xg for 1 
minute. Eluate was discarded and the spin basket was transferred to a new pre-labeled 
Eppendorf tube and 100 μl of nuclease-free H2O was added to the membrane and centrifuged 
at 13,000xg for 1 minute. RNA concentration was measure using Nanodrop. The eluted RNA 
was stored at -80.   
2.4.10.2 cDNA reverse transcription 
 
To prepare cDNA from the RNA isolated from iPSC-CMs the reaction mixture was prepared 
as described in table 3 followed by the PCR program described in table 4.  
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Table 3. Reaction mixture for cDNA reverse transcription 
2 µl of 10X PCR buffer II 
4 µl of 25 mM magnesium chloride.  
1 µl of 100 mM dNTP mix 
1 µl of RNase Inhibitor (20 U/μl) 
1 µl of 50 μM Oligo d(T)16 
100 ng of RNA 
1 µl of MuL V Reverse Transcriptase (50 U/μl) 
Nuclease-free H2O to 20 µl 
 
Table 4. PCR program for cDNA reverse transcription 
Segment Cycles Temperature Time 
 
1 
 
1 
22°C 10 minutes 
42°C 50 minutes 
95°C 10 minutes 
2 1 4°C hold 
 
2.4.10.3 PCR for gene expression analysis 
 
To perform gene expression analysis, PCR was performed using the cDNA templates 
prepared from the RNA isolated from iPSC-CMs. The PCR reaction mixture was prepared as 
described in table 5 followed by the PCR program described in table 6.  
Table 5. PCR reaction mixture for gene expression analysis 
5 µl of 5X PCR green buffer 
1 µl of 10 mM dNTP mix 
1 µl of 10 μM forward primer 
1 µl of 10 μM reverse primer 
3 µl of cDNA 
0.125 µl of GoTaq Polymerase 
Nuclease-free H2O to 25 µl 
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Table 6. PCR programme for gene expression analysis 
Segment Cycles Temperature Time 
1 1 95°C 2 minutes 
 
2 
GAPDH: 30 cycles 
EPG5: 35 cycles 
95°C 30 seconds 
X°C 30 seconds 
72°C 45 seconds 
3 1 4°C hold 
Annealing temperature (X): 
GAPDH primers: 60°C 
EPG5 1: 51.5°C 
EPG5 2: 51.5°C 
 
In order to observe the PCR products after the PCR step, gel electrophoresis was performed 
where 1.5% agarose gel was used.   
2.4.11 Statistical analysis and dot blot data representation 
 
The n value represents the number of experiments performed with different differentiations of 
the specific cell line. Data is presented as mean ± standard error of the mean (SEM). For 
statistical significance calculation, two-tailed unpaired Student’s t-test, or one-way ANOVA with 
Tukey’s post hoc test was used, depending on the data set. Figure legends contain detailed 
information for statistical test used for each represented panel. Statistical significance is 
presented as p<0.05 (*), p<0.01 (**) and p<0.001 (***). All statistical analysis was carried out 
by using GraphPad Prism software (Version 8).  
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3 Results 
 
3.1 Characterization of the autophagy defect in iVici iPSC-CMs 
 
3.1.1 IVici iPSC-CMs show reduced fusion between the autophagosome and the 
lysosome 
EPG5 plays an essential role as a tethering factor mediating the specific fusion between the 
autophagosome and the lysosome during autophagy by ensuring the specific assembly of the 
STX17-SNAP29-VAMP8 SNARE complex of the autophagosome and the lysosome. Defects 
in EPG5 have been associated with autophagy dysfunction due to impaired autophagosome 
and lysosome fusion (Wang et al., 2016). In order to investigate whether the fusion between 
the autophagosome and the lysosome in iVici iPSC-CMs is impaired, 3-month-old WT and iVici 
iPSC-CMs were treated for 12 hours with 100 nM rapamycin to induce autophagy and 200 nM 
bafilomycin A1 to block lysosomal degradation. This treatment allowed to observe successful 
fusion events in WT and iVici iPSC-CMs. The autophagosomes were immunostained using an 
antibody directed against LC3B which translocates to the autophagosomes during the early 
stages of autophagy whereas the lysosomes were immunostained using an antibody directed 
against the lysosomal membrane protein LAMP1 (lysosome-associated membrane 
glycoprotein 1) (Figure 6). The fused autophagosomes and lysosomes (LC3B+/LAMP1+) as 
well as the total number of lysosomes (LAMP1+) per cell were quantified, and the percentage 
of fused autophagosomes and lysosomes relative to total number of lysosomes per cell was 
calculated. As expected, iVici iPSC-CMs showed reduced fusion between the autophagosome 
and the lysosome compared to WT iPSC-CMs (Figure 6A, B). These results were intriguing as 
despite the EPG5 mutation, there is still some degree of successful fusion events taking place 
in iVici iPSC-CMs.  
In order to validate the immunofluorescence finding, immunoblot of LC3B in WT and iVici iPSC-
CMs under basal conditions was performed. In line with the fusion defect present in iVici iPSC-
CMs, iVici iPSC-CMs accumulated higher protein levels of both LC3B isoforms, LC3BI and the 
PE-conjugated isoform LC3BII, compared to WT control. These findings further support the 
presence of autophagy defect in the iVici iPSC-CMs (Figure 6C).  
Finally, the EPG5 mutation c.4952+1G>A present in iVici iPSC-CMs results in the removal of 
exon 28 and introduces a premature stop codon at exon 29. In order to investigate whether 
the EPG5 mutation c.4952+1G>A present in iVici iPSC-CMs affects EPG5 mRNA expression 
RNA was isolated from both WT and iVici iPSC-CMs. The isolated RNA was used as a 
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template to synthesize cDNA which was used as a template for gene expression analysis using 
RT-PCR. One primer pair for the detection of GAPDH was used as a loading control and two 
primers pairs for the detection of EPG5 were used. The first primer pair covered part of exon 
22 whereas the second primer pair covered part of exons 23 and 24. Our analysis showed that 
indeed EPG5 mRNA is stably expressed in iVici iPSC-CMs (Figure 6D). Next, we attempted 
to investigate EPG5 protein expression in WT and iVici iPSC-CMs, but we could not identify a 
reliable antibody for this purpose (data not shown).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. IVici iPSC-CMs show reduced fusion between the autophagosome and the 
lysosome. (A) Confocal images of WT and iVici iPSC-CMs stained with LC3B (red) and 
LAMP1 (green) antibodies 12 hours after bafilomycin A1 and rapamycin treatment. WT iPSC-
CMs show more autophagosomes engulfed by the lysosomes indicating successful fusion 
between the autophagosome and the lysosome, whereas iVici iPSC-CMs accumulate empty 
lysosomes indicating defective fusion between the autophagosome and the lysosome. Scale 
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bar = 5 µm. (B) Quantification of percentage of successful fusion events per cell. WT iPSC-
CMs show higher percentage of successful fusion events between the autophagosome and 
the lysosome compared to iVici iPSC-CMs. iBM76.3 n=4 (58 cells), iWTD2.3 n=2 (17 cells), 
iVici1.3 n=4 (104 cells), iVici1.2 n=3 (59 cells), each dot in the dot blot represents % fusion 
events in one cell. (C) Immunoblots for WT and iVici iPSC-CMs under basal condition using 
antibodies against GAPDH and LC3B. iVici iPSC-CMs accumulate higher protein levels of 
LC3BI and LC3BII indicating impaired autophagy. iBM76.3 n= 3 (10 biological replicas), iVici 
1.3 n= 3 (9 biological replicas), iVici 1.2 n=1 (2 biological replicas). (D) Gene expression 
analysis of EPG5 in WT and iVici iPSC-CMs. One primer pair for GAPDH was used as a 
loading control and Two primers pairs for EPG5 were used. The first primer pair covered part 
of exon 22 whereas the second primer pair covered part of exons 23 and 24. EPG5 mRNA is 
stably expressed in WT and iVici iPSC-CMs. iWTD2.3 n= 1, iVici 1.3 n= 1, iVici 1.2 n= 1. Error 
bars = SEM, statistical significance calculated using two-tailed unpaired Student’s t-test. 
3.1.2 SNARE proteins involved in the fusion between the autophagosome and 
lysosome are differentially expressed in iVici iPSC-CMs  
 
Previous work illustrated that EPG5 loss of function led to decreased expression of the SNARE 
proteins SNAP29, VAMP8 and STX17 in HeLa cells (Guo et al., 2014), as well as the formation 
of STX17-SNAP25-VAMP8 SNARE complex instead of the STX17-SNAP29-VAMP8 SNARE 
complex, leading to non-specific fusion of the autophagosome with endocytic vesicles (Wang 
et al., 2016). In order to investigate whether the EPG5 mutation in iVici iPSC-CMs alters the 
cellular content of SNARE proteins involved in the fusion step of autophagy, we measured the 
protein expression levels of the SNARE proteins SNAP29, VAMP8 and STX17 in iVici iPSC-
CMs compared to WT iPSC-CMs. In contrast to what has been described in EPG5 KD in HeLa 
cells, iVici iPSC-CMs expressed higher protein levels of SNAP29 and VAMP8 compared to 
WT iPSC-CMs (Figure 7A, B & C) and similar to what have been described before, expressed 
lower protein levels of STX17 compared to WT iPSC-CMs (Figure 7A, D). Next, we 
investigated SNAP25 protein levels in iVici iPSC-CMs and found that iVici iPSC-CMs 
expressed higher protein levels of SNAP25 compared to WT iPSC-CMs (Figure 7A, E). These 
findings illustrated that iVici iPSC-CMs express higher protein levels of the lysosome R-
SNARE protein VAMP8 and the autophagosome Qbc SNARE protein SNAP29 and express 
lower protein levels of the autophagosome Qa SNARE protein STX17 compared to WT iPSC-
CMs. This indicates that the impaired fusion of the autophagosome and the lysosome in iVici 
iPSC-CMs may not only be caused by the dysfunctional EPG5 but also by the reduced protein 
levels of the Qa SNARE STX17. Moreover, iVici iPSC-CMs expressed higher protein levels of 
the Qa SNARE protein SNAP25 compared to WT iPSC-CMs, suggesting the possibility that 
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there is increased formation of the STX17-SNAP25-VAMP8 SNARE complex in iVici iPSC-
CMs, which might lead to non-specific fusion of the autophagosome with endocytic vesicles. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. SNARE proteins involved in the autophagosome and lysosome fusion are 
differentially expressed in iVici iPSC-CMs. (A) Immunoblots for WT and iVici iPSC-CMs. 
Antibodies directed against SNAP29, GAPDH, VAMP8, EEF2, STX17 and SNAP25 were 
used. (B) Quantification of SNAP29 protein expression relative to GAPDH. IVici iPSC-CMs 
expressed higher SNAP29 protein levels compared to WT iPSC-CMs. iBM76.3 n=4 (19 
biological replicas), iWTD2.3 n=2 (12 biological replicas), iVici 1.3 n=6 (19 biological replicas), 
iVici 1.2 n=2 (7 biological replicas). (C) Quantification of VAMP8 protein expression levels 
relative to EEF2. IVici iPSC-CMs expressed higher VAMP8 protein levels compared to WT 
iPSC-CMs. iBM76.3 n=1 (3 biological replicas), iWTD2.3 n=1 (3 biological replicas), iVici 1.3 
n=2 (7 biological replicas), iVici 1.2 n=1 (3 biological replicas). (D) Quantification of STX17 
protein expression levels relative to EEF2. WT iPSC-CMs expressed higher STX17 protein 
levels compared to iVici iPSC-CMs. iBM76.3 n=1 (3 biological replicas), iWTD2.3 n=1 (3 
biological replicas), iVici 1.3 n=2 (7 biological replicas), iVici 1.2 n=1 (3 biological replicas). (E) 
Quantification of SNAP25 protein expression levels relative to GAPDH. IVici iPSC-CMs 
expressed higher SNAP25 protein levels compared to WT iPSC-CMs. iBM76.3 n=1 (15 
biological replicas), iWTD2.3 n=1 (11 biological replicas), iVici 1.3 n=2 (11 biological replicas), 
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iVici 1.2 n=1 (10 biological replicas). Each dot in the dot blots represents one biological replica. 
Error bars = SEM, statistical significance calculated using two-tailed unpaired Student’s t-test. 
3.2 Characterization of cellular insults in iVici iPSC-CMs 
 
3.2.1 Analysis of mitochondrial network morphology and function 
 
3.2.1.1 IVici iPSC-CMs accumulate fragmented mitochondria  
 
Analysis of Vici patient’s skeletal muscle biopsies suggested the presence of several 
mitochondrial abnormalities including enlarged mitochondria, abnormal cristae and deficiency 
of complex 1 and 4 (Balasubramaniam et al., 2018; Byrne et al., 2016; Cullup et al., 2012; 
Ebrahimi-Fakhari et al., 2016; Waldrop et al., 2018). To investigate whether mitochondrial 
abnormalities are present in iVici iPSC-CMs, we analyzed the mitochondrial network structure 
in WT and iVici iPSC-CMs using the cell permeable dye MitoTracker green which accumulates 
inside active mitochondria. Previous studies demonstrate that the accumulation of fragmented 
mitochondria is an indicator of mitochondrial dysfunction and has been observed in human and 
animal models of HF (Chen et al., 2009). Interestingly, the mitochondrial network in WT iPSC-
CMs appeared as large continuous reticulum spread homogenously throughout the cell, 
whereas iVici iPSC-CMs accumulated inhomogeneous fragmented mitochondrial network 
(Figure 8A). To obtain quantitative measure of mitochondrial network structure in WT and iVici 
iPSC-CMs, mitochondrial fusion and fission were scored using the aspect ratio. A higher 
aspect ratio indicates fused elongated mitochondria and a smaller aspect ratio indicates 
fragmented mitochondria. IVici iPSC-CMs accumulated higher amounts of fragmented 
mitochondria compared to WT iPSC-CMs evident by lower aspect ratio (Figure 8B). Taken 
together, the accumulation of fragmented mitochondria in iVici iPSC-CMs indicates the 
possible accumulation of dysfunctional mitochondria, which contributes to cardiomyopathy 
development (Stanley et al., 2005). 
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Figure 8. IVici iPSC-CMs accumulate fragmented mitochondria. (A) Representative 
images of WT and iVici iPSC-CMs stained with MitoTracker green to visualize mitochondrial 
network morphology. WT iPSC-CMs show homogenous elongated mitochondrial network, 
whereas iVici iPSC-CMs accumulate inhomogeneous fragmented mitochondrial network. (B) 
Quantification of mitochondrial aspect ratio as a measure of mitochondrial elongation or 
fragmentation. IVici iPSC-CMs have reduced mitochondrial aspect ratio compared to WT 
iPSC-CMs indicating fragmented mitochondrial network. iBM76.3 n=7 (120 cells), iWTD2.3 
n=2 (84 cells), iVici 1.3 n=7 (173 cells), iVici 1.2 n=3 (84 cells). Each dot in the dot blot 
represents average mitochondrial aspect ratio in one cell. Scale bar = 50 µm, error bars = 
SEM, statistical significance calculated using two-tailed unpaired Student’s t-test.  
3.2.1.2 IVici iPSC-CMs accumulate hyperpolarized mitochondria and have increased 
mtROS levels  
 
The accumulation of fragmented mitochondria in iVici iPSC-CMs might indicate the 
accumulation of depolarized mitochondria primed for removal by mitophagy (Stanley et al., 
2005). However, due to the autophagy defect in iVici iPSC-CMs, the fragmented mitochondria 
primed for removal will accumulate inside the iVici iPSC-CMs. Interestingly, under stress 
conditions during HF progression, fragmented depolarized mitochondria accumulate inside the 
cardiomyocytes as a result of depressed autophagy (Shirakabe et al., 2016). The mitochondrial 
membrane potential in WT and iVici iPSC-CMs was measured using the cell permeable dye 
TMRM. Surprisingly, despite the accumulation of fragmented mitochondria in iVici iPSC-CMs, 
iVici iPSC-CMs exhibited higher TMRM fluorescence intensity compared to WT iPSC-CMs as 
evidenced by higher TMRM median fluorescence intensity (MFI) (Figure 9A, B). This suggests 
a continuation of mitochondrial membrane hyperpolarization or a consequence of a higher total 
mitochondrial content in iVici iPSC-CMs. Mitochondrial hyperpolarization has been associated 
with increased mtROS production, which leads to a feedback loop of further mtROS 
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production, a phenomena known as ROS-induced ROS release (RIRR) (Galloway & Yoon, 
2012; Gerencser et al., 2012; Tse et al., 2016).  
To explore whether iVici iPSC-CMs exhibit higher oxidative stress and increased mtROS 
levels, we investigated general oxidative stress levels using the general oxidative stress 
indicator CM-H2DCFDA in both WT and iVici iPSC-CMs. Indeed, iVici iPSC-CMs exhibited 
higher levels of general oxidative stress compared to WT iPSC-CMs as evidenced by higher 
CM-H2DCFDA MFI (Figure 9C, D). In order to elucidate whether the increased oxidative stress 
observed is due to increased mtROS, the mitochondrial-specific superoxide detector dye 
MitoSOX red was used. IVici iPSC-CMs showed increased levels of mtROS compared to WT 
iPSC-CMs as evidenced by higher MitoSOX red MFI (Figure 9E, F). Taken together, iVici 
iPSC-CMs accumulate fragmented hyperpolarized mitochondria, which are a source of cellular 
oxidative stress, a well-characterized factor leading to cardiac dysfunction and to further 
induction of the defective autophagy process.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 9. IVici iPSC-CMs accumulate hyperpolarized mitochondria and have increased 
mtROS levels. (A) FACS histogram of TMRM fluorescence intensity in WT iPSC-CMs (Blue) 
and iVici iPSC-CMs (Pink). Compared to WT iPSC-CMs, iVici iPSC-CMs revealed a histogram 
shift to the right, indicating higher TMRM fluorescence intensity. (B) Quantification of TMRM 
median fluorescence intensity (MFI) in WT and iVici iPSC-CMs. IVici iPSC-CMs had higher 
TMRM MFI indicating the presence of hyperpolarized mitochondria. iBM76.3 n=3 (11 biological 
replicas), iWTD2.3 n=1 (2 biological replicas), iVici 1.3 n=3 (12 biological replicas), iVici 1.2 
n=1 (4 biological replicas). (C) FACS histogram of CM-H2DCFDA fluorescence intensity in WT 
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iPSC-CMs (Blue) and iVici iPSC-CMs (Pink). The iVici iPSC-CMs histogram is shifted to the 
right, indicating higher CM-H2DCFDA fluorescence intensity. (D) Quantification of CM-
H2DCFDA MFI in WT and iVici iPSC-CMs. IVici iPSC-CMs had higher CM-H2DCFDA MFI 
indicating increased general oxidative stress. iBM76.3 n=1(2 biological replicas), iWTD2.3 n=1 
(1 biological replicas), iVici 1.3 n=2 (4 biological replicas). (E) FACS histogram of MitoSOX red 
fluorescence intensity in WT iPSC-CMs (Blue) and iVici iPSC-CMs (Pink). The iVici iPSC-CM 
histogram is shifted to the right, indicating higher MitoSOX red fluorescence intensity. (F) 
Quantification of MitoSOX red MFI in WT and iVici iPSC-CMs. IVici iPSC-CMs had higher 
MitoSOX red MFI indicating increased production of mtROS in iVici iPSC-CMs. iBM76.3 n=6 
(32 biological replicas), iWTD2.3 n=4 (24 biological replicas), iVici 1.3 n=4 (27 biological 
replicas), iVici 1.2 n=2 (7 biological replicas). Each dot in the dot blot represents MFI in one 
biological replica, error bars = SEM, statistical significance was calculated using two-tailed 
unpaired Student’s t-test.  
3.2.1.3 AMPK phosphorylation under basal and glucose deprivation conditions in iVici 
iPSC-CMs 
 
AMPK is activated under nutritional stress condition when the AMP/ATP ratio is increased 
through phosphorylation of threonine 183 and threonine 172 of the catalytic subunit α1 and α2 
of AMPK, respectively (Carling et al., 2012). Given the observed mitochondrial fragmentation, 
hyperpolarization, and increased mtROS in iVici iPSC-CMs, it’s possible that iVici iPSC-CMs 
exhibit impaired bioenergetics and increased AMPK activity, which might lead to further 
activation of the defective autophagy process and further exacerbation of the disease 
phenotype. Analysis of AMPK phosphorylation in WT and iVici iPSC-CMs cultured in B27 
medium containing 11.1 mM D-glucose illustrated that there is no difference in AMPK 
phosphorylation between both cell lines (Figure 10A, B). These results indicate the possibility 
that iVici iPSC-CMs compensate for the possible mitochondrial defects via increased 
glycolysis. To investigate this, WT and iVici iPSC-CMs were incubated for four days in cardiac 
selection medium without glucose and supplemented with lactate. Surprisingly, analysis of 
AMPK phosphorylation under glucose deprivation conditions showed decreased AMPK 
phosphorylation in iVici iPSC-CMs compared to WT iPSC-CMs (Figure 10C, D).  
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Figure 10. AMPK phosphorylation under basal and glucose deprivation conditions. (A) 
Immunoblots for WT and iVici iPSC-CMs cultured in B27 medium containing 11.1 mM D-
glucose. Antibodies directed against AMPK total and phosphorylated threonine 183 of 
AMPKα1 and phosphorylated threonine 172 of AMPKα2 were used. (B) Quantification of 
phosphorylated threonine 183 of AMPKα1 and phosphorylated threonine 172 of AMPKα2 
relative to AMPK total. There was no difference between WT and iVici iPSC-CMs. iBM76.3 
n=1 (4 biological replicas), iVici 1.3 n=1 (3 biological replicas). (C) Immunoblots for WT and 
iVici iPSC-CMs incubated in cardiac selection medium without glucose but supplemented with 
lactate. Antibodies directed against AMPK total and phosphorylated threonine 183 of AMPKα1 
and phosphorylated threonine 172 of AMPKα2 were analyzed. (D) Quantification of 
phosphorylated threonine 183 of AMPKα1 and phosphorylated threonine 172 of AMPKα2 
relative to AMPK total. Compared to iVici iPSC-CMs, WT iPSC-CMs seemed to have higher 
activation of AMPK under glucose deprivation conditions. iBM76.3 n=1 (4 biological replicas), 
iVici 1.3 n=1 (3 biological replicas). Each dot in the dot blots represents one biological replica, 
error bars = SEM.  
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3.2.2 IVici iPSC-CMs seem to have increased ER stress through the IRE1α arm 
 
Given the autophagy defect present in iVici iPSC-CMs, it’s possible that iVici iPSC-CMs 
accumulate misfolded proteins and protein aggregates, which will lead to ER stress. The 
possible ER stress is by itself a known contributor to cardiomyopathy (Okada et al., 2004), and 
will result in further induction of the defective autophagy process leading to aggravated disease 
phenotype. In order to investigate whether iVici iPSC-CMs exhibit an increase in ER stress, 
the protein expression levels of three ER stress markers including binding immunoglobulin 
protein (BiP), ATF4 and IRE1α were analyzed. ATF4 and BiP protein levels were similar 
between WT and iVici iPSC-CMs (Figure 11A, B, and C). Whereas IRE1α protein levels were 
higher in iVici iPSC-CMs compared to WT iPSC-CMs (Figure 11A, D). These findings point to 
the presence of ER stress in iVici iPSC-CMs as made evident by the increased expression of 
the ER stress marker IRE1α.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11. IVici iPSC-CMs seem to have increased ER stress through the IRE1α arm. (A) 
Immunoblots for WT and iVici iPSC-CMs cultured in B27 medium. Antibodies directed against 
ATF4, GAPDH, BiP and IRE1α were analyzed. (B) Quantification of ATF4 protein expression 
levels relative to GAPDH. WT and iVici iPSC-CMs expressed similar ATF4 protein levels, 
iBM76.3 n=1 (4 biological replicas), iVici 1.3 n=1(3 biological replicas). (C) Quantification of 
BiP protein expression levels relative to GAPDH. WT and iVici iPSC-CMs expressed similar 
BiP protein levels. iBM76.3 n=1 (3 biological replicas), iVici 1.3 n=1 (3 biological replicas). (D) 
Quantification of IRE1α protein expression levels relative to GAPDH. WT iPSC-CMs expressed 
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lower IRE1α protein levels compared to iVici iPSC-CMs indicating possible ER stress in iVici 
iPSC-CMs. iBM76.3 n=1 (6 biological replicas), iWTD2.3 n=1 (3 biological replicas), iVici 1.3 
n=3 (9 biological replicas). Each dot in the dot blots represents one biological replica, error 
bars = SEM, statistical significance was calculated using two-tailed unpaired Student’s t-test.  
3.3 Characterization of contractile properties of iVici iPSC-CMs 
 
3.3.1 Video-based analysis of WT and iVici iPSC-CMs beating properties  
 
Previous work from our group showed that iVici iPSC-CMs exhibit sarcomere disarray (Qi, 
2016), a phenotype observed in iPSC-CMs model of hypertrophic cardiomyopathy and 
contributed to contractile abnormalities (Cohn et al., 2019). In order to check the contractile 
properties of iVici iPSC-CMs, videos of beating WT and iVici iPSC-CMs were captured. These 
videos were analyzed using a recently published MATLAB algorithm (Huebsch et al., 2014), 
which provides several parameters including beat per minute, contraction time, relaxation time, 
displacement and contraction and relaxation velocities as an output. IVici iPSC-CMs exhibited 
regular beating with lower beating frequency compared to WT iPSC-CMs (Figure 12A). 
Furthermore, iVici iPSC-CMs showed increased contraction and relaxation time compared to 
WT iPSC-CMs (Figure 12B, C). Finally, iVici iPSC-CMs showed higher displacement and 
increased contraction and relaxation velocities compared to WT iPSC-CMs (Figure 12D, E & 
F). These results indicate that iVici iPSC-CMs exhibit different beating properties compared to 
WT iPSC-CMs.  
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Figure 12. Video-based analysis of WT and iVici iPSC-CMs beating. (A) Quantification of 
beating rate per minute of WT and iVici iPSC-CMs. iVici iPSC-CMs show lower beating rate 
per minute compared to WT iPSC-CMs. (B, C) Quantification of contraction and relaxation time 
in WT and iVici iPSC-CMs. Vici iPSC-CMs show higher contraction as well as relaxation time. 
(D, E & F) Quantification of displacement and contraction and relaxation velocities of beating 
WT and iVici iPSC-CMs. iVici iPSC-CMs show higher displacement, contraction velocity and 
relaxation velocity compared to WT iPSC-CMs. iBM76.3 n=4 (24 biological replicas), iWTD2.3 
n=1 (6 biological replicas), iVici 1.3 n=4 (33 biological replicas), iVici 1.2 n=2 (9 biological 
replicas). Each dot in the dot blot represents one biological replica, error bars = SEM, statistical 
significance calculated using two-tailed unpaired Student’s t-test.  
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3.3.2 Analysis of spontaneous calcium transients in WT and iVici iPSC-CMs  
 
In order to complement our video analysis of the beating properties of WT and Vici iPSC-CMs, 
we analyzed spontaneous calcium transients using the intracellular calcium indicator Fura-2 
AM. Fura-2 AM is a ratiometric fluorescent dye that binds free intracellular calcium. It is excited 
at two different wavelengths 340 nm and 380 nm and emits fluorescence signal at 510 nm 
where the intracellular calcium content can be estimated by the ratio of the emissions at the 
excitation wavelengths 340 nm and 380 nm. This ratiometric measurement allows accurate 
estimation of intracellular calcium independent of conditions that may affect the measurement 
including uneven dye distribution and photobleaching.  
WT and iVici iPSC-CMs were loaded with 5 µM Fura-2 AM and incubated in Tyrode solution 
containing 1.8 mM calcium. Spontaneous calcium transients were detected using the IonOptix 
system. Analysis of spontaneous calcium transients in WT and iVici iPSC-CMs (Figure 13A) 
showed that iVici iPSC-CMs exhibit lower beat per minute compared to WT iPSC-CMs, which 
is in line with our video analysis findings (Figure 13B). Moreover, iVici iPSC-CMs exhibited a 
trend towards lower diastolic calcium levels, lower systolic calcium levels, and smaller calcium 
transient amplitude (Figure 13C, D & E). Finally, there was no difference in the duration of 
calcium transients between WT and iVici iPSC-CMs (Figure 13F). These results suggest the 
presence of defects in the process of calcium release from the SR in iVici iPSC-CMs. 
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Figure 13. Analysis of spontaneous calcium transients in WT and iVici iPSC-CMs. (A) 
Representative spontaneous calcium transient trace of WT and iVici iPSC-CMs. (B) 
Quantification of beating rate per minute of WT and iVici iPSC-CMs. IVici iPSC-CMs show 
lower beating rate per minute compared to WT iPSC-CMs. (C, D) Quantification of diastolic 
and systolic calcium levels in WT and iVici iPSC-CMs. IVici iPSC-CMs seems to have lower 
diastolic calcium levels and lower systolic calcium levels compared to WT iPSC-CMs. (E) 
Quantification of spontaneous calcium transient amplitude in WT and iVici iPSC-CMs. IVici 
iPSC-CMs exhibited smaller calcium transient amplitude compared to WT iPSC-CMs. (F) 
Quantification of spontaneous calcium transient duration in WT and iVici iPSC-CMs. The 
duration of spontaneous calcium transients was similar between WT and iVici iPSC-CMs. 
iBM76.3 n=3 (9 cells), iBM76.1 n=1 (9 cells), iWTD2.3 n=1 (6 cells), iVici 1.3 n=4 (15 cells). 
Each dot in the dot blot represents one cell, error bars = SEM, statistical significance calculated 
using two-tailed unpaired Student’s t-test.  
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3.3.3 Analysis of SR calcium content in WT and iVici iPSC-CMs 
 
In order to analyze SR calcium content in WT and iVici iPSC-CMs we adapted the published 
approach (Shannon et al., 2002). WT and iVici iPSC-CMs were loaded with the Fura-2 calcium 
indicator, incubated in Tyrode solution with 1.8 mM calcium and stimulated at 0.5 Hz to allow 
the cells to reach a steady state. After that, the Tyrode solution was switched to Tyrode solution 
without sodium and calcium supplemented with 1 mM of the ryanodine receptor inhibitor 
tetracaine. After 50 seconds, the solution was switched to Tyrode solution without sodium and 
calcium for 40 seconds followed by the application of 10 mM caffeine to induce the release of 
SR calcium (Figure 14A). Our analysis showed that under pacing conditions, iVici iPSC-CMs 
exhibit similar diastolic calcium levels, systolic calcium levels, amplitude and shorter time to 
peak compared to WT iPSC-CMs (Figure 14B-E). Moreover, analysis of SR calcium content 
following caffeine treatment showed that iVici iPSC-CMs exhibit increased SR calcium content 
compared to WT iPSC-CMs (Figure 14F). The increased relative SR calcium content in iVici 
iPSC-CMs further supported the possibility of the presence of defects in the process of calcium 
release from the SR in iVici iPSC-CMs. 
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Figure 14. Analysis of SR calcium content in WT and iVici iPSC-CMs. (A) Representative 
Shannon-Bers traces of WT and iVici iPSC-CMs. (B, C) Quantification of diastolic and systolic 
calcium levels in WT and iVici iPSC-CMs under constant pacing at 0.5 Hz. IVici iPSC-CMs 
showed similar diastolic calcium levels and systolic calcium levels compared to WT iPSC-CMs. 
(C) Quantification of calcium transient amplitude in WT and iVici iPSC-CMs under constant 
pacing at 0.5 Hz. IVici iPSC-CMs exhibited similar calcium transient amplitude compared to 
WT iPSC-CMs. (E) Quantification of calcium transient time to peak under constant pacing at 
0.5 Hz in WT and iVici iPSC-CMs. iVici showed shorter calcium transient time to peak 
compared to WT iPSC-CMs. (F) Quantification of relative SR calcium content after caffeine 
challenge in WT and iVici iPSC-CMs. iVici iPSC-CMs showed higher relative SR calcium 
content compared to WT iPSC-CMs. iBM76.3 n=3 (8 cells), iBM76.1 n=1 (8 cells), iWTD2.3 
n=1 (7 cells), iVici 1.3 n=4 (21 cells). Each dot in the dot blot represents one cell, error bars = 
SEM, statistical significance calculated using two-tailed unpaired Student’s t-test. 
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3.4 OGT inhibition as a potential therapeutic target 
 
Previous work showed that pharmacological inhibition of the enzyme OGT attenuates the 
autophagy defect resulting from EPG5 knockdown in HeLa cells (Guo et al., 2014). Here, we 
first characterized protein O-GlcNAcylation in WT and iVici iPSC-CMs, and then we 
investigated whether pharmacological inhibition of the enzyme OGT can attenuate the defect 
in autophagosome and lysosome fusion resulting from EPG5 mutation in iVici iPSC-CMs. For 
this purpose, we used the toxic glucose analogue and nonspecific OGT inhibitor alloxan 
(Konrad et al., 2002) as a proof of concept, then we used three specific OGT inhibitors 
ST078925, ST045849 and OSMI-1 (Ortiz-Meoz et al., 2015). 
3.4.1 IVici iPSC-CMs exhibit increased protein O-GlcNAcylation 
 
Previous work showed that pharmacological inhibition and genetic knockdown of the enzyme 
OGT could restore autophagy flux in C. elegans and HeLa cells with EPG5 mutation or genetic 
knockdown, respectively (Guo et al., 2014). In this study, we first investigated the protein O-
GlcNAcylation in iVici iPSC-CMs compared to WT iPSC-CMs. Interestingly, iVici iPSC-CMs 
revealed higher levels of protein O-GlcNAcylation compared to WT iPSC-CMs (Figure 15A, 
B). These findings suggest that pharmacological OGT inhibition may be a potential target in 
iVici iPSC-CMs. In order to elucidate whether the increased protein O-GlcNAcylation in iVici 
iPSC-CMs is a result of the autophagy defect, WT iPSC-CMs were treated with 200 nM 
bafilomycin A1 for 12 hours to block lysosomal degradation. Bafilomycin A1 treatment induced 
an increase in protein O-GlcNAcylation in WT iPSC-CMs (Figure 15C, D). Next, we 
investigated whether blocking lysosomal degradation of the successful fusion events in iVici 
iPSC-CMs with bafilomycin A1 has a similar effect on protein O-GlcNAcylation. Similar to WT 
iPSC-CMs, treatment of iVici iPSC-CMs with 200 nM bafilomycin A1 for 12 hours induced an 
increase in protein O-GlcNAcylation (Figure 15E, F). These results indicate that blockage of 
lysosomal degradation in WT iPSC-CMs leads to increased protein O-GlcNAcylation, 
suggesting that the increased protein O-GlcNAcylation in iVici iPSC-CMs is a result of the 
defects in the fusion between the autophagosome and the lysosome. Moreover, these results 
indicate that there is a direct relationship between protein O-GlcNAcylation and autophagy, as 
evidenced by the further increase in protein O-GlcNAcylation in iVici iPSC-CMs upon 
bafilomycin A1 treatment.  
Previous work showed that the transcription factor specificity protein 1 (SP1) is responsible for 
the control of SNAP25 expression, and that O-GlcNAcylation of SP1 increases the stability and 
activity of SNAP25 (Cai et al., 2008; Donovan et al., 2014; Du et al., 2000; Ngoh et al., 2010). 
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In order to check whether the increased SNAP25 protein levels observed in iVici iPSC-CMs is 
a result of the increased protein O-GlcNAcylation, WT iPSC-CMs were treated for 48 hours 
with 40 µM of the OGA pharmacological inhibitor PUGNAc,. This treatment led to significant 
increase in protein O-GlcNAcylation in WT iPSC-CMs (Figure 15G, H). However, despite this 
increase in protein O-GlcNAcylation levels, SNAP25 protein levels were similar between non-
treated and PUGNAc-treated WT iPSC-CMs (Figure 15G, I). Finally, we sought to investigate 
whether increased protein O-GlcNAcylation affect SNAP29 protein levels. Similar to SNAP25, 
SNAP29 protein levels were similar between non-treated and PUGNAc-treated WT iPSC-CMs 
(Figure 15G, J).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure legend in the next page 
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Figure 15. IVici iPSC-CMs exhibit increased protein O-GlcNAcylation. (A) Immunoblots 
for WT and iVici iPSC-CMs incubated in B27 medium. Antibodies directed against O-GlcNAc 
and GAPDH were used. (B) Quantification of protein O-GlcNAcylation levels relative to 
GAPDH. IVici iPSC-CMs showed higher protein O-GlcNAcylation compared to WT iPSC-CMs. 
iBM76.3 n=5 (25 biological replicas), iWTD2.3 n=2 (8 biological replicas), iVici 1.3 n=7 (25 
biological replicas), iVici 1.2 n=2 (6 biological replicas). (C) Immunoblots for WT iPSC-CMs 
without and with the treatment with 200 nM bafilomycin A1 for 12 hours. Antibodies directed 
against O-GlcNAc and GAPDH were applied. (D) Quantification of O-GlcNAcylation levels 
relative to GAPDH. Bafilomycin A1 treatment induced increased protein O-GlcNAcylation in 
WT iPSC-CMs. iBM76.3 n=1 (3 biological replicas for each condition). (E) Immunoblots for 
iVici iPSC-CMs without and with the treatment with 200 nM bafilomycin A1. Antibodies directed 
against O-GlcNAc and GAPDH were used. (F) Quantification of O-GlcNAcylation levels 
relative to GAPDH. Bafilomycin A1 treatment induced increased protein O-GlcNAcylation in 
iVici iPSC-CMs. iVici 1.3 n=1 (3 biological replicas for each condition).  (G) Immunoblots for 
WT iPSC-CMs without and with the treatment with 40 µM PUGNAc. Antibodies directed 
against O-GlcNAc, SNAP29, SNAP25 and GAPDH were analyzed. (H-J) Quantification of O-
GlcNAcylation (H), SNAP25 (I) and SNAP29 (J) levels relative to GAPDH. PUGNAc treatment 
induced increased protein O-GlcNAcylation in WT iPSC-CMs, (H; iWTD2.3 n=1 (3 biological 
replicas for each condition)), but did not affect SNAP25 (I; iBM76.3 n=1 (4 biological replicas 
for control and 3 biological replicas for PUGNAc treatment)), iWTD2.3 n=1 (3 biological replicas 
for each condition)) and SNAP29 (J; iWTD2.3 n=1 (3 biological replicas for each condition)) 
protein levels in WT iPSC-CMs. Each dot in the dot blots represents one biological replica, 
error bars = SEM, statistical significance was calculated using two-tailed unpaired Student’s t-
test. 
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3.4.2 Effect of alloxan on iVici iPSC-CMs 
 
Alloxan was described as a non-specific inhibitor of OGT and in biological research alloxan is 
commonly used to induce diabetes in mice by selectively destroying insulin-producing beta 
cells through the induction of oxidative stress and beta cells necrosis (Lenzen, 2008). To 
validate OGT as a potential therapeutic target for treating patients with Vici syndrome, WT and 
iVici iPSC-CMs were treated with 5 mM alloxan, and then its effects on iPSC-CMs were 
investigated. 
3.4.2.1 Alloxan does not seem to be toxic to iPSC-CMs  
 
To elucidate whether alloxan treatment has a toxic effect on WT and/or iVici iPSC-CMs, WT 
and iVici iPSC-CMs were treated for seven days with 5 mM alloxan. Cell viability was checked 
visually on daily basis, and WT and iVici iPSC-CMs were viable with no apparent toxic effect. 
Beating properties of WT and iVici iPSC-CMs after six days of alloxan treatment were analyzed 
using the video-based motion vector field analysis program. Alloxan had no effect on beating 
rate, contraction time, relaxation time and displacement of either WT or iVici iPSC-CMs (Figure 
16A-D). Moreover, analysis of mitochondrial network structure using the mitochondrial dye 
MitoTracker green after seven days of alloxan treatment showed that the mitochondrial 
network structure was not affected in either WT or iVici iPSC-CMs (Figure 16E, F). 
Furthermore, we investigated whether alloxan treatment induces oxidative stress in iPSC-CMs 
by detecting general oxidative stress levels using the general oxidative stress detection dye 
CM-H2DCFDA. Surprisingly, alloxan treatment for 24 hours resulted in the reduction of 
oxidative stress levels in both WT and iVici iPSC-CMs (Figure 16G). 
Taken together, these findings indicate that treatment of WT and iVici iPSC-CMs up to seven 
days with 5 mM alloxan does not seem to exhibit a toxic effect.  
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Figure 16. Alloxan does not seem to be toxic to iPSC-CMs. (A-D) Quantification of beating 
properties in WT and iVici iPSC-CMs with and without treatment with 5 mM alloxan for six 
days. Alloxan treatment did not affect beating properties of both WT and iVici iPSC-CMs. 
iBM76.3 n=4 (control = 24 biological replicas, alloxan treated = 23 biological replicas), iVici 1.3 
n=3 (control = 27 biological replicas, alloxan treated = 24 biological replicas), iVici 1.2 n=2 
(control = 9 biological replicas, alloxan treated = 8 biological replicas). (E) Representative 
images of WT and iVici iPSC-CMs non-treated and treated with 5 mM alloxan for seven days 
and stained with MitoTracker green to visualize mitochondrial network morphology. Alloxan 
treatment did not affect mitochondrial network structure in both WT and iVici iPSC-CMs but 
seemed to affect mitochondria density in WT iPSC-CMs. Scale bar = 50 µm. (F) Quantification 
of mitochondrial aspect ratio as a measure of mitochondrial elongation or fragmentation. 
Alloxan treatment affected mitochondrial network structure in neither WT nor iVici iPSC-CMs. 
iBM76.3 n=2 (control = 57 cells, alloxan treated = 16 cells), iVici 1.3 n=2 (control = 64 cells, 
alloxan treated = 43 cells), iVici 1.2 n=1 (control = 24 cells, alloxan treated = 24 cells). (G) 
Quantification of CM-H2DCFDA MFI in WT and iVici iPSC-CMs with and without treatment 
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with 5 mM alloxan for 24 hours. Alloxan treatment reduced general oxidative stress levels in 
both WT and iVici iPSC-CMs. iBM76.3 n=3 (control = 25 biological replicas, alloxan treated = 
14 biological replicas), iVici 1.3 n=3 (control = 33 biological replicas, alloxan treated = 21 
biological replicas). Each dot in the dot blot represents one biological replica (A-D & G), or 
average mitochondrial aspect ratio in one cell (F), error bars = SEM, statistical significance 
was calculated using one-way ANOVA with Tukey’s post hoc test. 
3.4.2.2 Alloxan enhances the autophagosome and lysosome fusion in iVici iPSC-CMs 
 
After excluding the possible toxic effect of alloxan treatment on WT and iVici iPSC-CMs, the 
effect of alloxan treatment on the fusion between the autophagosome and the lysosome in 
both WT and iVici iPSC-CMs was investigated. Both cell types were treated with 5 mM alloxan 
for seven days, and 12 hours prior to fixing the cells for immunostaining, iPSC-CMs were 
treated with 100 nM rapamycin to induce autophagy and 200 nM bafilomycin A1 to block 
lysosomal degradation. This treatment allowed to observe successful fusion events in WT and 
iVici iPSC-CMs. The autophagosomes were immunostained using the antibody against LC3B 
and the lysosomes were immunostained using the antibody against LAMP1. The fused 
autophagosomes and lysosomes (LC3B+/LAMP1+) as well as the total number of lysosomes 
(LAMP1+) per cell were quantified, and the percentage of fused autophagosomes and 
lysosomes relative to total number of lysosomes per cell was calculated. While alloxan 
treatment did not significantly affect the percentage of fused autophagosomes and lysosomes 
in WT iPSC-CMs (Figure 17A, B), it induced autophagosome and lysosome fusion in iVici 
iPSC-CMs (Figure 17C, D).  
 
 
 
 
 
 
 
 
 
Results 
 
75 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 17. Alloxan enhances autophagosome and lysosome fusion in iVici iPSC-CMs.  
(A) Confocal images of WT iPSC-CMs with and without the treatment with 5 mM alloxan for 
seven days and stained with LC3B (red) and LAMP1 (green) antibodies 12 hours after 
bafilomycin and rapamycin treatment. Alloxan treatment did not affect the fusion between the 
autophagosome and the lysosome in WT iPSC-CMs. (B) Quantification of percentage of 
successful fusion events per cell. WT iPSC-CMs with and without alloxan treatment show 
similar percentage of successful fusion events between the autophagosome and the lysosome. 
iBM76.3 n=2 (control = 46 cells, alloxan treated = 14 cells), iWTD2.3 n=1 (control = 10 cells, 
alloxan treated = 10 cells), scale bar = 5 µm. (C) Confocal images of iVici iPSC-CMs with and 
with the treatment with 5 mM alloxan for seven days and stained with LC3B (red) and LAMP1 
(green) antibodies 12 hours after bafilomycin and rapamycin treatment. Alloxan treatment 
increased the fusion between the autophagosome and the lysosome in iVici iPSC-CMs. (D) 
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Quantification of percentage of successful fusion events per cell. Alloxan-treated iVici iPSC-
CMs show higher percentage of successful fusion events between the autophagosome and 
the lysosome. iVici 1.3 n=3 (control = 84 cells, alloxan treated = 93 cells), iVici 1.2 n=2 (control 
= 46 cells, alloxan treated = 30 cells), scale bar = 5 µm. Each dot in the dot blot represents % 
of fusion events in one cell, error bars = SEM, and statistical significance was calculated using 
two-tailed unpaired Student’s t-test.  
Two isoforms exist for LC3B, the cytosolic LC3BI and the PE-conjugated LC3BII present on 
the isolation membrane and the autophagosomes. During autophagy LC3BII is degraded by 
the lysosomes, hence measurement of cellular LC3BII protein levels as the sole indicator of 
the functionality of the autophagy process and lysosomal degradation (autophagy flux) may 
provide misleading data. In order to accurately measure autophagy flux, the differences 
between LC3BII protein levels in the presence and absence of a lysosomal protease inhibitor 
such as bafilomycin A1 should be investigated. If blocking lysosomal degradation leads to 
further increase in LC3BII levels, this will indicate functional autophagy flux or lysosomal 
degradation, whereas if blocking lysosomal degradation does not induce an increase in LC3BII 
level, this will indicate defects in lysosomal degradation (Mizushima & Yoshimori, 2007).  
Increased fusion between the autophagosome and the lysosome in response to alloxan 
treatment in iVici iPSC-CMs may suggest an enhanced autophagy flux. To investigate whether 
alloxan treatment induced higher autophagy flux and LC3BII turnover, WT and iVici iPSC-CMs 
were treated for seven days with 5 mM alloxan, and 12 hours prior lysing the cells for 
immunoblotting, iPSC-CMs were treated with 200 nM bafilomycin A1 to block lysosomal 
degradation. First, in both WT and iVici iPSC-CMs, blocking lysosomal degradation by 
bafilomycin A1 resulted in an increase in LC3BII levels, which is more pronounced in WT iPSC-
CMs (Figure 18A, C). These data indicate the partially functional autophagy flux existing in 
iVici iPSC-CMs. Second, in WT iPSC-CMs, Alloxan treatment did not affect the LC3BII levels 
relative to GAPDH and the LC3BII/LC3BI ratio with and without bafilomycin A1 treatment, 
Indicating that Alloxan treatment did not affect autophagy flux in WT iPSC-CMs (Figure 18A, 
B), which is in line with our findings that alloxan did not affect the fusion between the 
autophagosome and the lysosome in WT iPSC-CMs. On the other hand, in line with the 
increased fusion between the autophagosome and the lysosome in iVici iPSC-CMs in 
response to alloxan treatment, alloxan treatment increased LC3BII turnover and autophagy 
flux in iVici iPSC-CMs, as evidenced by increased LC3BII levels relative to GAPDH and 
LC3BII/LC3BI ratio with and without bafilomycin A1 treatment (Figure 18C, D). It should be 
noted that measuring autophagy flux by assessing changes in LC3BII levels relative to GAPDH 
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and LC3BII/LC3BI ratio with and without bafilomycin A1 treatment are two different approaches 
of displaying autophagy flux findings (Gu et al., 2019; Mizushima & Yoshimori, 2007).  
Taken together, alloxan, a nonspecific OGT inhibitor, improved autophagy flux and the fusion 
between the autophagosomes and the lysosomes in iVici iPSC-CMs and had no effect on WT 
iPSC-CMs.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 18. Alloxan enhances autophagy flux in iVici iPSC-CMs. (A) Immunoblots for WT 
iPSC-CMs with and without the treatment with 5 mM alloxan for seven days and bafilomycin 
A1 12 hours prior to lysing the cells. Antibodies against GAPDH and LC3B were used. (B) 
Quantification of autophagy flux in alloxan treated and non-treated WT iPSC-CMs by 
calculating the ratio of LC3BII relative to GAPDH with and without bafilomycin A1 treatment 
and the LC3BII/LC3BI ratio with and without bafilomycin A1 treatment. Alloxan treatment did 
not affect autophagy flux in WT iPSC-CMs. iBM76.3 n=2 (6 biological replicas for each 
condition). (C) Immunoblots for iVici iPSC-CMs with and without the treatment with 5 mM 
alloxan for seven days and bafilomycin A1 12 hours prior to lysing the cells. Antibodies directed 
against GAPDH and LC3B were used. (D) Quantification of autophagy flux in alloxan treated 
and non-treated iVici iPSC-CMs by calculating the ratio of LC3BII relative to GAPDH with and 
without bafilomycin A1 treatment and the LC3BII/LC3BI ratio with and without bafilomycin 
treatment. Alloxan treatment increased autophagy flux in iVici iPSC-CMs. iVici 1.3 n=3 (at least 
8 biological replicas for each condition), iVici 1.2 n=1 (3 biological replicas for each condition). 
Each dot in the dot blots represents one biological replica, error bars = SEM, statistical 
significance was calculated using two-tailed unpaired Student’s t-test. 
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3.4.2.3 Alloxan treatment does not affect SNAP25 levels in WT and iVici iPSC-CMs 
 
Previous work showed that the autophagy defect resulting from hEPG5 knockdown in HeLa 
cells could be rescued by knockdown of SNAP25. In order to elucidate whether alloxan 
treatment enhances the fusion between the autophagosome and the lysosome in iVici iPSC-
CMs by attenuating SNAP25 protein levels, WT and iVici iPSC-CMs were treated for seven 
days with 5 mM alloxan, and then lysed for immunoblotting. Our analysis showed that alloxan 
treatment did not significantly affect SNAP25 protein levels in WT (Figure 19A, B) as well as 
in iVici (Figure 19C, D) iPSC-CMs. This indicates that the enhanced fusion in response to 
alloxan treatment in iVici iPSC-CMs is not mediated through reduced SNAP25 protein levels.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 19. Alloxan treatment does not affect SNAP25 levels in WT or iVici iPSC-CMs. (A) 
Immunoblots of SNAP25 in WT iPSC-CMs with and without treatment with 5 mM alloxan for 
seven days. GAPDH was used as an internal standard. (B) Quantification of SNAP25 protein 
levels relative to GAPDH. Alloxan treatment did not affect SNAP25 protein levels in WT iPSC-
CMs. iBM76.3 n=3 (control = 10 biological replicas, alloxan treated = 9 biological replicas), 
iWTD2.3 n=2 (control = 8 biological replicas, alloxan treated = 6 biological replicas). (C) 
Immunoblots of SNAP25 in iVici iPSC-CMs with and without treatment with 5 mM alloxan for 
seven days. GAPDH was used as an internal control. (D) Quantification of SNAP25 protein 
levels relative to GAPDH. Alloxan treatment did not affect SNAP25 protein levels in iVici iPSC-
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CMs. iVici 1.3 n=3 (control = 15 biological replicas, alloxan treated = 13 biological replicas), 
iVici 1.2 n=2 (control = 6 biological replicas, alloxan treated = 7 biological replicas). Each dot 
in the dot blots represents one biological replica, error bars = SEM. 
3.4.2.4 Alloxan seems to reduce protein O-GlcNAcylation of SNAP29 in iVici iPSC-CMs 
 
Previous work showed that loss of EPG5 in HeLa cells led to increased O-GlcNAcylation of 
SNAP29, a PTM which impairs SNAP29 function during the fusion between the 
autophagosome and the lysosome due to its reduced ability to form the Qabc SNARE complex 
with STX17 (Guo et al., 2014). Upon pharmacological inhibition of OGT using alloxan, SNAP29 
O-GlcNAcylation was reduced and its ability to form the Qabc SNARE complex with STX17 
was restored and as a result, the fusion between the autophagosome and the lysosome was 
recovered (Guo et al., 2014). In order to investigate whether alloxan improves the fusion 
between the autophagosome and the lysosome in iVici iPSC-CMs by a similar mechanism, we 
treated WT and iVici iPSC-CMs with 5 mM alloxan for seven days, then iPSC-CMs were lysed 
for immunoblotting and immunoprecipitation. First, we investigated the effect of alloxan on total 
protein O-GlcNAcylation levels in WT and iVici iPSC-CMs. Surprisingly, treatment of WT iPSC-
CMs with alloxan for seven days increased protein O-GlcNAcylation compared to non-treated 
controls (Figure 20A, B). However, in iVici iPSC-CMs, alloxan treatment resulted in the reduced 
protein O-GlcNAcylation (Figure 20C, D). These results suggest that alloxan may enhance the 
fusion between the autophagosome and the lysosome in iVici iPSC-CMs through modulating 
protein O-GlcNAcylation levels.  
In order to investigate whether alloxan treatment reduces SNAP29 O-GlcNAcylation levels and 
increases the interaction of SNAP29 with STX17, WT and iVici iPSC-CMs were treated with 5 
mM alloxan for seven days and then lysed for immunoprecipitation. First, proteins were pulled 
down using antibody-coupled agarose A beads against STX17 and then STX17 and SNAP29 
protein levels in the eluted proteins were investigated by western blotting. Interestingly, alloxan 
treatment did not affect the interaction between STX17 and SNAP29 in WT iPSC-CMs when 
compared to non-treated samples, whereas it seemed to increase the interaction between 
STX17 and SNAP29 in iVici iPSC-CMs (Figure 20E). Next proteins were pulled down using 
SNAP29 antibody-coupled agarose A beads and then the protein levels of the pulled down 
STX17 and SNAP29 as well as protein O-GlcNAcylation levels around 29 kDa were 
investigated. Interestingly alloxan treatment induced increased interaction between SNAP29 
and STX17 in alloxan-treated iVici iPSC-CMs. In addition, alloxan treatment seems to reduce 
protein O-GlcNAcylation levels of SNAP29 (Figure 20F). Taken together, our preliminary 
results suggest that alloxan enhances the fusion between the autophagosome and the 
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lysosome in iVici iPSC-CMs probably by reducing SNAP29 O-GlcNAcylation and increasing 
its interaction with STX17.  
 
 
 
 
 
 
 
 
 
 
 
Figure 20. Alloxan seems to reduce protein O-GlcNAcylation of SNAP29 in iVici iPSC-
CMs. (A) Immunoblot using antibody against O-GlcNAc in WT iPSC-CMs with and without 
treatment with 5 mM alloxan for seven days. GAPDH was used as an internal standard. (B) 
Quantification of protein O-GlcNAcylation levels relative to GAPDH. WT iPSC-CMs treated 
with 5 mM alloxan for seven days showed higher protein O-GlcNAcylation compared to non-
treated WT iPSC-CMs. iBM76.3 n=4 (control = 11 biological replicas, alloxan treated = 12 
biological replicas), iWTD2.3 n=1 (control = 3 biological replicas, alloxan treated = 3 biological 
replicas). (C) O-GlcNAc immunoblots for iVici iPSC-CMs with and without treatment with 5 mM 
alloxan for seven days. GAPDH was used as an internal standard. (D) Quantification of protein 
O-GlcNAcylation levels relative to GAPDH. IVici iPSC-CMs treated with 5 mM alloxan for seven 
days showed lower protein O-GlcNAcylation compared to non-treated iVici iPSC-CMs. iVici 
1.3 n=3 (control = 11 biological replicas, alloxan treated = 11 biological replicas), iVici 1.2 n=1 
(control = 3 biological replicas, alloxan treated = 3 biological replicas). (E) Immunoblots of WT 
and iVici iPSC-CMs with and without treatment with 5 mM alloxan for seven days after protein 
immunoprecipitation using STX17 antibody-coupled agarose A beads. Antibodies against 
EEF2 used as a control for the specificity of the antibody-coupled agarose A beads, STX17 
and SNAP29 were analyzed in eluted protein samples. Alloxan treatment did not seem to affect 
the interaction between STX17 and SNAP29 in WT iPSC-CMs whereas it seemed to increase 
the interaction between STX17 and SNAP29 in iVici iPSC-CMs. (F) Immunoblots of iVici iPSC-
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CMs with and without treatment with 5 mM alloxan for seven days after protein 
immunoprecipitation using SNAP29 antibody-coupled agarose A beads. Antibodies against 
EEF2 used as a control for the specificity of the antibody-coupled agarose A beads, STX17, 
O-GlcNAc and SNAP29 were investigated. Alloxan treatment seemed to increase the 
interaction between STX17 and SNAP29 and to reduce O-GlcNAcylation of SNAP29 in iVici 
iPSC-CMs. iVici 1.3 n=1. Each dot in the dot blots represents biological replica, error bars = 
SEM, and statistical significance was calculated using two-tailed unpaired Student’s t-test. 
3.4.3 Effect of ST078925 on iVici iPSC-CMs 
 
The compound ST078925 was identified as an inhibitor of the two OGT isoforms sOGT and 
ncOGT through a high throughput screen (Gross et al., 2005). Where the IC50 value for the 
sOGT isoform was ≈ 60 μM±10 μM, the IC50 value against the ncOGT was ≈ 100 -150 μM.  
In order to determine the concentration of ST078925 to use in our experiments, WT and iVici 
iPSC-CMs were treated with 5 µM, 10 µM, 25 µM and 50 µM ST078925 for 24 hours, and the 
effect of each concentration on cell viability by visual inspection and on general oxidative stress 
levels was investigated. None of the tested concentrations seemed to affect cell viability, in 
addition, there was a concentration dependent reduction of general oxidative stress levels in 
iVici iPSC-CMs (data not shown). Hence, we selected 25 µM ST078925 as concentration to 
use in our experiments. WT and iVici iPSC-CMs were treated with 25 µM ST078925, and then 
its effect on iPSC-CMs viability and autophagy was investigated.   
3.4.3.1 Assessment of ST078925 treatment effects on beating properties, 
mitochondrial network structure and oxidative stress in iPSC-CMs 
 
To elucidate whether ST078925 treatment has a toxic effect on WT and/or iVici iPSC-CMs, 
WT and iVici iPSC-CMs were treated for seven days with 25 µM ST078925. Cell viability was 
checked visually on daily basis, WT and iVici iPSC-CMs were viable with no apparent toxic 
effect. Analysis of beating properties of iVici iPSC-CMs after six days of ST078925 treatment 
using the video-based MATLAB analysis showed that ST078925 treatment resulted in the 
reduction of beating rate (Figure 21A), increased contraction time (Figure 21B), and increased 
relaxation time (Figure 21C) and had no effect on displacement of iVici iPSC-CMs (Figure 
21D). Analysis of mitochondrial network structure using the mitochondrial dye MitoTracker 
green showed that iVici iPSC-CMs after seven days of ST078925 treatment had slightly, but 
not significantly more elongated mitochondria compared to non-treated iVici iPSC-CMs, as 
demonstrated by the increased mitochondrial aspect ratio. ST078925 treatment had no effect 
on mitochondrial network structure in WT iPSC-CMs (Figure 21E, F). Furthermore, ST078925 
Results 
 
82 
 
 
treatment for 24 hours induced the significant reduction of general oxidative stress in iVici 
iPSC-CMs and a trend towards general oxidative reduction in WT iPSC-CMs, as evidenced by 
the CM-H2DCFDA MFI (Figure 21G). However, investigation of the effect of 25 µM ST078925 
treatment for 24 hours on mtROS levels using MitoSOX red showed that despite the reduction 
in general oxidative stress levels in iVici iPSC-CMs, it had no effect on mtROS in both WT and 
iVici iPSC-CMs, as evidenced by the similar MitoSOX red MFI between non-treated and 
treated iPSC-CMs (Figure 21H). Taken together, these findings indicate that treatment with 
ST078925 affected the beating properties of iVici iPSC-CMs by inducing further reduction in 
beating rate and further increase in contraction and relaxation time, which is different from 
those observed with alloxan. Moreover, treatment of iVici iPSC-CMs with ST078925 led to 
slightly more elongated mitochondrial network, and reduced general oxidative stress levels, 
but had no effect on mtROS in iVici iPSC-CMs. 
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Figure legend in the next page 
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Figure 21. Assessment of ST078925 treatment effects on beating properties, 
mitochondrial network structure and oxidative stress in iPSC-CMs. (A) Quantification of 
beating rate in iVici iPSC-CMs with and without treatment with 25 µM ST078925 for six days. 
ST078925 treatment reduced the beating rate of iVici iPSC-CMs. (B, C) Quantification of 
contraction and relaxation time in iVici iPSC-CMs with and without treatment with 25 µM 
ST078925 for six days. ST078925 treatment increased the contraction and relaxation time of 
iVici iPSC-CMs. (D) Quantification of displacement in iVici iPSC-CMs with and without 
treatment with 25 µM ST078925 for six days. ST078925 treatment did not affect the 
displacement of iVici iPSC-CMs. iVici 1.3 n=1 (control = 12 biological replicas, ST078925 
treated = 4 biological replicas). (E) Representative images of WT and iVici iPSC-CMs with and 
without treatment with 25 µM ST078925 for seven days and stained with MitoTracker green to 
visualize mitochondrial network morphology. ST078925 treatment did not affect mitochondrial 
network structure in WT iPSC-CMs, but slightly enhanced mitochondrial fusion in iVici iPSC-
CMs. (F) Quantification of mitochondrial aspect ratio as a measure of mitochondrial elongation 
or fragmentation. ST078925 treatment did not affect mitochondrial aspect ratio in WT iPSC-
CMs, but only slightly increased mitochondrial aspect ratio in iVici iPSC-CMs. iBM76.3 n=2 
(control = 57 cells, ST078925 treated = 14 cells), iVici 1.3 n=2 (control = 64 cells, ST078925 
treated = 34 cells), iVici 1.2 n=1 (control = 24 cells, ST078925 treated = 12 cells). Scale bar = 
50 µm. (G) Quantification of CM-H2DCFDA MFI in WT and iVici iPSC-CMs with and without 
treatment with 25 µM ST078925 for seven days. ST078925 treatment reduced general 
oxidative stress levels in iVici iPSC-CMs, as evidenced by reduced CM-H2DCFDA MFI. 
iBM76.3 n=1 (each condition = 5 biological replicas), iWTD2.3 n=1 (each condition = 5 
biological replicas), iVici 1.3 n=1 (each condition = 10 biological replicas). (H) Quantification of 
MitoSOX red MFI in WT and iVici iPSC-CMs with and without treatment with 25 µM ST078925 
for seven days. ST078925 treatment did not affect mtROS levels in both WT and iVici iPSC-
CMs. iBM76.3 n=2 (control = 18 biological replicas, ST078925 treated = 14 biological replicas), 
iWTD2.3 n=3 (control = 19 biological replicas, ST078925 treated = 14 biological replicas), iVici 
1.3 n=2 (control = 18 biological replicas, ST078925 treated = 22 biological replicas). Each dot 
in the dot blot represents one biological replica (A-D and G, H), and average mitochondrial 
aspect ratio in one cell (F), error bars = SEM. Statistical significance was calculated using one 
way ANOVA with Tukey’s post hoc (F-H) or two-tailed unpaired Student’s t-test (A-D).  
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3.4.3.2 ST078925 treatment does not enhance the autophagosome and lysosome 
fusion in iVici iPSC-CMs 
 
In order to investigate whether ST078925 treatment improves the fusion between the 
autophagosome and the lysosome in iVici iPSC-CMs, iVici iPSC-CMs were treated for seven 
days with ST078925, and 12 hours prior to fixing the cells for immunostaining, iVici iPSC-CMs 
were treated with 100 nM rapamycin to induce autophagy and 200 nM bafilomycin A1 to block 
lysosomal degradation. This treatment allowed to observe successful fusion events in iVici 
iPSC-CMs in response to ST078925 treatment. The autophagosomes were immunostained 
using the antibody directed against LC3B whereas the lysosomes were immunostained using 
the antibody against LAMP1. The fused autophagosomes and lysosomes (LC3B+/LAMP1+) 
as well as the total number of lysosomes (LAMP1+) per cell were quantified, and the 
percentage of fused autophagosomes and lysosomes relative to total number of lysosomes 
per cell was calculated. ST078925 treatment did not improve the fusion between the 
autophagosome and the lysosome in iVici iPSC-CMs (Figure 22A, B).  
 
 
 
 
 
 
 
 
 
 
Figure 22. ST078925 treatment does not enhance the autophagosome and lysosome 
fusion in iVici iPSC-CMs.  (A) Confocal images of iVici iPSC-CMs with and without treatment 
with 25 µM ST078925 for seven days and stained with LC3B (red) and LAMP1 (green) 
antibodies 12 hours after bafilomycin A1 and rapamycin treatment. Both treated and non-
treated iVici iPSC-CMs reveal empty lysosomes indicating defective fusion between the 
autophagosome and the lysosome. Scale bar = 5 µm. (B) Quantification of percentage of 
successful fusion events per cell. Both non-treated and treated iVici iPSC-CMs showed similar 
percentage of successful fusion events between the autophagosome and the lysosome. iVici 
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1.3 n=2 (control = 55 cells, ST078925 treated = 43 cells). Each dot in the dot blot represents 
% of fusion events in one cell, error bars = SEM. 
3.4.4 Effect of ST045849 on iVici iPSC-CMs 
 
The compound ST045849 was identified as an inhibitor of the two OGT isforms sOGT, ncOGT 
through a high throughput screen (Gross et al., 2005). Where the IC50 value for the sOGT 
isoform was ≈ 30 μM±2 μM and the IC50 value against the ncOGT was ≈ 53 μM±7 μM.  
In order to determine the concentration ST045849 to use in our experiments, WT and iVici 
iPSC-CMs were treated with 5 µM, 10 µM, 25 µM and 50 µM ST045849 for 24 hours, and the 
effect of each concentration on cell viability by visual inspection and on general oxidative stress 
levels was investigated. Treatment of WT and iVici iPSC-CMs with 50 µM ST045849 seemed 
to affect cell viability, hence we selected 25 µM ST045849 as concentration to use in our 
experiments as at this concentration, there was no effect on cell viability and at the same time 
no effect on general oxidative stress levels.  
3.4.4.1 Effect of ST045849 treatment on the beating properties of WT and iVici iPSC-
CMs  
 
To elucidate whether ST045849 treatment has a toxic effect on WT and/or iVici iPSC-CMs, 
WT and iVici iPSC-CMs were treated with 25 µM ST045849 for seven days. Cell viability was 
checked visually on daily basis, WT and iVici iPSC-CMs were viable with no apparent toxic 
effect. Analysis of beating properties of iVici iPSC-CMs after six days of ST045849 treatment 
using the video-based MATLAB analysis showed that ST045849 treatment resulted in the 
reduction of beating rate of iVici iPSC-CMs but an increase in beating rate of WT iPSC-CMs 
(Figure 23A), decreased contraction time and relaxation time of iVici iPSC-CMs (Figure 23B, 
C), decreased displacement of iVici iPSC-CMs and increased displacement of WT iPSC-CMs 
(Figure 23D). Taken together, these findings indicate that ST045849 treatment affects the 
beating properties of both WT iPSC-CMs and iVici iPSC-CM. 
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Figure 23. Effect of ST045849 treatment on the beating properties of WT and iVici iPSC-
CMs. (A) Quantification of beating rate per minute of WT and iVici iPSC-CMs treated with 25 
µM ST045849 for six days. ST045849 treatment reduced beating rate in iVici iPSC-CMs and 
increased beating rate in WT iPSC-CMs. (B, C) Quantification of contraction and relaxation 
time in WT and iVici iPSC-CMs treated with 25 µM ST045849 for six days. ST045849 treatment 
decreased contraction and relaxation time in iVici iPSC-CMs. (D) Quantification of 
displacement of WT and iVici iPSC-CMs treated with 25 µM ST045849 for six days. ST045849 
treatment reduced the displacement in iVici iPSC-CMs and increased the displacement in WT 
iPSC-CMs. iBM76.3 n=1 (control = 4 biological replicas, ST045849 treated = 2 biological 
replicas), iVici1.3 n=1 (control = 6 biological replicas, ST045849 treated = 3 biological replicas), 
each dot in the dot blot represents one biological replica, error bars = SEM, statistical 
significance calculated using one-way ANOVA with Tukey’s post hoc test. 
3.4.4.2 ST045849 enhances the fusion between the autophagosome and the lysosome 
in iVici iPSC-CMs but does not enhance autophagy flux 
 
Despite the effect of ST045849 on the beating properties of WT and iVici iPSC-CMs, the effect 
of ST045849 treatment on the fusion between the autophagosome and the lysosome in both 
WT and iVici iPSC-CMs was investigated. Both cell types were treated with ST045849 for 
seven days and prior to fixing the cells for immunostaining, iPSC-CMs were treated with 100 
nM rapamycin to induce autophagy and 200 nM bafilomycin A1 to block lysosomal degradation 
for 12 hours. The fused autophagosomes and lysosomes (LC3B+/LAMP1+) as well as the total 
number of lysosomes (LAMP1+) per cell were quantified, and the percentage of fused 
autophagosomes and lysosomes relative to total number of lysosomes per cell was calculated. 
Whereas ST045849 treatment did not affect the percentage of fused autophagosomes and 
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lysosomes in WT iPSC-CMs (Figure 24A, B), it induced autophagosome and lysosome fusion 
in iVici iPSC-CMs (Figure 24C, D).  
Higher fusion between the autophagosome and the lysosome in response to ST045849 
treatment in iVici iPSC-CMs suggests higher autophagy flux and LC3BII turnover. In order to 
investigate whether ST045849 treatment increases autophagy flux in iVici iPSC-CMs, iVici 
iPSC-CMs were treated with ST045849 for seven days and prior lysing the cells for 
immunoblotting, iVici iPSC-CMs were treated with 200 nM bafilomycin to block lysosomal 
degradation for 12 hours. Surprisingly, ST045849 treatment did not increase LC3BII turnover 
and autophagy flux in iVici iPSC-CMs, as evidenced by the LC3BII protein levels relative to 
GAPDH and the LC3BII/LC3BI ratio with and without bafilomycin treatment (Figure 24E, F). 
Taken together, ST045849, a specific OGT inhibitor, improved the fusion between the 
autophagosome and the lysosome in iVici iPSC-CMs but did not enhance autophagy flux in 
iVici iPSC-CMs.  
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Figure legend in the next page 
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Figure 24. ST045849 enhances the fusion between the autophagosome and the 
lysosome in iVici iPSC-CMs but does not enhance autophagy flux. (A) Confocal images 
of WT iPSC-CMs treated with 25 µM ST045849 for seven days and stained with LC3B (red) 
and LAMP1 (green) antibodies after bafilomycin and rapamycin treatment for 12 hours. 
ST045849 treatment did not affect the fusion between the autophagosome and the lysosome 
in WT iPSC-CMs. (B) Quantification of percentage of successful fusion events per cell. WT 
iPSC-CMs with and without ST045849 treatment show similar percentage of successful fusion 
events between the autophagosome and the lysosome. iBM76.3 n=1 (control = 36 cells, 
ST045849 treated = 8 cells), iWTD2.3 n=1 (control = 7 cells, ST045849 treated = 5 cells), scale 
bar = 5 µm. (C) Confocal images of iVici iPSC-CMs treated with 25 µM ST045849 for seven 
days and stained with LC3B (red) and LAMP1 (green) antibodies after bafilomycin and 
rapamycin treatment for 12 hours. ST045849 treatment increased the fusion between the 
autophagosome and the lysosome in iVici iPSC-CMs. (D) Quantification of percentage of 
successful fusion events per cell. ST045849 treated iVici iPSC-CMs show higher percentage 
of successful fusion events between the autophagosome and the lysosome. iVici 1.3 n=2 
(control = 49 cells, ST045849 treated = 35 cells), iVici 1.2 n=2 (control = 31 cells, ST045849 
treated = 32 cells), scale bar = 5 µm. (E) Immunoblots for iVici iPSC-CMs treated with 25 µM 
ST045849 for seven days and with bafilomycin for 12 hours prior to lysing the cells. Antibodies 
directed against GAPDH and LC3B were sued. (F) Quantification of autophagy flux in control 
and ST045849 treated iVici iPSC-CMs by calculating the ratio of LC3BII relative to GAPDH 
with and without bafilomycin treatment and the LC3BII/LC3BI ratio with and without bafilomycin 
treatment. ST045849 treatment did not affect autophagy flux in ST045849 iPSC-CMs. iVici 1.3 
n=1 (each condition = 3 biological replicas), (A-D) each dot in the dot blot represents % fusion 
events in one cell, (E-F) each dot in the dot blots represents one biological replica, error bars 
= SEM, statistical significance calculated using two-tailed unpaired Student’s t-test.  
3.4.4.3 ST045849 reduces SNAP25 protein levels and O-GlcNAcylation levels in iVici 
iPSC-CMs  
 
In order to elucidate whether ST045849 treatment enhances the fusion between the 
autophagosome and the lysosome in iVici iPSC-CMs by reducing SNAP25 protein levels, WT 
and iVici iPSC-CMs were treated with ST045849 for seven days, then cells were lysed for 
immunoblotting. Our analysis showed that ST045849 treatment did not affect SNAP25 protein 
levels in WT iPSC-CMs (Figure 25A, B), whereas it reduced SNAP25 protein levels in iVici 
iPSC-CMs (Figure 25C, D). This indicates that the enhanced fusion in response to ST045849 
treatment in iVici iPSC-CMs maybe mediated through reduction of SNAP25 protein levels. We 
further investigated the effect of ST045849 treatment on protein O-GlcNAcylation in WT and 
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iVici iPSC-CMs. WT and iVici iPSC-CMs were treated with 25 µM ST045849 for seven days, 
then cells were lysed for immunoblotting. Our analysis showed that ST045849 treatment did 
not affect protein O-GlcNAcylation levels in WT iPSC-CMs (data not shown), whereas it 
reduced protein O-GlcNAcylation levels in iVici iPSC-CMs (Figure 25E, F). Together, our 
findings indicate that ST045849 treatment may enhance the fusion between the 
autophagosome and the lysosome in iVici iPSC-CMs through two distinct mechanisms, the 
first through decreasing SNAP25 protein levels and the second through decreasing O-
GlcNAcylation of SNAP29. However, further detailed analysis is required to further support 
these findings.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 25. ST045849 reduces SNAP25 protein levels and O-GlcNAcylation levels in iVici 
iPSC-CMs. (A) Immunoblots for WT iPSC-CMs treated with 25 µM ST045849 for seven days. 
Antibodies directed against SNAP25 and GAPDH were applied. (B) Quantification of SNAP25 
protein levels relative to GAPDH. ST045849 treatment did not affect SNAP25 protein levels in 
WT iPSC-CMs. iBM76.3 n=3 (control = 10 biological replicas, ST045849 treated = 8 biological 
replicas), iWTD2.3 n= 1 (each condition = 3 biological replicas). (C) Immunoblots for iVici iPSC-
CMs treated with 25 µM ST045849 for seven days. Antibodies directed against SNAP25 and 
GAPDH were used. (D) Quantification of SNAP25 levels relative to GAPDH. ST045849 
treatment reduced SNAP25 protein levels in iVici iPSC-CMs. iVici 1.3 n=3 (control = 14 
biological replicas, ST045849 treated = 14 biological replicas), iVici 1.2 n= 2 (each condition = 
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6 biological replicas). (E) Immunoblots for iVici iPSC-CMs treated with 25 µM ST045849 for 
seven days. Antibodies directed against O-GlcNAc and GAPDH were analyzed. (F) 
Quantification of O-GlcNAc levels relative to GAPDH. ST045849 treatment reduced O-GlcNAc 
in iVici iPSC-CMs. iVici 1.3 n=3 (control = 13 biological replicas, ST045849 treated = 14 
biological replicas), iVici 1.2 n=2 (each condition = 6 biological replicas), each dot in the dot 
blots represents one biological replica, error bars = SEM, statistical significance calculated 
using two-tailed unpaired Student’s t-test.  
3.4.5 Effect of OSMI-1 on iVici iPSC-CMs 
 
OSMI-1 is a specific OGT inhibitor identified through a biased library screen followed by analog 
synthesis (Ortiz-Meoz et al., 2015). It has been shown that OSMI-1 inhibited ncOGT with an 
IC50 value ≈2.7 μM. In order to determine the concentration of OSMI-1 to use in our 
experiments, iVici iPSC-CMs were treated with 2.5 µM, 5 µM, 10 µM and 20 µM OSMI-1 for 
24 hours, and the effect of each concentration on cell viability by visual inspection and on 
general oxidative stress levels was investigated. Treatment of iVici iPSC-CMs with 20 µM 
OSMI-1 seemed to have no effect on iVici iPSC-CM viability based on visual inspection. 
However, OSMI-1 seemed to have a prominent negative effect on beating properties of WT 
and iVici iPSC-CMs evident by significant reduction of beating rate observed by the visual 
inspection. Moreover, general oxidative stress levels were reduced in iVici iPSC-CMs only in 
response to treatment with 20 µM OSMI-1 for 24 hours as evident by decreased CM-H2DCFDA 
MFI compared to non-treated controls (Figure 26A).  
 
 
 
 
 
 
 
Figure 26. OSMI-1 reduced general oxidative stress in iVici iPSC-CMs. (A) Quantification 
of CM-H2DCFDA MFI in iVici iPSC-CMs with and without the treatment with 20 µM OSMI-1. 
OSMI-1 treatment reduced general oxidative stress levels in iVici iPSC-CMs. iVici 1.3 n=3 
(each condition = 17 biological replicas), each dot in the dot blot represents MFI one biological 
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replica, error bars = SEM, statistical significance calculated using two-tailed unpaired Student’s 
t-test.   
3.4.5.1 OSMI-1 does not enhance the autophagosome and lysosome fusion in iVici 
iPSC-CMs  
 
In order to investigate whether OSMI-1 treatment improves the fusion between the 
autophagosome and the lysosome in iVici iPSC-CMs, WT and iVici iPSC-CMs were treated 
for seven days with OSMI-1. Prior to fixing the cells for immunostaining iPSC-CMs were treated 
with 100 nM rapamycin to induce autophagy and 200 nM bafilomycin to block lysosomal 
degradation for 12 hours. The fused autophagosomes and lysosomes (LC3B+/LAMP1+) as 
well as the total number of lysosomes (LAMP1+) per cell were quantified, and the percentage 
of fused autophagosomes and lysosomes relative to total number of lysosomes per cell was 
calculated. OSMI-1 treatment led to the reduction of the fusion between the autophagosome 
and the lysosome in WT iPSC-CMs (Figure 27A, B) and did not improve the fusion between 
the autophagosome and the lysosome in iVici iPSC-CMs (Figure 27C, D).  
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Figure 27. OSMI-1 does not enhance the autophagosome and lysosome fusion in iVici 
iPSC-CMs and impairs the fusion in WT iPSC-CMs. (A) Confocal images of WT iPSC-CMs 
with and without the treatment with 20 µM OMSI-1 for seven days and stained with LC3B (red) 
and LAMP1 (green) antibodies after bafilomycin and rapamycin treatment for 12 hours. (B) 
Quantification of percentage of successful fusion events per cell. Treatment of WT iPSC-CMs 
with OSMI-1 reduced the percentage of successful fusion events between the autophagosome 
and the lysosome. iBM76.3 n=1 (control = 10 cells OSM-1 treated = 7 cells), scale bar = 5 µm. 
(C) Confocal images of iVici iPSC-CMs with and without the treatment with 20 µM OMSI-1 for 
seven days and stained with LC3B (red) and LAMP1 (green) antibodies after bafilomycin and 
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rapamycin treatment for 12 hours. (D) Quantification of percentage of successful fusion events 
per cell. OSMI-1 treatment of iVici iPSC-CMs did not affect the percentage of successful fusion 
events between the autophagosome and the lysosome. iVici 1.3 n=1 (control = 28 cells OSM-
1 treated = 10 cells), scale bar = 5 µm. Each dot in the dot blot represents % of fusion events 
in one cell, error bars = SEM, statistical significance calculated using two-tailed unpaired 
Student’s t-test.  
3.4.5.2 OSMI-1 reduces SNAP25 protein levels and protein O-GlcNAcylation levels in 
iVici iPSC-CMs  
 
We further investigated the effect of OSMI-1 on SNAP25 protein levels, and protein O-
GlcNAcylation levels in iVici iPSC-CMs. iVici iPSC-CMs were treated with 20 µM OSMI-1 for 
seven days and then cells were lysed for immunoblots. Interestingly, OSMI-1 induced a 
reduction in SNAP25 protein levels in iVici iPSC-CMs (Figure 28A, B). Moreover, OSMI-1 
seemed to induce a reduction in protein O-GlcNAcylation levels in iVici iPSC-CMs (Figure 28A, 
C). These results were intriguing, despite reducing SNAP25 protein levels and protein O-
GLCNAcylation levels, OSMI-1 did not enhance the fusion between the autophagosome and 
the lysosome in iVici iPSC-CMs.   
 
 
 
 
 
 
 
Figure 28. OSMI-1 reduces SNAP25 protein levels and protein O-GlcNAcylation levels in 
iVici iPSC-CMs. (A) Immunoblots for iVici iPSC-CMs with and without treatment with 20 µM 
OSMI-1 for seven days. Antibodies against SNAP25, GAPDH and O-GlcNAc were analyzed. 
(B) Quantification of SNAP25 protein levels relative to GAPDH. OSMI-1 treatment reduced 
SNAP25 levels in iVici iPSC-CMs. iVici 1.3 n=1 (each condition = 3 biological replicas), iVici 
1.2 n=1 (control = 3 biological replicas, OSMI-1 treated = 4 biological replicas). (C) 
Quantification of O-GlcNAc levels relative to GAPDH. OSMI-1 treatment seems to reduce O-
GlcNAc levels in iVici iPSC-CMs. iVici 1.3 n=1 (each condition = 3 biological replicas), each 
dot in the dot blots represents one biological replica, error bars = SEM, statistical significance 
calculated using two-tailed unpaired Student’s t-test. 
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4 Discussion 
 
In this study, we first studied cellular insults including oxidative stress, mitochondrial 
dysfunction and ER stress in iVici iPSC-CMs, which are known to both induce autophagy and 
occur due to dysfunctional autophagy. Indeed, due to the autophagy defect, several molecular 
defects were identified in iVici iPSC-CMs including accumulation of fragmented mitochondria, 
increased protein O-GlcNAcylation and increased mtROS. As a result, iVici iPSC-CMs are 
stuck in a viscous cycle of chronic induction of the defective autophagy process and further 
accumulation of cellular insults leading to cellular dysfunction. These cellular insults are known 
contributors to the development of cardiomyopathy and may present mechanistic insight into 
the development of cardiomyopathy in Vici syndrome. Moreover, we tested the use of different 
pharmacological OGT inhibitors as a mean to enhance the fusion between the autophagosome 
and the lysosome and subsequently to enhance the autophygy flux in iVici iPSC-CMs. We 
identified two OGT inhibitors (alloxan and ST045849), which enhanced the fusion between the 
autophagosome and the lysosome in iVici iPSC-CMs. Furthermore, we provided preliminary 
insight for the mechanism of the enhanced autophagosome and lysosome fusion in response 
to treatment with the nonspecific OGT inhibitor alloxan. Below we discuss in more details the 
role of the identified molecular defects in cardiomyopathy development, the open questions for 
future studies.  
4.1 IVici iPSC-CMs show fusion between autophagosomes and 
lysosomes despite the EPG5 mutation 
 
In iVici iPSC-CMs, the autophagy flux was inhibited, as indicated by the reduced fusion of the 
autophagosome and the lysosome when compared to WT iPSC-CMs. However, despite the 
homologous EPG5 mutation in iVici iPSC-CMs, the fusion between the autophagosome and 
the lysosome was not completely abolished and successful fusion events between the 
autophagosome and the lysosome were observed. The successful fusion events indicate that 
EPG5 may be dispensable for the fusion between the autophagosome and the lysosome, 
rather it optimizes the fusion process. Furthermore, previous work showed that the amino acids 
(427-1094) are the essential amino acids required for EPG5 function in mediating the 
membrane fusion between the autophagosome and lysosome (Wang et al., 2016). The EPG5 
mutation c.4952+1G>A in iVici iPSC-CMs results in the removal of exon 28 and introduces a 
premature stop codon at exon 29. This mutation does not affect the essential amino acids for 
EPG5 function (427-1094).  
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In this study we used two set of primers to investigate the expression of EPG5 mRNA in iVici 
iPSC-CMs. The first primer pair covered part of exon 22 whereas the second primer pair 
covered part of exons 23 and 24. Our analysis showed that indeed EPG5 is expressed in iVici 
iPSC-CMs. It is possible that EPG5 expressed in iVici iPSC-CMs is able to mediate the 
observed fusion events between the autophagosome and the lysosome, however, this 
possibility will bring another major question. If indeed the mutant EPG5 in iVici iPSC-CMs can 
mediate some fusion events between the autophagosome and the lysosome, why is there 
reduced fusion between the autophagosome and the lysosome in iVici iPSC-CMs compared 
to WT iPSC-CMs? Moreover, in our study, in order to complement our EPG5 mRNA expression 
analysis, we attempted to investigate EPG5 protein expression in iVici iPSC-CMs, but the 
antibody used did not produce reliable EPG5 signal that can be utilized to investigate EPG5 
protein expression (data not shown). 
If indeed our future analysis showed stable EPG5 protein expression in iVici iPSC-CMs, two 
possible factors could explain the reduced fusion between the autophagosome and the 
lysosome in iVici iPSC-CMs. Our analysis of the protein expression levels of the SNARE 
proteins involved in the fusion between the autophagosomes and the lysosomes showed 
higher protein expression of SNAP29 and VAMP8 and lower protein expression STX17. Given 
the essential role of STX17 in mediating the fusion between the autophagosome and the 
lysosome during autophagy, the decreased fusion between the autophagosome and the 
lysosome in iVici iPSC-CMs maybe caused by the reduced STX17 expression. Moreover, 
previous work illustrated that EPG5 loss of function led to the formation of STX17-SNAP25-
VAMP8 SNARE complex instead of the STX17-SNAP29-VAMP8 SNARE complex, leading to 
non-specific fusion of the autophagosome with endocytic vesicles (Wang et al., 2016). In our 
analysis we observed higher protein expression of SNAP25 in iVici iPSC-CMs. Hence, it’s 
possible that the decreased fusion between the autphagosome and the lysosome in iVici iPSC-
CMs is a result of increased formation of STX17-SNAP25-VAMP8 SNARE complex. Although 
these two possibilities may explain the reduced fusion between the autophagosome and the 
lysosome in iVici iPSC-CMs assuming stable EPG5 protein expression, one key question is 
how the EPG5 mutation in iVici iPSC-CMs affects the protein expression levels of both 
SNAP25 and STX17.  
Furthermore, recent work identified another set of SNARE proteins playing a role in the fusion 
between the autophagosome and the lysosome. It was shown that the R-SNARE 
synaptobrevin homolog YKT6 (YKT6) is imported to the mature autophagosome during 
autophagy where it interacts strongly with the Qbc SNARE SNAP29 to form the YKT6-SNAP29 
complex which interacts with the lysosomal STX7 Qa SNARE (Matsui et al., 2018). It is 
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possible that this set of SNARE proteins does not require EPG5 as a tethering factor, and 
hence is responsible for the successful fusion events observed in Vici iPSC-CMs. Whether this 
set of SNARE proteins mediating the fusion between the autophagosome and the lysosome 
requires EPG5 as a tethering factor remains to be elucidated. Furthermore, whether these 
SNARE proteins play a role in autophagy in WT and iVici iPSC-CMs remains to be elucidated.  
Finally, in this study, we observed increased SNAP25 levels in iVici iPSC-CMs compared to 
WT iPSC-CMs. Beside SNAP25 role in the endocytic and exocytic pathways (Zhang et al., 
2013), SNAP25 have been shown to have a functional interaction with the L-Type calcium 
channel in neurons, regulating calcium influx and the release of neurotransmitters  (Wiser et 
al., 1996). Furthermore, SNAP25 was shown to be expressed in the glutamatergic neurons but 
absent in the GABAergic neurons. Upon membrane depolarization, there was a two-fold 
increase in intracellular calcium in GABAergic compared to glutamatergic neurons. The 
increased SNAP25 levels in glutamatergic neurons was responsible for their lowered calcium 
influx and responsiveness (Verderio et al., 2004). Based on these results, it will be interesting 
to investigate whether the increased SNAP25 levels in iVici iPSC-CMs negatively regulate the 
cardiac L-type calcium channel activity through possible interaction. This investigation may 
give novel insight into the role of SNAP25 in CMs and provide an explanation for the slower 
beating observed in iVici iPSC-CMs.  
4.2 Mitochondrial fragmentation, mtROS and HF  
 
Investigating the mitochondrial network structure in iVici iPSC-CMs showed that iVici iPSC-
CMs accumulate fragmented mitochondrial network. In addition, we observed increased 
mtROS in iVici iPSC-CMs. Both the accumulation of fragmented mitochondrial and the 
increase of mtROS are known contributing factors to cardiomyopathy development. On the 
other hand, our analysis revealed increased mitochondrial membrane potential despite the 
fragmented mitochondria. Moreover, we attempted to assess mitochondrial function in iVici 
iPSC-CMs by measuring oxygen consumption rate using the seahorse mitostress assay, 
however, due to high variability in data from experiment to experiment (data not shown), a 
reliable conclusion whether the mitochondria in iVici iPSC-CMs are functional or not could not 
be made. It seems that iVici iPSC-CMs are stuck in a feedback loop of mitochondrial 
hyperpolarization, increased mtROS and mitochondrial fragmentation, hence, maintaining iVici 
iPSC-CMs under pathological stress.  
Fragmented mitochondrial accumulation has been observed in animal and human models of 
HF (Chen et al., 2009)  and has been postulated to contribute to the development of 
cardiomyopathy and HF (Chen, et al., 2011; Dorn, 2015; Givvimani et al., 2012; Pennanen et 
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al., 2014; Twig & Shirihai, 2010; Wai et al., 2015). Mitochondrial network structure is controlled 
by different sets of GTPases, mitofusin 1 (MFN1) and 2 (MFN2), which are responsible for the 
fusion of the OMM, dynamin-related protein 1 (DRP1), which is responsible for mitochondrial 
fission (Youle & Van Der Bliek, 2012), and optic atrophy 1 (OPA1). OPA1 has two isoforms 
resulting from proteolytic processing by two different proteases. Processing of OPA1 by the 
inner mitochondrial membrane (IMM) i-AAA protease (YME1L) results in accumulation of the 
long OPA1 isoform (L-OPA1), which induces the fusion of the IMM (Mishra et al., 2014). 
Processing of OPA1 by the protease metalloendopeptidase OMA1, stimulated by stress 
conditions, leads to the accumulation of the short isoform of OPA1 (S-OPA1), which induces 
mitochondrial fragmentation (Anand et al., 2014; Baker et al., 2014). Mitochondrial 
fragmentation in iVici iPSC-CMs could be a result of increased activity/protein expression of 
DRP1, increased OPA-1 processing by OMA1 and/or decreased MFN1, MFN2 activity/ protein 
levels. Identifying the factor(s) leading to mitochondrial fragmentation in iVici iPSC-CMs will 
provide more insight into molecular mechanisms contributing to cellular defects in iVici iPSC-
CMs.  
The accumulation of fragmented mitochondria is often associated with mitochondrial 
depolarization, dysfunction, and removal by mitophagy. We were intrigued to observe that the 
mitochondria in iVici iPSC-CMs are hyperpolarized, a mitochondrial state which potentiates 
mtROS production and at the same time destabilizes PINK1 on the OMM preventing the 
initiation of mitophagy (Galloway & Yoon, 2012). In conditions of defective autophagy, 
mitochondrial hyperpolarization has been observed as a protective mechanism preventing the 
initiation of the defective autophagy process. This has been shown in iPSCs-based model of 
Parkinson disease with defects in autophagy and mitophagy where the iPSCs accumulated 
hyperpolarized mitochondria and the increased mitochondrial membrane potential blocked the 
initiation of the defective mitophagy process (Scheibye-Knudsen et al., 2014). It is possible 
that iVici iPSC-CMs adapt a similar mechanism to block the initiation of the defective mitophagy 
process hence the observed mitochondrial hyperpolarization. Moreover, Previous studies 
demonstrated that the increase of mtROS induced nuclear DNA breaks leading to activation 
of the DNA damage sensor Poly ADP ribose polymerase 1 (PARP-1) (Chen et al., 2017). The 
active PARP-1 could attenuate the expression and the activity of the uncoupling protein 2 
(UCP2) which protects the mitochondria against oxidative stress and induces mitochondrial 
depolarization for dysfunctional mitochondria removal (Fang et al., 2014).Hence, it is possible 
that the increased mtROS in iVici iPSC-CMs activates PARP-1 leading to the observed 
mitochondrial hyperpolarization. Finally, the mitochondrial hyperpolarization observed in iVici 
iPSC-CMs might be due to increased mitochondrial content in iVici iPSC-CMs. Future work 
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should investigate mitochondrial content in WT and iVici iPSC-CMs via measuring 
mitochondrial DNA content.  
Mitochondrial dysfunction is a contributing factor to cardiac mechanical failure and 
cardiomyopathy development (Neubauer, 2007). Previous studies using Vici patient samples 
showed deficiency of the mitochondrial ETC complexes 1 and 4 (Balasubramaniam et al., 
2018; Byrne, Jansen, Siddiqui, et al., 2016; Cullup et al., 2012; Ebrahimi-Fakhari et al., 2016; 
Waldrop et al., 2018). In animal and human models of HF, loss of mitochondrial ETC complex 
1 and/or 4 is postulated to induce mitochondrial fragmentation and mtROS production 
(Karamanlidis et al., 2013; Lemieux et al., 2011; Maranzana et al., 2013). It’s possible that iVici 
iPSC-CMs are deficient of mitochondrial ETC complexes 1 and 4, hence the increased 
mitochondrial fragmentation and increased mtROS observed in iVici iPSC-CMs. Analysis of 
the expression level and the activity of different ETC complexes iVici iPSC-CMs will not only 
provide insight into the factors leading to mitochondrial fragmentation as well as increased 
mtROS but also provide an insight into mitochondrial function in iVici iPSC-CMs. A more 
reliable alternative approach to the seahorse mitostress assay.  
Increased mtROS has been shown to contribute to HF progression through increased 
mitochondrial damage and fragmentation, and direct chemical oxidation of cardiac ion 
channels and of cardiac sarcomere proteins altering their sensitivity to calcium (Breitkreuz & 
Hamdani, 2015; Chan, 2006; Chen et al., 2017; Mishra et al., 2014; Zhou & Tian, 2018). 
Interestingly, our analysis of spontaneous calcium transients in iVici iPSC-CMs showed 
decreased systolic calcium levels compared to WT iPSC-CMs, and SR calcium content in iVici 
iPSC-CMs was higher when compared to WT iPSC-CMs. These data suggest that less calcium 
is released from the SR during each beat of iVici iPSC-CMs. We also observed that the beating 
rate was reduced in iVici iPSC-CMs, pointing out the possible impairment of the excitation-
contraction coupling in iVici iPSC-CMs. In addition, the contraction and relaxation velocity as 
well as the displacement were increased in iVici iPSC-CMs compared to WT iPSC-CMs, 
suggesting that iVici iPSC-CMs might beat stronger to generate more fore for compensating 
the lower beating rate. Similar data were reported when iVici iPSC-CMs were cultured in 3D 
engineered heart muscle (Qi, 2016). Taken together, these direct effects of mtROS lead to 
defects in excitation contraction coupling and the contractile machinery of the CMs. 
4.3 iVici iPSC-CMs may suffer from ER stress 
 
ER stress includes the activation of several protective pathways under conditions of protein 
aggregation and/or misfolded protein accumulation where defects in autophagy have been 
shown to cause ER stress (Yang et al., 2010). The protective pathway(s) activated during ER 
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stress lead to reduced protein synthesis and increased protein-folding capacity of the cell. In 
the heart, ER stress is believed to be an adaptive mechanism during cardiac hypertrophy to 
increase the ER capacity for the increased protein synthesis. However, studies using heart 
samples from dilated cardiomyopathy patients and mouse models of transverse aortic 
constriction (TAC) suggested that prolonged activation of ER stress contributed to cardiac 
dysfunction and apoptosis during heart failure via the transcription factor C/EBP homologous 
protein (CHOP)  (Okada et al., 2004; Xu et al., 2009). Moreover, ER stress induced oxidative 
stress leading to increased oxidative activation of CAMKII, which induces cardiac remodeling 
and contractile dysfunction (Roe & Ren, 2013).  
In iVici iPSC-CMs, we observed no increase in the expression of the ER stress markers ATF4 
and BiP, but an increase in the ER stress marker IRE1α, indicating possible ER stress 
activation in iVici iPSC-CMs through the IRE1α arm. Upon IRE1α activation, XBP1 is converted 
to its transcriptionally active short isoform (XBP1s) (Yoshida et al., 2001). To further investigate 
whether iVici iPSC-CMs exhibit ER stress through the IRE1α arm, future studies should focus 
on the investigation of phosphorylation of IRE1α and the expression of XBP1s in iVici iPSC-
CMs compared to WT iPSC-CMs.  
4.4 Protein O-GlcNAcylation and heart failure 
 
In this study, iVici iPSC-CMs showed increased protein O-GlcNAcylation when compared to 
WT iPSC-CMs. We also showed that treatment of WT iPSC-CMs with bafilomycin A1 for 12 
hours was sufficient to induce significant increase in protein O-GlcNAcylation. These results 
suggest that the defective autophagy in iVici iPSC-CMs is the stimulating factor of increased 
protein O-GlcNAcylation. However, the downstream mechanism leading to the increase of 
protein O-GlcNAcylation remains to be elucidated. Protein O-GlcNAcylation is controlled by 
two set of enzymes responsible for addition and removal of the O-GlcNAc modification. In 
mouse models of HF, the increased protein O-GlcNAcylation was associated with increased 
OGT levels and activity (Kolwicz & Tian, 2011). Moreover, in STZ diabetic rats, decreased 
autophagy flux was observed and contributed to the development of diabetic cardiomyopathy. 
The decreased autophagy flux was a result of increased O-GlcNAcylation modification of 
SNAP29. In the hearts of these rats the increased protein O-GlcNacylation was a result of 
increased OGT expression and decreased OGA expression (Huang et al., 2018). Future 
studies should investigate the mechanism leading to increased protein O-GlcNAcylation in iVici 
iPSC-CMs, either through increased OGT expression and/or decreased OGA activity and 
expression. 
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Under stress conditions, such as protein aggregation, protein O-GlcNAcylation is activated as 
a protective mechanism to prevent aggregation of proteins (Yang & Qian, 2017). Despite the 
protective role of protein O-GlcNAcylation, chronic protein O-GlcNAcylation is pathological. 
Failing human and mouse heart tissues have shown increased HBP activity and increased 
protein O-GlcNAcylation, where the increased protein O-GlcNAcylation is believed to be a 
major insult contributing to heart failure development via distinct mechanisms (Ducheix et al., 
2018; Lunde et al., 2012). For example, induction of pressure overload in mice by TAC led to 
increased protein O-GlcNAcylation, which induced the development of cardiac hypertrophy 
and HF by increasing the nuclear translocation and activity of nuclear factor of activated T-
cells (NFAT) (Facundo et al., 2012). Interestingly, to induce cardiac hypertrophy, increased O-
GlcNAcylation by itself was insufficient and required the presence of a pro hypertrophy signal 
(Facundo et al., 2012; Gélinas et al., 2018). Together these findings indicate the possibility that 
the increased surface area phenotype observed in iVici iPSC-CMs maybe a result of the 
increased protein O-GlcNAcylation. Investigating the role of the increased protein O-
GlcNAcylation in driving iVici iPSC-CMs should be of interest in future work.  
Moreover, increased protein O-GlcNAcylation has been shown to decrease OPA1 expression 
and to increase O-GlcNAcylation of DRP1 at threonine 585 and 586. DRP1 O-GlcNAcylation 
at these two sites increases its activity leading to enhanced mitochondrial fragmentation 
(Gawlowski et al., 2012). It will be interesting to investigate whether the increased O-
GlcNAcylation in iVici iPSC-CMs leads to increased DRP1 O-GlcNAcylation modification at 
threonine 585 and 586, hence increased mitochondrial fragmentation. In addition, previous 
research showed that CMs exposed to high glucose exhibit increase O-GlcNAcylation of 
mitochondrial proteins including mitochondrial complex I subunit NDUFA9 and the complex IV 
subunit COXI which subsequently lead to reduced mitochondrial ATP production (Hu et al., 
2009). As discussed earlier in the current work we could not obtain reliable data supporting 
mitochondrial function or dysfunction in iVici iPSC-CMs. Assuming that future analysis 
indicated mitochondrial dysfunction in iVici iPSC-CMs, it will be of interest to investigate 
whether there is a link between increased O-GlcNAcylation and mitochondrial dysfunction in 
iVici iPSC-CMs.  
In addition, increased protein O-GlcNAcylation observed during different forms of 
cardiomyopathy has been shown to decrease calcium sensitivity of contractile proteins 
including tropomyosin, troponin 1 and actin leading to myofilament dysfunction (Ducheix et al., 
2018; Ramirez-Correa et al., 2015; Ramirez et al., 2012). Increased protein O-GlcNAcylation 
has also been shown to induce arrhythmias by modification of the cardiac NaV1.5 (Yu et al., 
2018).  Taking together, these findings point out a possible role of increased protein O-
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GlcNAcylation in promoting mitochondrial fragmentation and the abnormal beating properties 
of iVici iPSC-CMs, which could also arise due to increased mtROS production as discussed 
earlier. This illustrates the complexity of providing a clear causal relationship while studying 
the pathologic phenotype in iVici iPSC-CMs, as different cellular insults are able to induce the 
same pathologic phenotype via similar or distinct mechanisms. 
4.5 Is Vici associated cardiomyopathy a form of diabetic 
cardiomyopathy? 
 
In our work we identified several molecular defects common between iVici iPSC-CMs and 
diabetic cardiomyopathy including increased protein O-GlcNAcylation and increased mtROS 
(Boudina & Abel, 2007; Tse et al., 2016). Diabetic cardiomyopathy is a form of non-ischemic 
cardiac disease which progressively develops in diabetic patients. It is characterized by 
hypertrophy, fibrosis and depressed contractility. Moreover, previous work in our group 
showed that iVici iPSC-CMs have reduced active AKT signaling, and increased FOXO3 and 
FOXO1 activity, evident by decreased AKT phosphorylation at serine 473 and threonine 308, 
and decreased FOXO3 phosphorylation at threonine 32 FOXO1 phosphorylation at threonine 
24 despite the presence of insulin in the medium, indicating insulin resistance (Qi, 2016), a 
common characteristic of diabetic cardiomyopathy (Battiprolu et al., 2012). Interestingly insulin 
resistance in the heart has been shown to induce mitochondrial fragmentation and was 
identified as a key insult contributing to the development of contractile dysfunction and diabetic 
cardiomyopathy (Katare et al., 2010; Kuzmicic et al., 2014; Parra et al., 2014) Protein O-
GlcNAcylation has been shown to induce insulin resistance in the adipose tissue, skeletal 
muscle and the heart by inhibiting the phosphorylation of AKT at threonine 308 and serine 473 
(Ducheix et al., 2018; Katare et al., 2010; X. Yang et al., 2008; Yang & Qian, 2017).. Whether 
the reduced AKT phosphorylation in iVici iPSC-CMs (Qi, 2016) is a result of the increased 
protein O-GlcNAcylation remains to be investigated.  
Moreover, we observed several beating defects in iVici iPSC-CMs, including decreased 
beating rate, increased contraction time, increased relaxation time and increased 
displacement. Similarly, several pieces of evidence indicated that the diabetic heart exhibits 
slow contraction rate, slow relaxation rate and decreased resting heart rate. Preliminary due 
to defects in the electrophysiological machinery of the cells, including SERCA2 and RYR2 and 
decreased calcium sensitivity of contractile machinery due to increased protein O-
GlcNAcylation (Penpargkul et al., 1981; Pierce & Russell, 1997; Ramirez-Correa et al., 2015; 
Trost et al., 2002). It’s possible that the increased protein O-GlcNAcylation in iVici iPSC-CMs 
is the cause of the similar phenotypes between iVici iPSC-CMs and diabetic cardiomyopathy.   
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Under normal physiological conditions in the heart, more than 90% of ATP is generated in 
mitochondria where 60-70% of the ATP produced is generated through free fatty acid (FAA) 
oxidation and the remaining amounts through glucose metabolism (Gertz et al., 1988; Wisneski 
et al., 1987). Moreover, in the healthy heart glucose is uptaken mainly through the insulin-
dependent glucose transporter type 4 (GLUT4), which is translocated from the cytoplasm to 
the cell membrane upon insulin stimulation and AKT activation (Bertrand et al., 2008). Because 
of insulin resistance in the diabetic heart, glucose uptake and metabolism are inhibited and as 
a result the uptake and metabolism of FFA is increased. Interestingly, this metabolic shift and 
the increased FFA uptake leads to accumulation of FFA inside the CMs and lipotoxicity 
development, a state which leads to increased oxidative stress, and cardiac dysfunction 
(Montaigne et al., 2014; Nagao et al., 2013; Van De Weijer et al., 2011). 
A recent study suggested that an in vitro disease model of diabetic cardiomyopathy should 
exhibit insulin resistance, metabolic shift toward reliance on FFA metabolism, lipotoxicity, 
hypertrophy, oxidative stress, mitochondrial dysfunction and contractile dysfunction (Burkart et 
al., 2016; Granéli et al., 2019). In iVici iPSC-CMs, we provide evidence of the presence of 
reduced AKT phosphorylation, hypertrophy, contractile dysfunction, and oxidative stress. 
Moreover, we provide evidence of increased protein O-GlcNAcylation, a common 
characteristic of diabetic cardiomyopathy. In order to further validate whether iVici iPSC-CMs 
share more characteristics with diabetic cardiomyopathy, future work should investigate the 
cellular localization of GLUT4, glucose uptake in iVici iPSC-CMs in response to insulin, the 
fuel choice of iVici iPSC-CMs and the accumulation of FFA in iVici iPSC-CMS. In our work, we 
attempted to investigate glucose uptake in iVici iPSC-CMs in response to insulin using the 
fluorescent glucose analog 2-NBDG, however, we could not obtain reliable fluorescent signals 
using this dye in our model (data not shown). Moreover, we tested BODIPY, a fluorescent 
indicator of intracellular FFA droplets and it provided evidence to be a reliable indicator that 
can be utilized in future research to investigate the accumulation of FFA in iVici iPSC-CMs.  
If indeed iVici iPSC-CMs share more characteristics with diabetic cardiomyopathy, it is possible 
that the defective autophagy is the common upstream mechanism in both pathologies. As 
autophagy is blunted in the diabetic hearts (Xie et al., 2011) and one study showed that in STZ 
diabetic rats, the autophagy defect leading to the development of cardiomyopathy is due to 
increased O-GlcNAcylation modification of SNAP29 and reduced fusion between the 
autophagosome and the lysosome. This is of interest as the EPG5 mutation leads to defects 
in the fusion between the autophagosome and the lysosome fusion. Whether the cause of the 
similar phenotype between the diabetic cardiomyopathy and iVici iPSC-CMs is the autophagy 
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defect remains to be elucidated. Or it’s possible that EPG5 have distinct roles other than the 
fusion leading to this phenotype.   
4.6 OGT inhibition as a pharmacological target in iVici iPSC-CMs 
 
In our work, we tested the effect of four different pharmacological OGT inhibitors on the fusion 
between the autophagosome and the lysosome in iVici iPSC-CMs. The first was the 
nonspecific inhibitor alloxan, which is used in biological research to induce diabetes in mice 
and rats (Konrad et al., 2002; Lenzen, 2008). Interestingly, despite its toxic effect on the beta 
cells of mice and rats, treatment with 5 mM alloxan up to seven days did not seem to have any 
toxic effect on WT and iVici iPSC-CMs. Moreover, alloxan treatment enhanced the fusion 
between the autophagosome and the lysosome in iVici iPSC-CMs and increased autophagy 
flux and higher LC3BII turnover due to the enhanced fusion between the autophagosome and 
the lysosome. Investigation of the mechanism through which alloxan enhances the fusion 
between the autophagosome and the lysosome indicated that alloxan treatment might reduce 
protein O-GlcNAcylation of SNAP29 and increase the interaction of SNAP29 with STX17. 
However, the data we obtained in that direction are preliminary and needs to be confirmed in 
future studies.  
Intriguingly, treatment of WT iPSC-CMs with 5 mM alloxan increased protein O-GlcNAcylation 
levels in contrast to what is expected based on its function as an OGT inhibitor. This 
observation can be attributed to the physiological homeostasis of protein O-GlcNAcylation 
required for cellular function. Previous work showed that in conditions of reduced UDP-GlcNAc 
such as glucose deprivation, an increase in OGT protein levels and activity and a decrease in 
OGA protein levels and activity are induced to maintain physiological protein O-GlcNAcylation 
homeostasis (Cheung & Hart, 2008; Kang et al., 2009; Taylor et al., 2008; Yang et al., 2002). 
Next, we tested the specific OGT inhibitor ST045849, ST045849 negatively affected the 
beating properties of WT and iVici iPSC-CMs and did not reduce general oxidative stress levels 
in iVici iPSC-CMs (data not shown). Moreover, it enhanced the fusion between the 
autophagosome and the lysosome, possibly through reducing SNAP25 protein levels and 
protein O-GlcNAcylation. However, future work should further investigate whether these 
proposed mechanisms indeed play a role in enhancing the fusion between the autophagosome 
and the lysosome after ST045849 in iVici iPSC-CMs. Despite enhancing the fusion between 
the autophagosome and the lysosome in iVici iPSC-CMs, ST045849 treatment did not 
enhance autophagy flux in iVici iPSC-CMs. It’s possible that ST045849 treatment has a 
negative effect on the degradative hydrolases present in the lysosome, hence the absence of 
effect on autophagy flux. Studies using lysotracker red, an indicator dye which accumulate 
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inside the lysosomes with active degradative hydrolases with an acidic pH can indicate whether 
ST045849 affect lysosomal enzymes function.  
The third OGT inhibitor tested in this study is the specific OGT inhibitor ST078925. Though it 
showed promising results in terms of reducing oxidative stress and increasing mitochondrial 
fusion in iVici iPSC-CMs, it had significant negative effect on the beating properties of iVici 
iPSC-CMs and did not enhance the fusion between the autophagosome and the lysosome in 
iVici iPSC-CMs. These findings are intriguing, as it indicates the possibility of attenuating some 
of the cellular insults in iVici iPSC-CMs without enhancing the fusion between the 
autophagosome and the lysosome, the main defect believed to cause the cellular insults 
present in iVici iPSC-CMs. Hence, it will be of interest for future work to dissect the mechanism 
through which ST078925 have these beneficial effects and whether the identified target(s) can 
be targeted in Vici syndrome. Moreover, from our results we hypothesized that the defective 
beating properties present in iVici iPSC-CMs maybe a direct effect of cellular oxidative stress. 
However, although ST078925 reduced general oxidative stress levels, it further impaired iVici 
iPSC-CMs beating properties. This indicates either that in iVici iPSC-CMs oxidative stress is 
not responsible for the impaired beating or that ST078925 have other cellular targets playing 
a role in cardiac cells beating.  
Finally, we tested the specific OGT inhibitor OSMI-1, similar to ST078925 and ST045849 it 
had a significant negative effect on the beating properties of WT and iVici iPSC-CMs evident 
by daily visual inspection (data not shown) and similar to ST078925 it reduced general 
oxidative stress levels in iVici iPSC-CMs. Moreover, although OSMI-1 treatment reduced 
SNAP25 levels and protein O-GlcNAcylation in iVici iPSC-CMs, it did not enhance the fusion 
between the autophagosome and the lysosome in iVici iPSC-CMs and impaired the fusion 
between the autophagosome and the lysosome in WT iPSC-CMs. These findings indicate that 
OSMI-1 treatment have other cellular targets responsible for the attenuated beating in WT and 
iVici iPSC-CMs and the impaired fusion between the autophagosome and the lysosome in WT 
iPSC-CMs.  
Our findings indicated that all specific OGT inhibitors tested in this study affected the beating 
of WT and/or iVici iPSC-CMs negatively. Moreover, we attempted to test the effect of inhibiting 
GFAT to block the HBP pharmacologically using 5 µM azaserine, hence reducing protein O-
GlcNAcylation. However, this treatment exhibited significant toxic effect on WT and iVici iPSC-
CMs (data not shown). This indicates that specific pharmacological inhibition of the process of 
protein O-GlcNAcylation is detrimental to iPSC-CMs function, a phenotype not observed with 
the nonspecific pharmacological inhibitor alloxan. Interestingly, the detrimental role of specific 
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inhibition of protein O-GlcNAcylation was also observed in EPG5 mutant Caenorhabditis 
elegans as RNA knockdown of GFAT increased embryonic lethality (Guo et al., 2014).   
Our findings indicate that pharmacological targeting of OGT is a potential therapy for Vici 
syndrome. Moreover, our findings indicate that some of the cellular insults observed in iVici 
iPSC-CMs can be attenuated without enhancing the fusion between the autophagosome and 
the lysosome. This highlights the potential of multiple pharmacological targets leading to better 
outcome in Vici syndrome. However, to reach this step, specific detailed mechanisms of the 
OGT inhibitors used in this study and other OGT inhibitors available should be investigated. 
4.7 Conclusion 
 
Ancient Greek philosophers described the chicken or the egg paradox to describe the problem 
of determining cause and effect. Considering the results of our work, the same paradox 
represented itself in several instances. As we observed several cellular insults including 
oxidative stress, mitochondrial fragmentation, and increased protein O-GlcNAcylation and 
each of the identified cellular insults is known to promote cardiomyopathy development and 
HF. This indicates the complexity of the molecular mechanisms contributing to cardiomyopathy 
development in Vici syndrome. Moreover, these findings brought the question whether 
autophagy is the major cellular process controlling cell physiological function and defects in 
autophagy can lead directly or indirectly to multiple cellular insults. 
Based on the results obtained through this study, our initial hypothesis is altered. Our current 
hypothesis is that iVici iPSC-CMs tend to deactivate autophagy flux due to the fusion defect 
present. This evident by the increased mitochondrial membrane potential leading to blockage 
of mitophagy, as well as the increased protein O-GlcNAcylation. This raises the counter 
intuitive question whether testing pharmacological agents which are known to induce 
autophagy will lead to the identification to possible therapeutic option(s), especially that iVici 
iPSC-CMs showed some degree of successful fusion between the autophagosome and the 
lysosome.  
Moreover, we tested four different pharmacological OGT inhibitors where only two enhanced 
the fusion between the autophagosome and the lysosome. Intriguingly, we observed 
attenuation of some of the identified cellular insults in iVici iPSC-CMs by the treatment with the 
OGT inhibitors which did not enhance the fusion between the autophagosome and the 
lysosome. Future work should investigate in great details the mechanisms of the enhanced 
fusion and cellular insults attenuation to provide better understanding of the feasibility of using 
OGT inhibition as a therapeutic approach in iVici iPSC-CMs. 
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6 Appendix 1: Calcineurin regulation of zebrafish 
outward potassium channel Kcnk5B activity 
 
6.1 Introduction 
 
The proportional growth and the control of allometric and isometric growth phases of 
developing and regenerating organs and limbs is a tightly controlled process, coordinated by 
both intrinsic and extrinsic signals (Bryant & Simpson, 1984; Twitty & Schwind, 1931). The 
terms isometry and allometry were first introduced in 1936 to describe the relative growth of 
body parts (Huxley & Teissier, 1936). Isometry is defined as the growth rate of part identical to 
a standard or the body, whereas allometry was defined as the growth rate of part different to a 
standard or the body as a whole. One example of proportional growth control through tight 
regulation of allometric and isometric phases of growth is (Danio rerio) zebrafish fin 
development and regeneration. During the juvenile stage of zebrafish development, the 
zebrafish fins grow allometrically in relation to the body (Goldsmith et al., 2006), then upon 
reaching the final fin shape at the adult stage, the zebrafish fin growth shifts to isometric growth 
(Goldsmith et al., 2003). Zebrafish have the ability to regenerate their fins within three weeks 
after amputation. Similarly, to zebrafish development, the regenerating zebrafish fin grows 
allometrically during the initial stages of regeneration and upon reaching the pre-amputation 
fin to body ratio the regenerating fin return to isometric growth (Lee et al., 2005).  
Several zebrafish mutants including long fin (lof), rapunzel (rap), and another long fin (alf) show 
loss of proportional growth control and hyperactive fin growth, producing fin structures that are 
much longer than normal (Goldsmith et al., 2003; Perathoner et al., 2014). Understanding the 
mutations present in different zebrafish mutants that have enhanced fin growth can provide 
insight into the regulation of proportional growth control.  
The zebrafish fin consists of 16-18 bony rays separated by soft inter-ray tissue. The bony rays 
are covered by epidermal tissue layers and enclose nerves, blood vessels and pigment cells.  
After zebrafish fin amputation, non-proliferative lateral epidermal cells migrate to cover the 
wound to form the wound epidermis (WE). This is followed by distal migration of fibroblasts 
(mesenchymal cells) to form a pool of undifferentiated cells called the blastema. This pool of 
undifferentiated cells is postulated to be responsible for regenerating the amputated fin via 
proliferation to maintain blastema outgrowth as well as differentiation to form the different fin 
cell types giving rise to a full length fin with all the original cellular structure (Poss et al., 2000; 
Whitehead et al., 2005).  
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Various growth factors have been shown to play an essential role in controlling the rate of 
regenerative outgrowth of zebrafish fins. For instance, fibroblast growth factor (fgf) signalling 
is required for the blastema formation, blastema cell proliferation and outgrowth of the 
regenerating fin tissues (Lee et al., 2005; Poss et al., 2000; Whitehead et al., 2005)  Another 
example is Activin-βA, a member of the Transforming Growth Factor beta (TGF-β) family. TGF-
β acts through the serine/threonine kinase receptor Alk4. It regulates blastema outgrowth 
during fin regeneration, and the inhibition of Alk4 receptor caused a decrease in blastema 
proliferation (Badakov et al.,2007). In addition, signaling from retinoic acid, Wnt/β-catenin and 
notch were shown to maintain the proliferation of the blastema and to control the regeneration 
rate of the fin (Blum et al., 2012; Stoick-cooper et al., 2007).  
Beside the role of classical signaling pathways in the regulation of zebrafish fin proportional 
growth control, a discovery made in our lab showed that pharmacological inhibition of the 
calcium and calmodulin- dependent serine/threonine phosphatase calcineurin (CN) results in 
elongated segmented fin rays and disproportional growth of the fins during regeneration as 
well as in uninjured conditions (Kujawski et al., 2014). However, the downstream targets 
controlled by CN in controlling zebrafish fins growth are not known. The zebrafish mutant alf 
shows increased growth rate and elongated zebrafish fin rays similar to the observed 
phenotype induced by CN inhibition. This mutant carries a gain-of-function point mutation in 
the outward potassium channel Kcnk5b, a member of the TWIK/TASK two pore family (K2P) 
of potassium channels. Analysis of these animals showed that this disproportional growth of 
fins is a direct cause of the increased K+ ion conductance at the plasma membrane resulting 
from the gain of function mutation (Perathoner et al., 2014).   
Given the similar loss of proportional growth control of zebrafish fins in alf zebrafish mutants 
and upon CN inhibition, we hypothesized that there is an interplay between CN and bioelectric 
signaling in the regulation of growth control. We hypothesized that CN regulates proportional 
growth control through the regulation of Kcnk5b activity. In our group, we generated proof that 
there is a functional interaction between calcineurin and Kcnk5b (Figure S1). Thus, the aim of 
this work was to identify the putative CN binding site(s) in zebrafish Kcnk5b and to identify the 
serine or threonine through which calcineurin regulates Kcnk5b activity. 
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Figure S1. CN interacts with zebrafish Kcnk5b and negatively regulates its activity (A) 
Immunoblots showing an interaction between FLAG-tagged zebrafish Kcnk5b, endogenous 
CN, and myc-tagged CN. (B) Current densities of WT Kcnk5b and WT Kcnk5b treated with the 
pharmacological CN inhibitor FK506. CN inhibition lead to increased Kcnk5b current density. 
(C). Current densities of WT Kcnk5b and WT Kcnk5b co-expressed with constitutively active 
CN (CaN). Co-expression of WT Kcnk5b with CaN lead to decreased current density compared 
to WT Kcnk5b. HEK293 cells were used for IP and electrophysiology characterization. This 
figure was provided by Dr. Christopher Antos.  
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6.2 Materials and methods 
 
6.2.1 Materials 
 
 
6.2.1.1 Cell lines 
 
Cell line 
 
Source 
HEK293 cells (Graham et al., 1977) Human embryonic kidney cells 
 
6.2.1.2 Chemicals 
 
Chemical 
 
Source 
 
Cat# 
Adenosine 5′-triphosphate disodium salt 
hydrate (ATP) 
Sigma-Aldrich A6419 
Calcium chloride Roth A119 
4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid (HEPES) 
Serva 25245 
D (+)-Glucose Merck 1.08337 
L-Glutamic acid Sigma-Aldrich G1251 
Magnesium chloride hexahydrate Merck 1.05833 
Potassium chloride Merck 1.04936 
Sodium chloride Roth 3957 
Sodium hydroxide solution Merck 1.09956 
Sodium phosphate monobasic Sigma-Aldrich S0751 
 
6.2.1.3 Kits 
 
Kit 
 
Source 
 
Cat# 
FuGENE® 6 Transfection Reagent Promega E2691 
Plasmid Midi Kits Qiagen 12143 
QuikChange XL Site-Directed 
Mutagenesis 
Agilent 200517-5 
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6.2.1.4 Bacterial culture 
 
Reagent 
 
Source 
Ampicillin sodium salt A0166 
Kanamycin sulfate from Streptomyces 
kanamyceticus 
K1637 
Lysogeny broth (LB)  
Obtained from the Center for Regenerative 
Therapies Dresden (CRTD) media kitchen 
LB Agar plates with ampicillin 100 μg/ml 
LB agar plates with kanamycin 15 μg/ml 
 
6.2.1.5 Cell culture media and reagents 
 
Reagent/Resource 
 
Source 
 
Cat# 
Dulbecco's Modified Eagle Medium 
(DMEM), high glucose, pyruvate 
Thermo Fisher Scientific 41966029 
Fetal Bovine Serum (FBS) Sigma-Aldrich F7524 
Opti-MEM™ I Reduced Serum Medium Thermo Fisher Scientific 31985062 
Penicillin-Streptomycin Sigma-Aldrich P0781 
1X Phosphate-buffered saline (PBS) Sigma-Aldrich D8537 
Trypsin 0.25% EDTA Thermo Fisher Scientific 2500056 
 
6.2.1.6 Plastic disposals 
 
Resource 
 
Source 
 
Cat# 
CELLSTAR® 15 ml, CONICAL BOTTOM, 
sterile tube 
Greiner Bio-One 188271 
CELLSTAR® 50 ml CONICAL BOTTOM, 
sterile tube 
Greiner Bio-One 227261 
Corning® Serological pipettes 5 mL  Sigma-Aldrich  CLS4487 
Corning® Serological pipettes 10 mL Sigma-Aldrich CLS4488 
Corning® Serological pipettes 25 mL Sigma-Aldrich CLS4489 
Corning® 0.1 – 10 μL filter tips Sigma-Aldrich CLS4135 
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6.2.1.6 Plastic disposals cont. 
 
Resource 
 
Source 
 
Cat# 
Corning® 1 – 20 μL filter tips Sigma-Aldrich CLS4136 
Corning® 1 – 200 μL filter tips Sigma-Aldrich CLS4138 
Corning® 100 – 1000 μL filter tips Sigma-Aldrich CLS4140 
Nunc™ cell culture petridish 35x10 mm Thermo Fisher Scientific 150318 
Nunc™ cell culture petridish 100x17 mm Thermo Fisher Scientific 150350 
 
6.2.1.7 Appliances 
 
Appliance 
 
Source 
Avanti JXN-30 centrifuge Beckman Coulter 
DMZ-UNIVERSAL PULLER Dagan 
EPC9 Patch Clamp Amplifier HEKA 
Fireboy plus Integra Biosciences 
Hera Safe 2020 Thermo Fisher Scientific 
Heracell™ VIOS 160i CO2-Incubator Thermo Fisher Scientific 
Heraeus™ Megafuge™ 8 Thermo Fisher Scientific 
Heraeus™ Fresco™ 21 microcentrifuge Thermo Fisher Scientific 
IX50 microscope Olympus 
NanoDrop™ One/One Thermo Fisher Scientific 
Pipetus® Pipette boy Hirschmann 
TC-344B temperature controller Warner Instruments 
Thermomixer compact Sigma-Aldrich 
UNIHOOD 650 UNiEquip 
UNITWIST 400 UNiEquip 
U-RFL-T power supply for mercury burner Olympus 
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6.2.1.8 Software 
 
Software 
 
Source 
Mendelay Elsevier 
Prism 8 GraphPad Software 
Patch master HEKA 
SnapGene viewer GSL Biotech LLC 
 
6.2.1.9 Plasmids  
 
1- pCMV-Kcnk5b-GFP: 
The plasmid contains the cDNA of zebrafish Kcnk5b fused to GFP under the control of CMV 
promotor (Figure S2). Fusing Kcnk5b to GFP allowed visually identifying cells positive after 
transfection. Expression under the control of CMV promotor ensure constitutive expression in 
mammalian cells. The plasmid contains kanamycin resistance gene which allows selection of 
bacterial colonies which successfully acquired the plasmid. This plasmid was used as a 
template in all site directed mutagenesis experiments made during the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S2. pCMV-Kcnk5b-GFP plasmid map 
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2- pcDNA6-CA-CaN-mCherry: 
The plasmid contains constitutively active calcineurin (CaN) fused to mCherry under the 
control of CMV promotor (Figure S3). Fusing CaN to mCherry allowed visually identifying 
cells positive after transfection. Expression under the control of CMV promotor ensure 
constitutive expression in mammalian cells. The plasmid contains ampicillin resistance gene 
which allows selection of bacterial colonies successfully acquired the plasmid.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure S3. pcDNA6-CA-CaN-mCherry plasmid map 
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6.2.1.10 List of primers 
 
Primer 
 
Sequence 
Melting 
temprature 
S330A For tggcacgatccaagagctgcGCtgaccttttgcaaggcctg > 75°C 
S330A Rev caggccttgcaaaaggtcaGCgcagctcttggatcgtgcca > 75°C 
S332A For ctggcacgatccaagGCctgcagtgaccttttgcaaggcc > 75°C 
S332A Rev ggccttgcaaaaggtcactgcagGCcttggatcgtgccag > 75°C 
S345A For aggcctggtcatcccgcttgatcacGctcctcgtctgcaac > 75°C 
S345A Rev gttgcagacgaggagCgtgatcaagcgggatgaccaggcct > 75°C 
S330E For tggcacgatccaagagctgcGAGgaccttttgcaaggcctg > 75°C 
S330E Rev caggccttgcaaaaggtcCTCgcagctcttggatcgtgcca > 75°C 
S332E For gaggaactggcacgatccaagGAGtgcagtgaccttttgcaag > 75°C 
S332E Rev cttgcaaaaggtcactgcaCTCcttggatcgtgccagttcctc > 75°C 
S345E For gtcatcccgcttgatcacGAGcctcgtctgcaacggcgg > 75°C 
S345E Rev ccgccgttgcagacgaggCTCgtgatcaagcgggatgac > 75°C 
LEEP BSM1 VATA 
For 
gcgatattccaaatcGTCGCGACGGCGaatttaaattcagct 72.4°C 
LEEP BSM1 VATA 
Rev 
agctgaatttaaattCGCCGTCGCGACgatttggaatatcgc 72.4°C 
LVIP BSM2 VATA 
For 
accttttgcaaggcGTGGCCACCGCGcttgatcactctcc > 75°C 
LVIP BSM2 VATA 
Rev 
ggagagtgatcaagCGCGGTGGCCACgccttgcaaaaggt > 75°C 
Kcnk5b 
sequencing primer 
For 
ttttggatccagtattatggcagataaaggacct 65.9°C 
Kcnk5b 
sequencing primer 
Rev 
tttggcgcgccgacttacttgtacagctcgtc 70.9°C 
 
* All primers were obtained from Eurofins genomics. Highlighted in red are the 
mutations inserted in the WT Kcnk5b sequence by each primer set.  
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6.2.2 Media and buffers composition 
 
 
6.2.2.1 Cell culture media 
Medium Composition 
 
HEK293 cell culture medium 
• 500 ml Dulbecco's Modified Eagle Medium 
(DMEM), high glucose, pyruvate 
• 10% FBS  
• 1% Penicillin-Streptomycin  
 
6.2.2.2 Patch clamp solutions 
Solution Composition 
 
 
 
Tyrode solution with 2 mM calcium 
• 8.065 g sodium chloride  
• 0.298 g potassium chloride 
• 2 ml (1 M) calcium chloride  
• 1 ml (1 M) magnesium chloride 
• 0.330 ml (1 M) Sodium phosphate 
monobasic 
• 1.802 g glucose 
• 2.383 g HEPES 
• Complete to 1 liter with Mili-Q-H2O 
• Adjust pH to 7.3 with sodium hydroxide 
• Store at 4°C 
 
 
 
 
Potassium-glutamate pipette solution  
• 19.127 g glutamic acid 
• 0.746 g potassium chloride 
• 4 ml (1 M) magnesium chloride 
• 2.383 g HEPES 
• Complete to 1 liter with Mili-Q-H2O Store 
at 4°C 
• On the day of experiment dissolve 0.061 g 
ATP per 50 ml pipette solution.  
• Adjust pH to 7.2 with potassium hydroxide 
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6.2.3 Methods 
 
6.2.3.1 Maintenance of HEK293 cells 
 
HEK293 cells were passaged every 3 to 4 days when cells confluency reaches ≈ 90%. In brief 
HEK293 culture media was removed and cells were washed twice with 1X PBS then 5 ml 
trypsin 0.25% EDTA was added and cells were incubated at 37°C for five minutes. Upon cell 
dissociation, 5 ml of HEK293 culture media was added to inactivate trypsin. Next, cells were 
centrifuged for 3 minutes at 1000xg. Supernatant was removed and the cell pellet was 
resuspended in 5 ml HEK293 culture media. 1/5 of the cell suspension was used for further 
culture and maintenance. HEK293 cells were maintained at 37°C, 5% CO2.  
6.2.3.2 Site directed mutagenesis 
 
Site directed mutagenesis was performed using the QuikChange Site-Directed Mutagenesis 
kit following the manufacturer protocol. In brief, the reaction mixture was prepared on ice as 
described in table S1 after that the PCR program was followed as described in table S2. 
Table S1. Reaction mixture for site directed mutagenesis 
5 µl of 10X reaction buffer 
25 ng of dsDNA plasmid (pCMV-Kcnk5B-GFP) 
125 ng of forward primer 
125 ng of reverse primer 
1 µl of dNTP mix 
ddH2O to a final volume of 50 µl 
1 µl of PfuTurbo DNA polymerase (2.5 U/µl) 
 
Table S2. PCR programme for site directed mutagenesis 
Segment Cycles Temperature Time 
1 1 95°C 30 seconds 
 
2 
 
18 
95°C 30 seconds 
55°C 1 minute 
68°C 1 minute/kb of 
plasmid length 
3 1 4°C hold 
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After PCR amplification 1 µl of the Dpn I restriction enzyme (10 U/µl) was added to the reaction 
mixture and incubated for 1 hour at 37°C to digest the (non-mutated) parental template. After 
that the super competent XL1 Blue bacterial cells were transformed with the reaction mixture 
to allow the identification of single bacterial colonies carrying the plasmid with the target 
mutation. In brief, XL1 Blue cells were thawed on ice for 30 minutes. 50 µl aliquots of the XL1 
Blue cells were made in 2 ml Eppendorf tubes, and 1 µl of the Dpn1 treated reaction mixture 
was added per tube. The XL1 Blue cells and the DNA mix were incubated on ice for 30 minutes 
then the bacterial cells were heat shocked at 42°C for 45 seconds. The mixture was incubated 
on ice for 2 minutes then the transformed XL1 Blue cells were spread on LB agar plates with 
the appropriate antibiotic and incubated at 37°C for >16 hours. On the next day single bacterial 
colonies were picked and incubated in 250 ml LB medium with the appropriate antibiotic at 
37°C for >16 hours with constant swirling to allow isolation of the plasmid and use for cells 
culture experiments and validate the insertion of the intended mutation by DNA sequencing. 
For plasmids carrying ampicillin resistance gene, the working concentration of ampicillin was 
100 µg/ml, whereas for plasmids carrying kanamycin resistance gene the working 
concentration of kanamycin was 50 µg/ml. 
6.2.3.3 Plasmid midi-prep 
 
Plasmid purification was performed using the Qiagen plasmid midi-prep kit following the 
manufacturer protocol. In brief, O/N bacterial culture was harvested by centrifuging at 6000xg 
for 15 minutes at 4°C. Bacterial pellet was resuspended in 4 ml buffer P1 following by the 
addition of 4 ml buffer P2 and incubation at room temperature for 5 minutes. Next, 4 ml buffer 
P3 were added followed by incubation on ice for 15 minutes. After that, the lysed bacterial 
pellet was centrifuged at 20,000xg for 30 minutes at 4°C. During the centrifugation step, the 
Qiagen tip 100 was equilibrated by running 4 ml QBT buffer through the column. After that the 
supernatant from the centrifugation step was passed through the Qiagen tip 100 following 
gravity flow. The Qiagen tip was washed 2 times with 10 ml buffer QC. Then the plasmid DNA 
was eluted with 5 ml QF buffer into a new 15 ml falcon tube. DNA was precipitated by the 
addition of 3.5 ml isopropanol to the DNA eluate. The precipitated DNA was centrifuged at 
20,000xg for 15 minutes at 4°C. Supernatant was carefully discarded and the DNA pellet was 
washed with 2 ml 70% ethanol followed by centrifugation at 20,000xg for 10 minutes at 4°C. 
Supernatant was carefully discarded, and the DNA pellet was allowed to air dry for 10 minutes. 
Finally, DNA pellet was dissolved in ddH2O and DNA concentration and quality were measured 
using Nanodrop.  
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6.2.3.4 Transfection of HEK293 cells 
 
For transfection of HEK293 cells, 90% confluent HEK293 cells were splitted 1:10 in Nunc™ 
cell culture petridish 35x10 mm. 24 hours after splitting the HEK293 cells, HEK293 cells were 
around 60-75% confluent, an appropriate confluency to transfect the cells using the Fugene 6 
transfection reagent. For transfection, 2 µl Fugene 6 transfection reagent was mixed with 33 
µl Opti-mem reduced serum medium and incubated for 5 minutes at room temperature. Next, 
the DNA (plasmid(s)) used for transfection were mixed with the Fugene 6 and Opti-mem 
medium and incubated for 15 minutes at room temperature. Next, the transfection mixture was 
added directly to HEK293 cells. 24 hours after transfection, transfected HEK293 cells were 
splitted and transferred to new Nunc™ cell culture petridish 35x10 mm with glass cover slips 
and allowed to attach by incubating the cells for 6-8 hours at 37°C, 5% CO2 prior to 
electrophysiology experiments. For electrophysiology experiments, HEK293 cells were 
transfected with 50 ng of pCMV-Kcnk5B-GFP carrying the WT Kcnk5B or the different mutants 
generated using site directed mutagenesis. Whereas HEK293 cells were transfected with 250 
ng of pcDNA6-CA-CaN-mCherry for all experiments with co-expression analysis.  
6.2.3.5 Patch clamp analysis 
 
The seeded coverslips were transferred into Tyrode solution and cells selected for patch clamp 
were selected based on the expression of the appropriate fluorescence marker. Membrane 
currents were measured in the whole-cell configuration and patched using borate glass 
pipettes pulled using the two-stage puller (DMZ universal puller). Only glass pipets with 3-6 
MΩ resistance were used. After Giga-seal formation, cells were clamped at -80 mV. Potassium 
conductance was measured using voltage clamp set-up (HEKA) from -100 mV to 70 mV in 10 
mV increments. The resulting tracings were used to quantify current densities using the patch 
master software. All experiments were performed at room temperature (22–25 °C).  
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6.3 Results 
 
6.3.1 Mechanism of CN binding to Kcnk5B 
 
6.3.1.1 Screen for putative CN binding sites on Kcnk5b 
 
In order to identify the CN binding site(s) on Kcnk5b and to elucidate the mechanism by which 
CN regulates Kcnk5b activity, Kcnk5b amino acid sequence was screened for putative CN 
binding sequence. CN has been shown to bind to the putative amino acid sequences LXXP 
and PXIXIT (Martínez-Høyer et al., 2013). Two possible CN binding sites were identified 
(Figure S4A, B) LEEP at Kcnk5b N-terminus starting at amino acid 26 and LVIP located at 
Kcnk5B C-terminus starting at amino acid 338. In order to investigate whether CN regulates 
Kcnk5B activity through binding to either or both putative binding sites, using site directed 
mutagenesis and the plasmid pCMV-Kcnk5b-GFP containing WT Kcnk5b cNDA sequence as 
a template, single LEEP to VATA mutant (BSM-1), single LVIP to VATA mutant (BSM-2) and 
double VATA mutant for both putative binding sites (BSM-D) were generated under the control 
of CMV promoter. These mutants were later used for electrophysiological assessment.  
 
 
 
 
 
 
 
 
Figure S4. Schematic illustration of KcnK5b. (A) Schematic illustration of the outward 
potassium channel Kcnk5b, showing the two possible putative CN binding sites at the C and 
N terminus. (B) The amino acids sequence of KcnK5B showing the two possible putative CN 
binding sequences LEEP (red) and LVIP (blue).  
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6.3.1.2 CN regulates Kcnk5b activity through LVIP putative binding site 
 
 In order to investigate whether calcineurin regulates Kcnk5b activity through the LEEP putative 
binding site, HEK293 cells were transfected with wildtype (WT) Kcnk5B and BSM-1 Kcnk5B. 
24 hours after transfection, Kcnk5B current density was assessed using whole cell patch clamp 
where the current density was measured in response to gradual membrane depolarization. 
Interestingly the LEEP to VATA mutation completely abolished Kcnk5B activity (Data not 
shown). Next, in order to investigate whether calcineurin regulates Kcnk5B through binding to 
the LVIP binding site, HEK293 cells were transfected with WT Kcnk5B, WT Kcnk5B together 
with constitutively active calcineurin (CaN), BSM-2 and finally BSM-2 together with CaN for 
assessment of Kcnk5B current density. Interestingly the current density of the BSM-2 LVIP to 
VATA mutant was similar to WT Kcnk5b. Furthermore, CaN led to decreased current density 
of WT Kcnk5B and did not affect current density in BSM-2 Kcnk5B mutant (Figure S5). These 
findings strongly indicated that calcineurin regulate Kcnk5B activity through binding to the LVIP 
putative binding sequence.  
 
 
 
 
 
 
 
 
 
Figure S5. CN regulates Kcnk5b activity through LVIP putative binding site. Current 
densities of WT Kcnk5b, BSM-2, WT Kcnk5B + CaN and BSM-2 + CaN. WT Kcnk5B had 
similar current density to BSM-2. Moreover, CaN negatively affected current density of WT 
Kcnk5B and had no effect on the current density of BSM-2. This indicates that CN regulates 
Kcnk5B activity through binding to LVIP binding site on the C terminus. WT Kcnk5B N= 9 cells, 
BSM-2 N= 11 cells, WT Kcnk5B+CaN= 7 cells and BSM-2+CaN= 10 cells, error bars=SEM.
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6.3.2 Mechanism of CN regulation of Kcnk5b activity 
 
6.3.2.1 Selection of three serine residues as potential sites for CN regulation of 
Kcnk5b activity 
 
CN is a protein phosphatase, which dephosphorylates the amino acids serine and threonine. 
In order to identify the amino acid(s) through which CN regulates Kcnk5b activity, serines 
330, 332 and 345 located in the vicinity of CN LVIP putative binding sequence in Kcnk5b 
were selected for further investigation as potential sites through which CN regulates Kcnk5b 
activity (Figure S6A,B). Using site directed mutagenesis; and the plasmid pCMV-Kcnk5B-
GFP containing WT Kcnk5B cDNA sequence as a template, two mutants were generated for 
each selected serine, a serine-to-alanine mutant and a serine-to-glutamic acid mutant. The 
serine-to-alanine mutation represents the dephosphorylated form of serine and cannot be 
phosphorylated, and the serine-to-glutamic acid mutation represents the phosphorylated 
form of serine and cannot be dephosphorylated. These mutants were used for 
electrophysiological assessment.  
  
 
 
 
 
 
 
 
Figure S6. Selection of three serine residues as potential sites for CN regulation of 
Kcnk5b activity (A) Schematic illustration of the outward potassium channel Kcnk5b, showing 
the identified putative CN binding site at the C terminus. (B) The amino acids sequence of 
KcnK5b showing the identified putative CN binding site LVIP (blue) and the selected serine 
residues 330, 332 and 345 located in the vicinity of CN LVIP putative binding sequence (red).  
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6.3.2.2 Assessment of serine to alanine Kcnk5b mutants current density  
  
In order to identify the potential serine(s) through which CN regulates Kcnk5b activity, three 
serine residues, serine 330, 332 and 345, located in the vicinity of the putative CN binding 
sequence were selected as potential candidates. Using site directed mutagenesis and the 
plasmid pCMV-Kcnk5B-GFP containing WT Kcnk5B cDNA sequence as a template, serine to 
alanine mutants of the selected serine residues, S330A, S332A and S345A, were generated 
to be used in electrophysiology studies. HEK293 cells were transfected with the S330A, 
S332A, S345A mutants and WT Kcnk5B. Then, the current densities of each serine to alanine 
mutant and WT Kcnk5B were measured. Both S330A and S332A mutants had similar current 
densities to WT Kcnk5B (Figure S7A, B); whereas, S345A mutant had significantly lower 
current density compared to WT Kcnk5B (Figure S7C). These results indicated that calcineurin 
regulates Kcnk5b activity through dephosphorylation of serine 345. 
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Figure legend in the next page 
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Figure S7. Assessment of serine to alanine Kcnk5b mutants current density. (A) Current 
density of WT Kcnk5B and S330A Kcnk5B mutant. WT and S330A showed similar current 
density. (B) Current density of WT Kcnk5B and S332A Kcnk5B mutant. WT and S332A showed 
similar current density. (C) Current density of WT Kcnk5B and S345A Kcnk5B mutant. WT 
Kcnk5B showed higher current density compared to S345A mutant. This indicates that serine 
345 is a possible site through which CN regulates Kcnk5B activity. A; WT Kcnk5B N= 10 cells 
and S330A N= 8 cells, B; WT Kcnk5B N= 10 cells, S332A N= 10 cells, C; WT Kcnk5B N= 26 
cells, S345A N= 18 cells, error bars = SEM.  
6.3.2.3 Assessment of serine to glutamic acid Kcnk5B mutants current density 
 
In order to further support the findings that CN regulates Kcnk5B activity through 
dephosphorylation of serine 345, serine to glutamic acid (Phosphomimetic) mutants of serine 
residues 330 (S330E), 332 (S332E) and 345 (S345E) were generated. These mutations 
represent the phosphorylated form of serine and cannot be dephosphorylated. To investigate 
if either of the mutations have a functional consequence, HEK293 cells were transfected with 
the S330E, S332E, S345E mutants without and with CaN and WT Kcnk5B. Both S330E and 
S332E mutants showed similar current densities to WT Kcnk5B and CaN induced reduction in 
their activity (Figure S8A, B). These findings further support the notion that CN does not 
regulate Kcnk5B activity through modulation the phosphorylation status of serine residues 330 
and 332. On the other hand, S345E mutant showed similar current density to WT Kcnk5B and 
CaN did not affect the current density of S345E mutant (Figure S8C). These findings support 
the notion that serine 345 is the site of CN regulation of Kcnk5B. Together, our data indicate 
that CN regulates Kcnk5B activity through modulation of the phosphorylation status of serine 
345.  
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Figure S8. Assessment of serine to glutamic acid Kcnk5b mutants current density. (A) 
Current density of WT Kcnk5B and S330E Kcnk5b mutant with and without CaN. WT and 
S330E showed similar current density, in addition CaN induced a reduction in S330E current 
density (B) Current density of WT Kcnk5B and S332E Kcnk5B mutant with and without CaN. 
WT and S332E showed similar current density, in addition CaN induced a reduction in S332E 
current density. (C) Current density of WT Kcnk5b and S345E Kcnk5b mutant with and without 
CaN. WT and S345E showed similar current density, however, CaN did not induce a reduction 
in S345E current density. These findings indicate that CN regulates Kcnk5b activity through 
modulating the phosphorylation status of serine 345. A; WT Kcnk5B N= 15 cells and S330E 
N= 10 cells, S330E + CaN N= 14 cells B; WT Kcnk5b= 21 cells, S332E N= 23 cells, S332E + 
CaN N= 21 cells, C; WT Kcnk5b N= 9 cells, S345E N= 11 cells, S345E + CaN N= 7 cells, error 
bars = SEM. 
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6.4 Discussion  
 
The aim of this work was to complement the findings generated in our lab showing that there 
is a functional interaction between Kcnk5B and CN, where CN negatively regulates the activity 
of Kcnk5B in vitro. First, we selected two CN putative binding sequence where we 
hypothesized that CN regulates Kcnk5B activity through binding to both or either of the putative 
CN binding sites. Through in vitro site directed mutagenesis and electrophysiology analysis, 
we showed that CN seems to regulate Kcnk5B activity through binding to the putative binding 
sequence LVIP located at the C terminus. Moreover, we further expanded our analysis to 
identify the potential serine(s) through which CN regulates Kcnk5B activity. We identified 
serine 345 as the serine through which CN regulates Kcnk5B activity.  
Though our analysis provided further insight into the mechanism through which CN regulates 
Kcnk5B activity, we did not provide evidence that the physical interaction between CN and 
Kcnk5B is lost upon mutating the LVIP site. Moreover, in our analysis we did not investigate 
other potential serine or threonine residues through which CN regulates Kcnk5B activity. 
Hence, future work should aim to further investigate these points to support our findings.  
Moreover, our results indicated that in an in vivo context there is an interplay between 
bioelectric signaling and CN in the regulation of proportional growth control. However, several 
questions remain to be investigated to further understand this link and whether the functional 
interaction we illustrated in our in vitro experiments plays a role in an in vivo context. Moreover, 
several classical pathways have been shown to regulate fin growth and regeneration. It will be 
of interest to further elucidate the complete pathway comprising an upstream signal leading to 
control of CN activity and as a result regulating Kcnk5B activity to maintain proportional growth 
control. 
The genetically encoded Förster resonance energy transfer (FRET)-based CN activity reporter 
(Mehta et al., 2014) offers the possibility of efficient in vitro screen for classical signaling 
pathways regulating CN activity. This reporter consists of a modified version of the transcription 
factor Nuclear factor of activated T-cells (NFAT) in which Cerulean 3 (Donor Fluorophore) and 
YPET (Acceptor fluorophore) are bound to the N-Terminus of the NFAT which contains the 
docking site of CN and serves as a regulatory domain for NFAT. In the absence of CN activity, 
FRET signal will be absent. However, upon dephosphorylation of the multiple serine residues 
present on NFAT by CN, Cerulean 3 and YPET will be in close proximity, which will allow the 
detection of FRET signal. To utilize this reporter for the identification of the upstream signaling 
pathway regulating CN activity, an approach is to transfect HEK293 cells with the FRET-based 
CN activity reporter and measure the changes in its FRET activity upon pharmacological or 
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genetic manipulation of the different classical signaling pathways known to regulate zebrafish 
fin development and regeneration.  
Furthermore, the clustered regularly interspaced short palindromic repeats (CRISPR)/ 
CRISPR associated protein 9 (CAS9) technology is a powerful tool used for precise site 
directed genome editing. Recent work showed that with the use of CRISPR/CAS9 homology 
directed repair different point mutations could be introduced precisely in the zebrafish genome 
(Armstrong et al., 2016). Taking advantage of the CRISPR/CAS9 technology it will be possible 
to specifically mutate the putative CN binding site identified in our study and serine 345 through 
which we hypothesize that CN regulates Kcnk5B activity. Analysis of fin growth and 
regeneration in the generated zebrafish mutants will provide key insight into whether CN 
regulates proportional growth control through binding to Kcnk5B and modulating the 
phosphorylation status of serine 345.  
Contrary to our in vitro findings, recent work illustrated that indeed CN regulates Kcnk5B 
activity through functional interaction to Kcnk5B C-Terminus, the authors concluded that CN 
positively regulates Kcnk5B activity. As they observed decrease in Kcnk5B conductance in 
Xenopus oocytes expressing WT zebrafish Kcnk5B treated with the pharmacological CN 
inhibitor FK506 and the CN peptide inhibitor VIVIT. Interestingly, in this study the authors also 
showed that FK506 treatment have low effect on zebrafish fin growth in Kcnk5B-/- fish and 
leads to no further increase in the rate of growth of fins of fish with a gain of function mutation 
of Kcnk5B (Alf mutants). Together, the authors concluded that Kcnk5B is a key component of 
the effect of CN inhibition of proportional growth control and that the interaction between 
Kcnk5B and CN act as a signaling node to regulate allometric growth (Daane et al., 2018).  
The differences between our results and the results by Daane et al on the effect of CN inhibition 
on Kcnk5B activity could be due to different experimental conditions in vitro. In order to further 
understand whether CN positively or negatively regulates Kcnk5B activity, zebrafish lines 
expressing the recently published in vivo genetically encoded voltage indicator (GEVI) can be 
generated and used (Gong et al., 2015). As using this zebrafish line, it will be possible to 
observe the voltage changes in developing and regenerating WT zebrafish fins, Kcnk5B -/- fish 
and zebrafish mutant lines for the LVIP putative binding sequence and serine 345 upon CN 
inhibition. Measurement of voltage changes in these different zebrafish lines will allow us to 
further understand the regulation of Kcnk5B by CN and how it correlates with proportional 
growth control.  
Together our results show a mechanism through which CN regulates the activity of the 
zebrafish outward potassium channel Kcnk5B. However, future studies should provide further 
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insight whether this functional interaction between CN and Kcnk5B plays a role in vivo to 
regulate proportional growth control.  
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